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ABSTRACT 
MT1-MMP is a crucial enzyme for cellular invasion in tissues, and its 
polarised cell surface localisation is thought to be an important regulatory 
mechanism. In this thesis, the mechanisms regulating localisation of MT1-MMP 
to motility-associated structures were investigated. Using a series of MT1-MMP 
domain deletion mutants, it was found that an eight amino acid region in the 
catalytic domain called the “MT-Loop” is involved in localisation of the enzyme to 
matrix attachment sites. A previously described mechanism by which MT1-MMP 
localises to lamellipodia is association with CD44. Interestingly, knockdown of the 
CD44 in HT-1080 cells increased MT1-MMP localisation to the matrix attachment 
sites, whereas CD44 overexpression in COS-7 cells decreased this localisation. 
These results indicate that CD44-mediated localisation to lamellipodia may 
compete with the localisation to the matrix attachment sites. One of the 
previously reported mechanisms localising MT1-MMP to the matrix attachment 
sites is by targeting the enzyme to cortactin-mediated invadopodia structures. 
However, silencing of the cortactin gene in HT-1080 cells unexpectedly 
enhanced this localisation, suggesting that invadopodia may not be required. For 
MT1-MMP to appear on the cell surface, the newly expressed molecules need to 
be trafficked from the trans-Golgi network to the plasma membrane by kinesin 
motor proteins (KIFs). 17 KIFs were tested for their involvement in the 
intracellular trafficking of MT1-MMP-containing vesicles. Silencing of the KIF3A 
or KIF13A genes markedly decreased MT1-MMP-dependent gelatin and collagen 
film degradation, whereas silencing of the KIF9 and KIF1C genes enhanced 
degradation of the underlying matrix. These and other data presented in this 
thesis suggest that KIF3A, KIF13A, KIF9 and KIF1C may be involved in vesicle 
trafficking of MT1-MMP to different areas of the plasma membrane and regulate 
spatial localisation of the enzyme. Taken together, these findings indicate that 
polarised cell surface localisation of MT1-MMP is regulated by multiple 
mechanisms, which may be important for the enzyme to promote cellular 
invasion in different microenvironments. 
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1.1 CELL MIGRATION 
Cell migration plays a central role in a wide variety of biological 
phenomena, including embryonic development, immune defense (Korpos et al.), 
wound repair, rheumatoid arthritis (Miller et al., 2009), as well as cancer invasion 
and metastasis (Friedl and Wolf, 2009; VanSaun and Matrisian, 2006). Initial 
studies regarding cell migration studied a single cell moving on a glass or plastic 
surface (Abercrombie, 1980). Basic steps involved in this migration have been 
well defined and include extension of the leading edge, formation of cell–
substratum attachments, contraction of the body, and detachment of the trailing 
edge (Lauffenburger and Horwitz, 1996). Although these studies gave rise to the 
basic concepts of cell locomotion, they poorly reflect cellular migration that takes 
place in vivo (Friedl and Wolf, 2009). In multicellular organisms, cells are 
surrounded by a thick extracellular matrix (ECM), which acts as a physical barrier 
to the migrating cells. Under this condition, cells utilise proteolytic enzymes to 
degrade ECM components and generate a path for migrating cells (Itoh, 2006; 
Murphy and Gavrilovic, 1999). Matrix metalloproteinases (MMPs) are a group of 
enzymes that play a key role in tissue remodeling and cell migration (Nelson et 
al., 2000; Page-McCaw et al., 2007; Sato et al., 2005). Investigating MMP action 
and regulation will improve understanding of their role in health and disease.   
 
1.2 MATRIX METALLOPROTEINASES (MMPs)  
Matrix metalloproteinases (MMPs) or matrixins are a multidomain zinc-
dependent group of proteases, which degrade virtually all components of the 
ECM. The first member of the MMP family was discovered in 1962 by Gross and 
Lapiere (1962), who reported collagenolytic activity in the tadpole tail during 
amphibian metamorphosis (Brinckerhoff and Matrisian, 2002; Gross and Lapiere, 
1962). This enzyme turned out to be an interstinal collagenase, known today as 
MMP-1. Further studies have led to the discovery of 23 MMPs in humans. The 
presence of the zinc binding motif and homology of the catalytic domain with 
MMP-1 are signatures used to assign an enzyme to this family. A typical MMP 
consists of a signal peptide, a prodomain, a catalytic domain, a linker peptide, 
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also called a ‘hinge region’, and a hemopexin domain. However, only the signal 
peptide, the prodomain and the catalytic domain are common for all MMPs 
(Nagase et al., 2006). The schematic representation of MMP domain 
organisation is shown in Figure 1.1.  
The signal peptide directs MMP secretion or localisation to the plasma 
membrane (Blobel et al., 1979). It is cleaved in the endoplasmic reticulum and 
thus is not detectable in the mature enzyme.  
The prodomain, consisting of approximately 80 amino acids, keeps the 
enzyme in a latent, inactive form. It contains a conserved PRCG(V/N)PD 
sequence, which lies in the substrate binding site. The unpaired cysteine residue 
coordinates with Zn2+ in the catalytic site, blocking the access of water 
molecules. When the prodomain is destabilised or cleaved, the catalytic Zn2+ 
dissociates from the cysteine residue and binds to a water molecule and the 
active site, as a result, becomes available to the substrate. This mechanism is 
known as the "cysteine-switch" (Becker et al., 1995; Van Wart and Birkedal-
Hansen, 1990). The "cysteine-switch" motif is a common feature of MMPs and 
the only exception is MMP-23, where the PRCG(V/N)PD sequence is absent 
(Velasco et al., 1999). Activation of MMPs is often stepwise and requires two 
independent cleavage events. The first step produces an intermediate form of the 
enzyme, which is only partially active and needs to be fully activated by 
intermolecular processing or by cleavage by another MMP (Suzuki et al., 1990). 
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Figure 1.1:  Domain structure of MMPs. Schematic representation of MMPs. 
Signal, signal peptide; Pro, propeptide; RXKR, pro-hormone convertase cleavage 
site; Cat, catalytic domain; L1, linker 1; Hpx, hemopexin domain; FN, fibronectin 
type II repeats; VN, vitronectin type domain; Type II, membrane type II domain; 
Cys, cysteine rich; Ig, immunoglobulin; L2, linker 2; Tm, transmembrane domain; 
CP, cytoplasmic domain; GPI, GPI-anchor signal sequence.  
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The catalytic domain consists of a 5-stranded β-pleated sheet, three α-
helices and connective loops. It contains the consensus sequence 
HEXGHXXGXXH, with a conserved glutamate residue and three histidines, 
which coordinate the catalytic zinc. Downstream of the Zn2+ binding region is a 
conserved methionine, called the ‘Met-turn’, which provides structural integrity to 
the active site (Bode et al., 1993). When a substrate binds to the catalytic site 
cleft, the carbonyl group of the substrate peptide bond coordinates with the 
active-site zinc. This displaces the water molecule from the zinc. The carboxyl 
group of the glutamate serves as a general base to draw a proton from the 
displaced water molecule, thereby facilitating nucleophilic attack of the water 
molecule on the carboxyl carbon of the peptide scissile bond (Coleman, 1998). 
Immediately to the right of the catalytic Zn2+, the S1’- specificity pocket 
invaginates. This pocket accommodates a side chain of the substrate, which 
becomes a new N-terminus after cleavage. The S1’-pocket differs considerably in 
size and shape between various MMPs and thus is thought to determine 
substrate specificity. Besides the catalytic zinc, the catalytic domain contains 
another zinc ion, the structural zinc, and two (MMP-8, MT1-MMP) or three bound 
calcium ions (MMP-1, MMP-3, MMP-7), which stabilise the conformation of the 
active site (Bode et al., 1999; Visse and Nagase, 2003). MMP-2 and MMP-9 
have three repeats of fibronectin-type II inserted in the catalytic domain, which 
binds gelatins and collagens (Allan et al., 1995; Banyai et al., 1994). 
The linker-1 region, or the hinge region, is a variable stretch of amino 
acids that connects the catalytic and the hemopexin domains of MMPs. This 
region is considered to be flexible, although, because of the presence of many 
proline residues, it may have some structural constraints (Rosenblum et al., 
2007). The linker-1 region has been shown to be important for collagenolytic 
activity of MMP-1 (Tsukada and Pourmotabbed, 2002) and MMP-8 (Knauper et 
al., 1997b), supporting the notion that correct arrangement between the catalytic 
and the hemopexin domains is important for the activity of MMPs.  
The C-terminal hemopexin domain, consisting of about 210 amino acids, 
has structural similarities to a heam-binding glycoprotein haemopexin.  It consists 
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of four four-stranded antiparallel beta sheets stabilised on its fourfold axis by a 
calcium cation (Li et al., 1995). The hemopexin domain is important for the 
collagenolytic activities of MMP-1 (Clark and Cawston, 1989), MMP-2 (Patterson 
et al., 2001), MMP-13 (Knauper et al., 1997a) and MT1-MMP (Itoh et al., 2006). It 
also stabilises the interaction of some MMPs with their endogenous inhibitors, the 
tissue inhibitors of metalloproteinases (TIMPs). For instance, the hemopexin 
domain of proMMP-2 mediates binding to TIMP-2 and cell surface activation of 
the enzyme (Murphy et al., 1992). 
In addition to soluble MMPs, there are six membrane-type MMPs (MT-
MMPs). They are tethered to the cell surface, either through a C-terminal 
transmembrane domain followed by a short cytoplasmic tail, or by a 
glycosylphosphatidylinositol (GPI) anchor (Murphy and Nagase, 2008). 
Classification of MMPs based on their domain structure is shown in Figure 1.1. 
 
1.2.1 Diversity of MMPs 
Based on substrate specificity, sequence similarity and domain 
organisation, MMPs can be subdivided into six groups: collagenases; 
gelatinases; stromelysins; matrilysins; membrane-type MMPs (MT-MMPs) and 
others, which can not be classified in any of the above categories (Nagase et al., 
2006; Visse and Nagase, 2003). Classification of MMPs is outlined in Table 1.1.  
Collagenases (MMP-1, MMP-8 and MMP-13) cleave fibrillar collagen 
types I, II and III into characteristic ¾ and ¼ fragments and the Hpx domain is 
required for this activity (Clark and Cawston, 1989; Knauper et al., 1997a; 
Nagase et al., 2006; Visse and Nagase, 2003). 
Gelatinases (MMP-2 and MMP-9) readily digest gelatin. They contain 
three repeats of the fibronectin type-II motif that bind to gelatin and collagen 
(Allan et al., 1995). Their substrates also include native type IV, V and XI 
collagens, laminin and aggrecan core proteins. MMP-2 can digest collagens type 
I, II and III, generating the specific ¾ and ¼-length fragments (Allan et al., 1995; 
Patterson et al., 2001). 
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Stromelysins (MMP-3, MMP-10 and MMP-11) are expressed in stromal 
cells (Basset et al., 1990). They do not cleave interstitial collagens. MMP-3 and 
MMP-10 are similar in structure and substrate specificity. MMP-11 activity 
towards ECM components is weak (Murphy et al., 1993). 
Matrilysins lack the Hpx domain (de Coignac et al., 2000; Park et al., 
2000). They digest several ECM components and process cell surface 
molecules, including Fas-ligand, syndecan-1 and E-cadherin (Nagase et al., 
2006; Visse and Nagase, 2003). Interestingly, MMP-26, unlike most other MMPs, 
has been shown to be stored in its proenzyme form intracellularly (Marchenko et 
al., 2004). 
Membrane type MMPs (MT-MMPs) include four type-I transmembrane 
proteins and two glycosylphosphatidylinositol (GPI)-anchored proteins. GPI-
anchored MT-MMPs, MT4- and MT6-MMP, are attached to the plasma 
membrane via a GPI molecule that contains 2-3 fatty acids (Itoh et al., 1999). 
Type-I transmembrane MT-MMPs, MT1-, MT2-, MT3- and MT5-MMP, localise to 
the cell surface through the transmembrane domain, which is followed by the 
short cytoplasmic tail. MT-MMPs have an additional insertion between the 
propeptide and the catalytic domain, which is cleaved by furin-like serine 
proteases in secretory pathway compartments of the cell, leading to the 
intracellular activation of these enzymes (Thomas, 2002). 
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Table 1.1: Classifications of MMPs.  
 
Enzyme group 
 
 
MMP 
 
Collagenases 
 
MMP-1 (interstitial collagenase, collagenase 1), 
MMP-8 (neutrophil collagenase, collagenase 2),  
MMP-13 (collagenase 3) 
 
Gelatinases 
MMP-2 (gelatinase A)  
MMP-9 (gelatinase B) 
 
Stromelysins 
MMP-3 (stromelysin 1) 
MMP-10 (stromelysin 2) 
MMP-11 (stromelysin 3) 
 
Matrilysin 
MMP-7 (matrilysin 1) 
MMP-26 (matrilysin 2) 
 
Membrane-type 
(MT-MMPs) 
Transmembrane-type             
MMP-14 (MT1-MMP) 
MMP-15 (MT2-MMP) 
MMP-16 (MT3-MMP) 
MMP-24 (MT5-MMP) 
 
GPI-anchored  
MMP-17 (MT4-MMP) 
MMP-25 (MT6-MMP) 
 
Others 
MMP-12 (macrophage elastase) 
MMP-19 (RASI 1) 
MMP-20 (enamelysin) 
MMP-21 
MMP-23 (CA-MMP) 
MMP-27 
MMP-28 (epilysin) 
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There are seven unclassified MMPs. MMP-12 is produced mainly by 
macrophages and digests elastin (Shapiro et al., 1993). MMP-19, also called 
RASI (rheumatoid arthritis synovial inflammation) is present in activated 
lymphocytes and the plasma of patients with rheumatoid arthritis (Sedlacek et al., 
1998). MMP-19 can hydrolyse basement membrane components including type-
IV collagen and laminin, but is unable to cleave triple-helical collagen (Stracke et 
al., 2000). MMP-21 is expressed in basal keratinocytes (Ahokas et al., 2003). 
MMP-23, also called a cysteine array MMP (CA-MMP), is predominantly 
expressed in reproductive tissues including ovary, testis and prostate. It shares 
sequence similarity with MMPs, but displays a different domain structure. It lacks 
the cysteine switch motif in the propeptide and the hemopexin domain. Instead it 
contains a cysteine-rich domain, followed by an immunoglobulin-like domain 
(Velasco et al., 1999). MMP-27 was first cloned from cultured primary chicken 
embryo fibroblasts and digests gelatin and casein (Yang and Kurkinen, 1998). 
MMP-28 is expressed in basal keratinocytes in skin and has been associated 
with wound repair (Saarialho-Kere et al., 2002). Its expression is also elevated in 
cartilage from patients with osteoarthritis (Kevorkian et al., 2004) and rheumatoid 
arthritis (Momohara et al., 2004). 
 
 
1.3 MEMBRANE TYPE-I MATRIX METALLOPROTEINASE (MT1-MMP)  
MT1-MMP was the first identified member of MT-MMP family. It was 
cloned and described by Sato et al. (1994) as a specific activator of progelatinase 
A (proMMP-2). MT1-MMP shares a common domain organisation with other 
MMPs and consists of a signal peptide (SP), a prodomain (Pro), a catalytic 
domain (Cat), a hinge region (linker-1, L1), a hemopexin domain (Hpx), a stalk 
region (linker-2, L2), a transmembrane domain (Tm) and a cytoplasmic tail (CP) 
(Sato et al., 1994) (Figure 1.2).  
 
 
Chapter 1  Introduction 
 
 26 
 
 
Figure 1.2: Domain structure of MT1-MMP: SP, signal peptide (M1- T20); Pro, 
prodomain (A21-R111); Cat, catalytic domain (Y112-G285); MT-Loop (163P-G170); L1, 
linker-1 (E286-I318); Hpx, hemopexin domain (C319-C508); L2, linker-2 (P509-S538); 
Tm, transmembrane domain (A539-F562); CP, cytoplasmic tail (R563-V582). 
 
 
MT1-MMP is one of the most studied MMPs, because of its involvement in 
many physiological and pathological processes. MT1-MMP has been shown to 
be involved in wound healing (Okada et al., 1997), bone development (Holmbeck 
et al., 1999; Zhou et al., 2000) and angiogenesis (Chun et al., 2004; Hiraoka et 
al., 1998; Zhou et al., 2000). The enzyme is expressed in human synovium and 
has been shown to promote synovial pannus invasion into cartilage in rheumatoid 
arthritis (Miller et al., 2009; Rutkauskaite et al., 2005). MT1-MMP expression 
level is elevated in tumors and is associated with cellular invasiveness and 
malignancy. The enzyme has been implicated in lung (Sato et al., 1994; 
Tokuraku et al., 1995), cervical (Gilles et al., 1996; Tsunezuka et al., 1996), colon 
(Ohtani et al., 1996), breast (Jiang et al., 2006; Tetu et al., 2006; Ueno et al., 
1997) and gastric (Nomura et al., 1995) cancers and is a potential target for anti-
cancer therapy. In fact, a selective inhibitor of MT1-MMP, DX2400, has been 
shown to slow tumor growth and the formation of metastatic lesions in the MDA-
MB-231 breast cancer xenograft mouse model (Devy et al., 2009). 
 
1.3.1 Substrates of MT1-MMP 
 
1.3.1.1 ECM components 
MT1-MMP cleaves a number of ECM molecules, among which collagen type 
I, II and III appear to be the major substrates (d'Ortho et al., 1997; Ohuchi et al., 
1997). MT1-MMP-deficient mice possess severe phenotypes, including 
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craniofacial dysmorphism, arthritis, osteopenia, dwarfism and fibrosis of soft 
tissues. The mutant mice show no signs of sexual maturation and die between 
days 50 and 90 after birth due to wasting. Importantly, cells derived from MT1-
MMP-deficient animals are unable to cleave type I/II collagen-rich matrices, 
suggesting that the abnormalities observed in the MT1-MMP-null mice are due to 
loss of the ability to degrade and remodel interstitial collagens (Holmbeck et al., 
1999). 
In addition to collagens, MT1-MMP has been shown to degrade fibronectin, 
tenascin, nidogen, aggrecan, perlecan (d'Ortho et al., 1997), fibrin (Hiraoka et al., 
1998), laminin 5 (Koshikawa et al., 2000) and lumican (Li et al., 2004).  
 
1.3.1.2 Soluble MMPs 
Although MT1-MMP is unable to cleave collagen type IV, a component of 
basement membranes, it triggers its degradation through activation of proMMP-2. 
Overexpression of MT1-MMP has been shown to enhance invasion of HT-1080 
cells into Matrigel, a reconstituted basement membrane-like matrix (Sato et al., 
1994). Interestingly, a colon epithelial cell line from MT1-MMP null mice 
transfected with an inducible expression system for MT1-MMP and implanted into 
wild-type mice grew rapidly when MT1-MMP expression was induced. In 
contrast, upon implantation into MMP-2 null mice, these cells grew very slowly, 
even in the presence of MT1-MMP. These results suggest that cooperation 
between MT1-MMP and MMP-2 is important for tumour growth in vivo (Taniwaki 
et al., 2007).  
MT1-MMP processes 72-kDa proMMP-2 to a 68-kDa intermediate form, 
and intermolecular cleavage of the intermediate proMMP-2 generates a 66-kDa 
fully active form (Atkinson et al., 1995). In this activation process, an assembly of 
a trimolecular complex of MT1-MMP-TIMP-2-proMMP-2 is essential (Butler et al., 
1998; Kinoshita et al., 1998; Strongin et al., 1995). TIMP-2 is an endogenous 
inhibitor of MT1-MMP. It binds to the catalytic domain of the enzyme, acting as a 
receptor for proMMP-2 (Fernandez-Catalan et al., 1998; Itoh et al., 1998). Since 
MT1-MMP in the ternary complex is inhibited by TIMP-2, another MT1-MMP 
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molecule is required to carry out proMMP-2 activation. MT1-MMP molecules form 
a homophilic complex through the Hpx domains. Overexpression of an MT1-
MMP mutant containing the hemopexin, transmembrane, and cytoplasmic 
domains inhibits proMMP-2 activation in a dominant-negative fashion (Itoh et al., 
2001; Lehti et al., 2002). TIMP-2 knockout mice, and cells derived from them, are 
deficient in proMMP-2 activation, supporting this widely accepted model.  
MT1-MMP has been shown to activate proMMP-13. The mechanism has 
not yet been elucidated, but TIMP-2 is not thought to be involved as MT1-MMP 
expressing cells from the TIMP-2 null mice efficiently activate proMMP-13 
(Knauper et al., 2002). 
 
1.3.1.3 Cell surface molecules 
MT1-MMP cleaves the core protein of syndecan-1, a transmembrane 
heparan sulfate proteoglycan expressed on adherent cells. It binds to fibronectin, 
thrombospondin and collagens and its shedding by MT1-MMP enhances cell 
migration, presumably by causing dissociation of cells from the ECM (Endo et al., 
2003).   
MT1-MMP has been implicated in proteolytic processing of integrins. It 
directly processes a single chain precursor of the αv integrin subunit (pro-αv) into 
heavy and light α-chains, stimulating cell migration on vitronectin (Deryugina et 
al., 2002; Ratnikov et al., 2002). 
Tissue transglutaminase (tTG) is a ubiquitously expressed integrin-binding 
adhesion co-receptor involved in binding of cells to fibronectin. Shedding of tTG 
by MT1-MMP has been shown to suppress cell adhesion and migration on 
fibronectin, but stimulated migration on collagen matrices (Belkin et al., 2001). 
 Low density lipoprotein receptor related protein, LRP, is a transmembrane 
endocytic receptor and a signaling molecule that regulates endocytosis and 
degradation of soluble MMPs (Strickland and Ranganathan, 2003). Proteolytic 
processing by MT1-MMP decreases the level of the cellular LRP, resulting in an 
increase in levels of soluble MMPs in the ECM and enhanced cell migration 
(Rozanov et al., 2004).  
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CD44, a hyaluronan receptor, is a well established substrate for MT1-
MMP (Kajita et al., 2001; Nakamura et al., 2004; Suenaga et al., 2005). 
Processing of CD44 by MT1-MMP has been shown to stimulate cell motility as 
measured by a phagokinetic track motility assay (Kajita et al., 2001; Mori et al., 
2002). MT1-MMP has been shown to bind the stem region of CD44 via its Hpx 
domain and cleave the receptor, releasing soluble 37-40 kDa and 50 kDa 
fragments into the medium (Suenaga et al., 2005). It is not clear how MT1-MMP-
mediated processing of CD44 stimulates cell migration. It is possible that the 
shedding simply releases cells from the ECM, but it is also possible that the 
released CD44 fragments stimulate cell motility in an autocrine and paracrine 
manner (Kajita et al., 2001). Excessive CD44 shedding has been associated with 
many pathological events. For instance, CD44 fragments have been shown to be 
elevated in rheumatoid arthritis (Haberhauer and Kittl, 1998; Kittl et al., 1997) and 
malignant metastasis (Guo et al., 1994; Masson et al., 1999; Yamane et al., 
1999). 
 
1.3.2 Regulation of MT1-MMP activity 
MT1-MMP expression and activity are tightly controlled. Once present on 
the cell surface, the enzyme is regulated by endogenous inhibitors, proteolytic 
processing, internalisation and localisation to motility-associated structures. 
 
1.3.2.1 Gene expression 
The human MT1-MMP gene consists of ten exons and nine introns. The 
MT1-MMP promoter has different structural and functional features compared to 
many other MMP genes. Transcription starts at multiple sites located in a cluster 
and a typical upstream TATA box is missing. The 5′-flanking region contains four 
CCAAT-boxes and one Sp-1 binding site, which has been shown to be important 
for MT1-MMP transcription in humans (Lohi et al., 2000). In contrast, an Egr-1 
site appears to be essential for MT1-MMP transcription in rodents (Haas et al., 
1999). As MT1-MMP has a wide variety of biological activities, the transcription of 
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the gene is likely to be tightly regulated, but the detailed mechanism is not 
known. 
Concanavalin A, ConA, was one of the first stimuli of MT1-MMP 
expression to be reported (Overall and Sodek, 1990; Yu et al., 1995). Type-I 
collagen also induces MT1-MMP expression and proMMP-2 activation (Azzam 
and Thompson, 1992; Haas et al., 1998; Theret et al., 1999). In contrast, type-IV 
collagen, laminin, fibronectin, gelatin and Matrigel are all ineffective in inducing 
proMMP-2 activation (Azzam and Thompson, 1992; Kadono et al., 1998; Theret 
et al., 1999; Thompson et al., 1994). Specific antibodies against α2β1 integrin, the 
major collagen-I receptor, have been shown to partially inhibit collagen-induced 
proMMP-2 activation, indicating its involvement in MT1-MMP upregulation 
(Theret et al., 1999). Upon collagen stimulation, an enhanced production of Egr-1 
transcription factor has been observed. Egr-1 has been shown to bind to the 
MT1-MMP promoter and enhance MT1-MMP transcription. Mutations in the Egr-1 
binding site abrogate the increased transcription of MT1-MMP in stimulated cells 
(Haas et al., 1999).  
Extracellular signal-regulated kinase (ERK) has been shown to be 
activated in cells cultured on a type-1 collagen matrix. Activated ERK induced 
MT1-MMP expression and subsequent cell migration (Takino et al., 2004). 
MT1-MMP is induced in response to PMA (phorbol 12-myristate 13-
acetate), also known as TPA (12-O-tetradecanoylphorbol-13-acetate) (Brown et 
al., 1990; Hofmann et al., 1998; Lehti et al., 1998; Lim et al., 1996). PMA is a 
phorbol ester originally extracted from croton oil. It is an activator of protein 
kinase C (PKC) and a potent tumor promoter (Isakov et al., 1985; Janoff et al., 
1970). 
Heat shock at 42°C has been reported to suppress MT1-MMP gene 
transcription in HT-1080 cells, resulting in inhibition of proMMP-2 activation and 
increased release of TIMP-2 from the cell surface (Sato et al., 1999). Flavonoids 
have been shown to inhibit MT1-MMP expression in human endothelial cells 
(Kim, 2003), whereas calmodulin negatively regulated transcription in cervical 
uterine fibroblasts (Ito et al., 1998). 
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1.3.2.2 Activation of MT1-MMP zymogen (proMT1-MMP) 
MT1-MMP is synthesised as a zymogen and requires removal of the 
propeptide to become an active enzyme. MT1-MMP contains a 108RRKR motif at 
the C-terminus of the prodomain, which is recognised by proprotein convertases 
(Sato et al., 1994). This sequence acts as a general recognition motif for at least 
four members of the secretory pathway processing enzymes of the protein 
convertase family: furin, PACE4, PC6 and PC7 (Zhou et al., 1999). Among them, 
furin was the first proprotein convertase to be described and is the best 
characterised member of the family. It is a ubiquitously expressed calcium- 
dependent serine endopeptidase, which is localised mainly in the trans-Golgi 
network. Furin has been shown to activate a wide variety of precursor proteins, 
including human stromelysin-3 zymogen (Nakayama, 1997; Pei and Weiss, 
1995). 
Studies by Yana and Weiss (2000) have demonstrated that proMT1-MMP 
is efficiently activated by furin. However, a furin-independent pathway also takes 
place. Interestingly, mutation of the 108RRKR motif to 108AAAA only partially 
prevented activation of proMT1-MMP, suggesting the existence of an alternative 
cleavage site for the proprotein convertases in the MT-MMP prodomain. Indeed, 
additional mutation of the R89 in the 86KAMRRPR motif to 89A completely 
prevented proMT1-MMP processing and blocked proteolytic activity of the 
enzyme (Yana and Weiss, 2000). As MT1-MMP is activated during secretion in 
the Golgi-network, the enzyme is expressed on the cell surface in its active form. 
 
1.3.2.3 Inhibition by endogenous inhibitors 
Inhibition is one of the most important mechanisms regulating MT1-MMP 
activity. TIMPs are endogenous inhibitors of metalloproteinases. The family 
consists of four members in vertebrates, TIMP-1,-2,-3 and -4 (Brew et al., 2000). 
TIMPs consist of two domains, referred to as the N- and C-terminal domains. The 
N-terminal inhibitory domain, when isolated, retains metalloproteinase inhibitory 
activity and forms a non-covalent 1:1 molar stoichiometric complex with MMPs 
(Murphy et al., 1991). MT1-MMP is inhibited by TIMP-2,-3 and -4, but not TIMP-1 
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(Will et al., 1996). Interestingly, primary mouse embryonic fibroblasts (MEFs) 
from TIMP-3 null mice have been reported to accelerate proMMP-2 activation 
independently of TIMP-2, suggesting that TIMP-3 may be an important inhibitor 
of MT1-MMP in vivo (English et al., 2006). This is also supported by the 
localisation of TIMP-3, which unlike other TIMPs, is sequestered in the ECM and 
at the cell surface (Pavloff et al., 1992). 
In addition to TIMPs, another endogenous inhibitor of MT1-MMP has been 
reported. RECK, reversion-inducing cysteine rich protein with Kazak motif, is a 
110 kDa GPI-anchored glycoprotein. It is expressed in various human tissues 
and untransformed cells, but undetectable in tumor-derived cell lines. Although 
RECK was originally discovered as an MMP-9 inhibitor (Takahashi et al., 1998), it 
also inhibits MMP-2 and MT1-MMP (Oh et al., 2001). Disruption of the RECK 
gene is embryonic lethal and mutant mice show defects in collagen fibrils, basal 
lamina, and vascular development, a phenotype that may result from excessive 
MMP activity (Oh et al., 2001). 
 Testicans are chondroitin/heparan sulfate proteoglycans expressed 
predominantly in the normal brain. Their expression level has been shown to 
decrease as tumor grade increases. Testican-1, -3 and a splicing variant of 
testican-3, N-tes, have all been shown to inhibit MT1-MMP. Overexpression of 
testican-1, -3 or N-tes in human embryonic kidney 293T cells has been shown to 
inhibit MT1-MMP-mediated processing of proMMP-2. Interestingly, coexpression 
of testican-2 with other testican family members abrogates the inhibitory effect 
(Nakada et al., 2003). The mechanism of MT1-MMP inhibition by testicans is 
currently unknown. 
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1.3.2.4 Autolytic degradation and processing  
Active MT1-MMP undergoes further processing to an inactive ~40 kDa 
species (Lehti et al., 1998; Stanton et al., 1998; Toth et al., 2002). This species 
lacks the catalytic domain and its increase is concomitant with proMMP-2 
activation (Hernandez-Barrantes et al., 2000; Stanton et al., 1998). This suggests 
that MT1-MMP processing may be a consequence of increased MT1-MMP 
activity on the cell surface. In vitro studies have shown that the 40 kDa form 
could be generated by cleavage of membrane-bound native MT1-MMP with 
several recombinant MMPs, including active MT1-MMP and MMP-2 (Stanton et 
al., 1998). It raises the possibility that truncation of MT1-MMP represents a self-
regulatory end-point in proMMP-2 activation (Stanton et al., 1998).  Analysis of 
the released forms of the enzyme in various cells has revealed the presence of 
two major soluble fragments of 50 kDa and 18 kDa in the medium (Toth et al., 
2002). Mass spectrometry analysis of the purified 50-kDa soluble form has 
revealed that this species is formed due to cleavage of Val524-Ile525 bond in the 
linker-2 region (Toth et al., 2005). As MT1-MMP must be membrane-tethered to 
remain functional, shedding of the ectodomain constitutes a mechanism for 
downregulating the activity of the enzyme (Cao et al., 1995; Hotary et al., 2000; 
Itoh, 2006; Sabeh et al., 2004). 
 
1.3.2.5 Internalisation from the cell surface 
MT1-MMP is internalised from the cell surface by clathrin-mediated (Jiang 
et al., 2001; Uekita et al., 2001) and caveolae-mediated endocytic pathways 
(Remacle et al., 2003). The clathrin-dependent internalisation is regulated 
primarily by the LLY573 motif in the cytoplasmic tail of the enzyme. This di-leucine 
motif is a binding site for the µ2 subunit of adaptor protein 2 (AP-2), a component 
of clathrin-coated pits (Uekita et al., 2001). AP-2 binds to epidermal growth factor 
receptor substrate 15 (Eps15), which docks AP-2 to the membrane, regulating 
coated-pit assembly (Benmerah et al., 1999). Interestingly, selective blocking of 
clathrin-dependent endocytosis with a dominant negative form of Eps15 (EGFP-
Eps ∆95-295) in HT-1080 cells did not completely inhibit MT1-MMP 
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internalisation, suggesting the existence of a clathrin-independent mechanism. 
Indeed, a cholesterol-binding drug, nystatin, which disturbs caveolae-mediated 
endocytosis without interfering with clathrin-coated pit formation, has been shown 
to decrease MT1-MMP internalisation in HT-1080 cells. Moreover, MT1-MMP has 
been shown to co-immunoprecipitate with caveolin-1 in HT-1080 cells (Remacle 
et al., 2003).   
Although internalisation is thought to downregulate the cell surface amount 
of MT1-MMP, an internalisation-deficient mutant of MT1-MMP (MT1-∆CP) failed 
to stimulate cell migration and invasion when overexpressed in CHO-K1 cells 
(Uekita et al., 2001). This suggests that internalisation may provide a mechanism 
for the relocalisation of MT1-MMP on the cell surface. In fact, MT1-MMP 
endocytosis has been shown to take place primarily at the adherent edge 
(Remacle et al., 2003; Uekita et al., 2001), and the internalised molecules co-
localise with Rab4-positive recycling endosomes and are recycled to the cell 
surface within 60 minutes (Remacle et al., 2003; Wang et al., 2004). In Madin-
Darby Canine Kidney (MDCK) epithelial cells, MT1-MMP has been shown to co-
recycle with MT3-MMP (Wang et al., 2004). The DKV582 sequence in the 
cytoplasmic tail of the enzyme is required for the recycling, although the exact 
mechanism is unknown (Wang et al., 2004).  
Palmitoylation is the reversible attachment of fatty acids, such as palmitic 
acid, to cysteine residues of membrane proteins. Studies in COS-7 and HT-1080 
cells using metabolic labeling with [3H] radiolabeled palmitate have revealed that 
MT1-MMP is palmitoylated at Cys574. Palmitoylation-deficient mutants of MT1-
MMP, Cys574Ala or Cys574Ser, were internalised much slower than the wild-
type enzyme and failed to promote MT1-MMP-dependent cell migration. This 
suggests that palmitoylation regulates internalisation of the enzyme (Anilkumar et 
al., 2005). 
At least a fraction of the internalised MT1-MMP has been shown to 
undergo lysosomal degradation (Bravo-Cordero et al., 2007; Takino et al., 2003). 
CD63 tetraspanin, a component of late endosomes and lysosomes membranes, 
has been shown to interact with the Hpx domain of MT1-MMP via its N-terminal 
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domain (Takino et al., 2003). Treatment with chloroquine, an inhibitor of 
lysosomal proteinases, suppressed degradation of internalised MT1-MMP and 
enhanced its accumulation in CD63-positive lysosomes (Takino et al., 2003). 
 
1.3.2.6 Polarised localisation of MT1-MMP on the cell surface 
Localisation of MT1-MMP on the cell surface is highly polarised (Galvez et 
al., 2001; Itoh et al., 2001; Mori et al., 2002; Sato et al., 1997; Takino et al., 
2003). Cells cultured in two dimensional (2D) culture systems accumulate MT1-
MMP at the migration front (lamellipodium) and substrate attachment sites. Two 
proteins, CD44 and cortactin, have been shown to be involved in enzyme 
localisation (Artym et al., 2006; Clark and Weaver, 2008; Clark et al., 2007; Mori 
et al., 2002). More recent studies have focused on intracellular vesicular 
transport as a major regulator of MT1-MMP localisation on the cell surface 
(Bravo-Cordero et al., 2007; Remacle et al., 2005; Wiesner et al., 2010).  
 
 
1.4 INTRACELLULAR TRANSPORT AND KINESIN MOTOR PROTEINS 
Intracellular transport is responsible for organisation of macromolecules 
and organelles within the cell in a temporal and spatial manner. Intracellular 
motion was first reported in the 18th century, and chromosome movements were 
already well documented in the 19th century (Vale, 2003). Organelle movement 
through the cytoplasm can be observed in almost all cell types and is particularly 
well developed in neurons, where the organelles are transported in axons of up 
to 1 metre in length (Schliwa, 1984).  
 
1.4.1 Discovery of kinesin motor proteins 
Initial studies on intracellular trafficking of organelles revealed that in squid 
giant axons, organelles move along cytoplasmic filaments. These filaments were 
visualised by video-enhanced differential interference contrast microscopy and 
guided directed movement of organelles in the presence of ATP (Vale et al., 
1985b). Interestingly, organelles moving in the same or opposite directions along 
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the same filament could pass each other without colliding, suggesting that each 
transport filament provided several tracks (Schnapp et al., 1985). Using electron 
microscopy and immunofluorescence, these transporting filaments were later 
identified as microtubules (Schnapp et al., 1985). To better understand the 
phenomenon of organelle transport, a reconstituted system has been developed 
(Vale et al., 1985b). Axoplasm from the squid giant axon was separated into 
soluble supernatant and organelle-enriched fractions. Movement of isolated 
organelles along microtubules occurred only in the presence of axoplasmic 
supernatant and ATP. The axoplasmic supernatant was shown to support 
movement of microtubules along a glass surface and carboxylated latex beads 
along microtubules. These data suggested that translocation of organelles, beads 
and microtubules was supported by a soluble factor present in the axoplasmic 
supernatant. This soluble factor was sensitive to heat, trypsin, 5 mM AMP-PNP 
(adenylyl imidiophosphate, a non-hydrolysable ATP analog), and 100 µM 
vanadate (Vale et al., 1985b). Purification of the factor was possible due to its 
unusual property of forming a high affinity complex with microtubules in the 
presence of AMP-PNP (Vale et al., 1985a). The isolated protein was named 
‘kinesin’, from the Greek word kinein, meaning to move (Vale et al., 1985a).  
Discovery of two new genes that showed high homology with the 350 
amino acid sequence of the motor domain of the first identified kinesin, 
suggested the existence of a superfamily (Enos and Morris, 1990; Meluh and 
Rose, 1990). Today the kinesin superfamily (KIF) has more than 600 members 
identified from different species, allowing directional intracellular localisation of 
various cargos, including membranous organelles, protein complexes and 
mRNAs to their appropriate locations in the cell  (Marx et al., 2005). The human 
genome-sequencing project has revealed the presence of 45 H.sapiens kinesin 
genes (Miki et al., 2001). 
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1.4.2 Kinesin domain organisation 
The first identified member of the kinesin superfamily was a ‘conventional 
kinesin’ or kinesin-1 (Vale et al., 1985a). This prototypical member of the kinesin 
superfamily consists of two 120-kDa heavy chains (KHCs) and two 64-kDa light 
chains (KLCs) (Vale et al., 1985a). When observed by low-angle rotary-
shadowing microscopy, it appears as a rod-like structure composed of two 
globular heads, a stalk and a fan-like end (Hirokawa et al., 1989). All kinesins 
possess a globular motor domain, also called the head, which shows high 
homology between kinesins and contains microtubule- and ATP-binding sites 
(Hirokawa et al., 1989; Scholey et al., 1989). Beyond the motor domain each 
kinesin contains unique sequences (Hirokawa and Takemura, 2005; Vale, 2003). 
The head is connected to a neck linker, which is a mechanical element that 
undergoes nucleotide-dependent conformational changes (Rice et al., 1999). Its 
docking and undocking to microtubules creates a power stroke and determines 
directionality of the kinesin movement (Rice et al., 1999; Vale and Milligan, 
2000). The neck linker is followed by a stalk region or coiled-coil region, which 
plays an essential role in kinesin dimerisation (Marx et al., 2005). The coiled-coil 
region leads to a globular tail domain that regulates the cargo-binding affinity of 
the kinesin (Vale and Fletterick, 1997). Kinesin domain organisation is outlined in 
Figure 1.3 A. The kinesin light chain (KLC), present in conventional kinesins, 
localises to the tail region and modulates the interaction with cargo vesicles 
(Hirokawa et al., 1989; Stenoien and Brady, 1997) (Figure 1.3 B). Specificity of 
cargo attachment is provided by the tail region and light chains of the different 
kinesins.  
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A.                                                            B. 
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Figure 1.3: Kinesin domain organisation. (A) Typical kinesin consists of a 
motor domain (also called a head), a neck region, a stalk region (also called a 
coiled-coil region), and a cargo-binding tail domain. The motor domain contains 
microtubule- and ATP-binding sites. (B) Domain organisation of the conventional 
kinesin. Apart from the standard domains, the conventional kinesin contains the 
kinesin light chain (KLC), which localises at the kinesin tail domain and 
modulates interaction with the cargo. 
 
 
The motor domain can be localised at the N- (N-type kinesins) or C-
terminus (C-type kinesins) of the molecule, as well as in the middle (M-type 
kinesins) (Figure 1.4 B). Microtubules form a dynamic and polarised 
cytoskeleton. In fibroblasts, the microtubule plus ends elongate towards the 
plasma membrane, whereas the minus ends are stably tethered to the 
microtubule organising centre (MTOC) (Caviston and Holzbaur, 2006) (Figure 1.4 
A). N-type kinesins generally move towards the plus end of microtubules, C-type 
kinesins move towards the minus end, whereas M-kinesins have plus-end 
directed motility and a unique microtubule-depolymerising activity (Hirokawa, 
1998; Yildiz and Selvin, 2005).  
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A. 
 
B. 
 
 
 
Figure 1.4: (A) Organisation of microtubules in fibroblasts. Microtubule plus 
ends grow dynamically from the microtubule organising centre (MTOC), whereas 
the minus ends are stably tethered. (B) Positioning of the motor domain in N-, 
C- and M-type kinesins. N-type kinesins contain the motor domain at the N-
terminus and move towards microtubule plus ends. C-type kinesins contain the 
motor domain at the C-terminus and move towards microtubule minus ends. M-
type kinesins have plus-end direct motility and contain the motor domain in the 
middle. 
 
 
1.4.3 Kinesin nomenclature  
Early classification of kinesins led to confusion, since the same proteins 
were named by different criteria, including the position of the motor core and their 
evolutionary relation to other kinesins. To overcome this problem, a new 
standardised nomenclature of kinesins has been proposed (Lawrence et al., 
2004).  All known kinesins have been divided into 14 families (Table 1.2). Each 
family bears the name ‘kinesin’ followed by an Arabic number; for instance the 
family of the conventional kinesin, also known as kinesin heavy chain (KHC), is 
now named kinesin-1 (Lawrence et al., 2004).  
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Table 1.2: Nomenclature of kinesin motor proteins. Abbreviations: v, splicing 
variants. 
 
Type Family Gene name 
N  Kinesin-1  KIF5A, KIF5B, KIF5C,   
N  Kinesin-2  KIF3A,  KIF3B,  KIF3C,  KIF17 
N  Kinesin-3 
 KIF1A,  KIF1B (-v1,-v2),  KIF1C, KIF13A, KIF13B,   
 KIF14, KIF28, KIF16A, KIF16B 
N  Kinesin-4  KIF4A,  KIF4B ,KIF21A,  KIF21B,  KIF7,  KIF27 
N  Kinesin-5  KIF11 
N  Kinesin-6  KIF20A,  KIF20B,  KIF23 (-v1,-v2) 
N  Kinesin-7  KIF10 
N  Kinesin-8  KIF19A,  KIF19B, KIF18A,  KIF18B 
N  Kinesin-9  KIF9 (-v1,-v2,-v3),  KIF6 
N  Kinesin-10  KIF22 
N  Kinesin-11  KIF26A,  KIF26B 
N  Kinesin-12  KIF12,  KIF15 
M  Kinesin-13  KIF2A,  KIF2B,  KIF2C 
C  Kinesin-14  KIFC1,  KIFC2, KIFC3,  KIF25 (-v1,-v2) 
 
1.4.4 Diversity of kinesin cargoes 
Kinesins were once believed to exclusively transport membrane 
organelles. However, it is now well established that they provide specific 
transport of a wide variety of diverse cargoes, including organelles, intracellular 
vesicles, protein complexes, RNA granules and chromosomes (Hirokawa, 1998; 
Hirokawa and Takemura, 2005; Kanai et al., 2004; Mayr et al., 2007; Mazumdar 
et al., 2004). The cargo-motor interaction has a high level of specificity, although 
redundancy may also take place. Studies on the kinesin-1 family well illustrate 
the diversity of intracellular trafficking. This family comprises three members, 
namely KIF5A, KIF5B, and KIF5C, and was initially reported to be involved in fast 
axonal transport of membranous organelles including mitochondria and 
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lysosomes (Nakata and Hirokawa, 1995; Tanaka et al., 1998; Vale et al., 1985a; 
Vale et al., 1985b). Furthermore, the KIF5 motors have been shown to transport 
intracellular vesicles (Jaulin et al., 2007; Setou et al., 2002), soluble tubulin 
(Kimura et al., 2005) and RNA granules (Kanai et al., 2004). 
 
1.4.5 Kinesin-cargo interaction 
Major emphasis has been placed on the identification and characterisation 
of proteins that link kinesins to a variety of intracellular cargoes and provide 
specificity of kinesin-mediated transport. The first such protein to be discovered 
was kinectin, a putative kinesin receptor, believed to attach various organelles to 
KIF5 motors (Kumar et al., 1995; Toyoshima et al., 1992). However, kinectin-
deficient mice are viable, fertile and showed no gross abnormalities up to 1 year 
of age. Furthermore, distribution of mitochondria and lysosomes is not affected in 
these mice, suggesting that it is not the universal receptor for the kinesin-1 family 
(Plitz and Pfeffer, 2001).  
New interaction partners of kinesins, which link them to their cargo, have 
been identified using yeast two hybrid screening. KIF5 motors have been shown 
to interact through KLC with the c-jun NH2-terminal kinase (JNK)-interacting 
protein (JIP)-1, JIP-2 and JIP-3, which are scaffolding proteins for the JNK kinase 
signaling pathway. This interaction was shown to be important for the KIF5-
mediated transport of the apolipoprotein E receptor 2 (ApoER2) (Bowman et al., 
2000; Verhey et al., 2001). Similarly to JIPs, mLin-2, -7, and -10 have been 
shown to form a scaffold carrying vesicles containing the N-methyl-D-aspartate 
(NMDA) receptor subunit 2B (NR2B subunit) and the entire complex was 
transported to dendrites by KIF17 (Setou et al., 2000). These studies indicate 
that the KIF5 and KIF17 motors are linked to their cargoes indirectly via 
scaffolding proteins. However, not all kinesins utilise the scaffolding proteins to 
link to their cargoes. KIF3 motors have been proposed to link themselves to the 
vesicles via the structural protein fodrin (Takeda et al., 2000). KIF20A 
(Rabkinesin-6), has been shown to connect to its cargo through Rab6 GTPase 
protein (Echard et al., 1998). KIF13A has been reported to transport vesicles 
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containing the mannose-6-phosphate receptor (M6PR) to plasma membrane 
through interaction with the adaptor protein 1 (AP-1) (Nakagawa et al., 2000). 
Amyloid precursor protein (APP) has been shown to interact directly through its 
C-terminus with the KLC of KIF5 motors (Kamal et al., 2000). Schematic 
representation of the mechanisms utilised by kinesins to attach to cargoes is 
summarised in Figure 1.5. 
 
 
Figure 1.5: Schematic representations of mechanisms utilised by kinesins 
to attach to their cargos. AP, adaptor proteins. Modified from (Klopfenstein et 
al., 2000). 
 
1.4.6 Regulation of kinesins 
Kinesins use energy derived from ATP hydrolysis to walk along 
microtubules (Yildiz and Selvin, 2005). Alanine-scanning mutagenesis studies 
revealed that the interaction between kinesins and microtubules has an 
electrostatic character and positively charged microtubule-interacting kinesin 
residues interact with negatively charged glutamic acid residues at the C-
terminus of α/β tubulin subunits (Woehlke et al., 1997). When not bound to the 
cargo, the kinesin’s motor domain is inhibited by the tail domain to minimise the 
dispersion of ATP and to prevent mislocalisation of kinesins in the cell (Coy et al., 
1999; Hackney and Stock, 2000). Deletion of the tail has been shown to activate 
ATPase without the need for cargo binding, and subsequent addition of the tail 
peptide re-established the inhibition. Interestingly, the tail domain does not 
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interfere with the binding to microtubules, but rather reduces the motor’s stepping 
rate (Coy et al., 1999).  
The mechanism controlling cargo release from kinesins is still not clear. 
However, new light has been shed on the question with the discovery that the 
neuronal, plus-end-directed motor KIF17 releases its cargo upon phosphorylation 
of its C-terminal tail domain (Ally et al., 2008; Guillaud et al., 2008). KIF17 has 
been demonstrated to bind to the scaffolding protein Mint1 (mLin10) to transport 
the N-methyl-D-aspartate (NMDA) receptor subunit 2B (NR2B) in neurons (Setou 
et al., 2000). KIF17 tail domain has been shown to be phosphorylated on Ser1029 
by calcium-calmodulin-dependent protein kinase II (CaMKII). Using direct 
visualisation of protein-protein interactions by FRET (fluorescence resonance 
energy transfer), it has been demonstrated that CaMKII-dependent 
phosphorylation of KIF17 disrupted its interaction with Mint1, resulting in release 
of the transported cargo (Ally et al., 2008; Guillaud et al., 2008). Further studies 
are required to assess if phosphorylation of the tail domain is a common 
mechanism shared by kinesins to release their cargoes. 
 
1.4.7 Intracellular vesicular transport of MT1-MMP 
 The molecular mechanism of intracellular transport of MT1-MMP is not 
well understood. MT1-MMP has been reported to be delivered to the plasma 
membrane inside intracellular Golgi-derived vesicles moving bidirectionally along 
the microtubule cytoskeleton (Bravo-Cordero et al., 2007; Remacle et al., 2005; 
Wiesner et al., 2010). Dissociation of these vesicles by nocodazole suggests an 
essential role for the microtubule cytoskeleton in the vesicular trafficking of MT1-
MMP (Remacle et al., 2005). MT1-MMP-containing vesicles have been shown to 
accumulate at the sites of active collagen degradation during MDA-MB-231 cell 
invasion in 3D-Col I matrices, suggesting that the polarised exocytosis of the 
enzyme may regulate its localisation to proinvasive structures (Bravo-Cordero et 
al., 2007). In that study, polarised exocytosis was induced by β1 integrin-
mediated binding to collagen and regulated by Rab8, a member of the Rab family 
of Ras-related GTP-ases.  
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A more recent study has implicated KIF5B and KIF3A/KIF3B kinesin motor 
proteins in trafficking of MT1-MMP-containing vesicles to the plasma membrane 
in primary human macrophages (Wiesner et al., 2010). Knockdown of KIF5B or 
KIF3A/KIF3B was shown to decrease cell surface levels of MT1-MMP as well as 
MT1-MMP-dependent matrix degradation and shedding of cell surface receptors 
CD44 and syndecan-1 (Wiesner et al., 2010). It is not clear if the same kinesins 
regulate trafficking of MT1-MMP-containing vesicles in other cell types.  
  
 
1.5 LOCALISATION OF MT1-MMP TO MOTILITY-ASSOCIATED 
STRUCTURES 
Localisation of MT1-MMP on the cell surface is highly polarised (Galvez et 
al., 2001; Mori et al., 2002; Sato et al., 1997; Takino et al., 2003). In order to 
facilitate directed cell migration, MT1-MMP activity must be concentrated at the 
migration front, where the enzyme creates the path for migrating cells. In 
osteoclasts MT1-MMP has been detected at specific plasma membrane areas 
corresponding to lamellipodia and podosomes involved, respectively, in migratory 
and attachment activities of these cells (Sato et al., 1997). Localisation of MT1-
MMP to motility-associated structures has also been reported in actively 
migrating endothelial cells (Galvez et al., 2001), indicating that this may be an 
important regulatory mechanism for the enzyme.  
 
1.5.1 Motility-associated structures 
The ability of cells to migrate through tissues involves formation of motility-
associated plasma membrane protrusive structures, including lamellipodia and 
invadopodia. These structures provide new cell adhesions to the extracellular 
substrate and accumulate proteolytic enzymes, allowing for the focal degradation 
of the ECM.  
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1.5.1.1 Lamellipodium 
The lamellipodium, also referred to as a leading lamella or a leading edge, 
is a thin (approximately 0.2 µm) membrane that protrudes at the front of 
spreading or migrating cells (Abercrombie, 1980). Microinjection of fluorescent 
rhodamine-actin into living fibroblasts revealed that the lamellipodium is a primary 
site of actin incorporation (Glacy, 1983). The Arp2/3 complex has been shown to 
localise to the lamellipodium (Machesky et al., 1997; Welch et al., 1997) and 
controls the assembly of a branching network of actin filaments (Mullins et al., 
1998). It binds to preexisting actin filaments (mother filaments) and initiates 
nucleation of a new filament at a 70° angle. The Arp2/3 complex has low intrinsic 
activity and requires activation to initiate actin nucleation.   
Arp2/3 activators, referred to as nucleation promoting factors (NPF), 
comprise members of a Wiscott-Aldrich-syndrome protein (WASP) family, 
including WASP, N-WASP, WAVE-1, -2 and -3 (Machesky and Insall, 1998; Miki 
et al., 1998). Both WASP and N-WASP bind to activated Cdc42 and Rac 
(Aspenstrom et al., 1996). Cdc42 and Rac are members of a Rho family of small 
GTPases, which have been shown to induce formation of filopodia and 
lamellipodia, respectively (Kozma et al., 1995; Nobes and Hall, 1995; Ridley et 
al., 1992) (Figure 1.6). The activation of Rac and Cdc42 can be mediated by 
stimulation by both growth factors (Hall, 1998; Ridley et al., 1992) and integrins 
(Price et al., 1998). Hyaluronic acid (HA) binding to CD44 has been shown to 
activate Rac1 and induce lamellipodia outgrowth (Oliferenko et al., 2000). Recent 
evidence indicates that whereas WAVE-2 is required for lamellipodia formation, 
WAVE-1 and N-WASP are dispensable (Yamaguchi et al., 2005; Yamazaki et al., 
2003). 
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Figure 1.6: Effect of Cdc42 and Rac activation on actin organisation in 
Swiss 3T3 fibroblasts. (A) Non-activated cells contain very few organised actin 
filaments. (B) Cdc42 activation induces filopodia formation. (C) Rac activation 
induces lamellipodia formation. Modified from (Hall, 1998). 
 
Actin filament branches induced by activation of the Arp2/3 complex have 
been found to be inherently metastable, dissociating from the mother filament 
with a half life of 500 seconds (Blanchoin et al., 2000). Stabilisation of the branch 
points is therefore required for sustained actin branching. Cortactin, a cortical 
actin binding protein, has been reported to stabilise branched actin networks after 
they are formed (Uruno et al., 2001; Weaver et al., 2001).  Cortactin has been 
shown to localise to lamellipodia and promote lamellipodia persistence (Bryce et 
al., 2005; Weed et al., 1998; Weed et al., 2000). 
 
1.5.1.2 Invadopodium 
Invadopodia, or foot processes, are defined as actin-rich adhesions which 
establish new contacts to the substratum and degrade components of the ECM. 
Invadopodia were discovered in fibroblasts transformed with the src oncogene 
and they have similar function and molecular characteristics to podosomes 
(Chen, 1989; Chen et al., 1985). Both invadopodia and podosomes depend on 
Src-kinase and branched actin assembly, however, they have different 
morphology and are present in different cell types. Podosomes have been 
reported in monocyte-derived cells such as macrophages (Marchisio et al., 1987) 
and osteoclasts (Marchisio et al., 1984), whereas invadopodia have been 
associated with invasive tumour cells (Chen, 1989; Mueller and Chen, 1991). 
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Both invadopodia and podosomes are enriched in Src-kinase substrates, 
including cortactin (Bowden et al., 1999),  p130Cas, Tks5/FISH (Seals et al., 
2005), dynamin-2 (Baldassarre et al., 2003)  and N-WASP (Mizutani et al., 2002; 
Yamaguchi et al., 2005).  
Invadopodia differ from lamellipodia in their use of use of effectors to 
stimulate actin polymerization (Oser et al., 2009). Formation and maturation of 
invadopodia have been shown to involve four distinct stages: (1) formation of 
invadopodium precursor, (2) actin polymerization, (3) stabilization of invadopodia 
and (4) matrix degradation (Oser et al., 2009). Formation of invadopodia in 
response to epidermal growth factor (EGF) has been shown to rely on N-WASP 
and Arp2/3 complex, and their upstream regulators, Nck1, Cdc42 and WIP. 
WAVE-1, but not WAVE-2, has been shown to be important for invadopodia-
associated matrix degradation, but not for invadopodia formation (Yamaguchi et 
al., 2005). Cofilin, a critical regulator of actin dynamics, has been reported to 
stabilise invadopodia and its knockdown resulted in small, less invasive, shorter-
lasting invadopodia (Yamaguchi et al., 2005). Adhesion receptors found in 
invadopodia include integrins (Mueller et al., 1999) and CD44 (Bourguignon et 
al., 2001; Chabadel et al., 2007).The role of cortactin has been of particular 
interest in the invadopodia field. It is thought to be involved in invadopodia 
formation and is a widely accepted marker for these structures (Artym et al., 
2006). In the initial stage of invadopodium formation cortactin has been shown to 
form a scaffold that brings together N-WASp, Arp2/3 and cofilin to form an 
invadopodium precursor. Once the precursor is formed, cortactin becomes 
phosphorylated which releases cofilin, resulting in the formation of cofilin-
mediated free barbed ends for actin polymerization. Following recruitment of 
MT1-MMP, dephosphorylation of cortactin allows the formation of a mature 
matrix-degrading invadopodium (Oser et al., 2009). 
The function of invadopodia is to provide focal pericellular degradation of 
the ECM. MT1-MMP has been shown to be a key invadopodial enzyme 
responsible for matrix degradation (Artym et al., 2006; Clark and Weaver, 2008; 
Clark et al., 2007; Nakahara et al., 1997). Invadopodia are believed to have a 
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role in cancer cells invasion. It has been proposed that invadopodia are required 
for degradation of the basement membrane (BM), a thin highly cross-linked 
meshwork that separates epithelial cells from connective tissues. However, 
conclusive evidence supporting this hypothesis has yet to be reported.   
Invadopodia can be induced in vitro by seeding cancer cells onto a matrix 
cushion. They can be visualised as actin/cortactin-rich puncta and their activity 
detected by degradation of fluorescently-labeled matrix. Degradation of 
underlying matrix by invadopodia results in fluorescence negative cavities, which 
can be visualised by confocal microscopy (Artym et al., 2006; Bowden et al., 
1999; Bowden et al., 2006; Chen et al., 1985; Clark et al., 2007; Weaver, 2006; 
Yamaguchi et al., 2006).  
Invadopodia have been less characterised in vivo, and future studies are 
needed to confirm and assess their presence. If invadopodia are indeed 
specialised cell structures involved in cancer invasion, then strategies aimed at 
disrupting invadopodia could form the basis of novel anti-invasive therapies 
(Weaver, 2006). 
 
1.5.2 Lamellipodia and invadopodia associated proteins: Role of CD44 and 
cortactin 
 
1.5.2.1 CD44  
CD44 is a widely expressed type I transmembrane glycoprotein, 
traditionally known as ‘homing factor’, due to its involvement in lymphocyte 
homing (Pure and Cuff, 2001). It is a principal receptor for hyaluronic acid (HA) 
(Aruffo et al., 1990) and is closely associated with the actin cytoskeleton (Tsukita 
et al., 1994). CD44 accumulates in lamellipodia (Kawano et al., 2000; Mori et al., 
2002; Okamoto et al., 1999a) and invadopodia (Bourguignon et al., 2001; 
Chabadel et al., 2007). The protein interacts with ezrin/radixin/moesin (ERM) 
proteins (Tsukita et al., 1994; Yonemura et al., 1998) and ankyrin (Bourguignon 
et al., 1992), both of which bind to actin filaments.  
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CD44 is encoded by a single gene located on chromosome 11p13 and 
contains 20 exons, which can produce a large number of protein products due to 
alternative splicing (Screaton et al., 1992). The most common form of CD44, 
referred to as standard CD44 or hematopoietic CD44 (CD44H), consists of an N-
terminal signal sequence (exon 1), a Link-homology hyaluronan-binding 
sequence (exons 2 and 3), a stem region (exon 4, 5 16 and 17), a single-pass 
transmembrane domain (exon 18) and a cytoplasmic domain (exon 20) (Figure 
1.7). The cytoplasmic tail of CD44 contains ERM and ankyrin binding sites (Legg 
et al., 2002; Tsukita et al., 1994). Alternative splicing of CD44 involves insertion 
of different arrangements of exons 6-15 (also known as variant exons v1-v10) 
into the stem region. The amino acid sequence of CD44 predicts a theoretical 
molecular weight of 37 kDa, however, the estimated weight of the protein by 
SDS-PAGE is 80-95 kDa. This is due to extensive post-translational glycosylation 
of the ectodomain (Martin et al., 2003). Expression of alternatively spliced 
isoforms (CD44v) has been reported for several human cancers (Sasaki et al., 
1998; Tokue et al., 1998), but the exact roles of these isoforms remains unclear. 
 
 
Figure 1.7: (A) CD44 genomic organisation. The human gene encoding CD44 
consists of 20 exons. CD44 has multiple isoforms containing alternatively spliced 
exons 6-15, which are also known as variant exons v1-v10. The most common 
form of CD44 (CD44H) comprises exons 1-5, 16-18 and 20. (B) Domain 
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organisation of CD44H. CD44H contains a ligand binding domain, a stem 
region, a transmembrane domain (Tm) and cytoplasmic domain (CP). The 
cytoplasmic domain contains ERM- and ankyrin-binding sites. 
 
 
Proteolytic shedding of CD44 has emerged as an important regulatory 
mechanism for this protein (Okamoto et al., 1999b). The soluble form of CD44 
(sCD44) has been shown to be elevated in the serum of patients with advanced 
gastric or colon cancer and decreased after surgical resection of tumors (Guo et 
al., 1994; Ristamaki et al., 1997). Shedding of CD44 can be triggered by different 
stimuli, including activation of protein kinase C (PKC), extracellular Ca2+ influx, 
activation of Ras or activation of Rac (Kawano et al., 2000; Okamoto et al., 
1999a). Shedding of the CD44 ectodomain has been shown to be mediated by 
both MMPs and ADAMs (a disintegrin and metalloproteinase) and can be 
blocked by inhibitors of metalloproteinases (Kajita et al., 2001; Nakamura et al., 
2004; Okamoto et al., 1999b). Among the ADAM family, ADAM-10 and ADAM-17 
have been implicated in CD44 cleavage (Nagano et al., 2004) (Figure 1.8). 
Among the MMPs, MT1-MMP has been shown to shed CD44 and promote cell 
migration (Kajita et al., 2001; Nakamura et al., 2004; Suenaga et al., 2005). 
Interestingly, MT1-MMP has been reported to bind directly to the CD44 stem 
region through its Hpx domain and this interaction plays a crucial role in the 
shedding (Mori et al., 2002; Suenaga et al., 2005). The shedding of CD44 
ectodomain has been shown to be followed by further proteolytic processing of 
the residual transmembrane and cytoplasmic domains, resulting in the release of 
a CD44 intracellular domain (ICD) fragment (Murakami et al., 2003; Okamoto et 
al., 2001). This ICD fragment is proposed to act as a signal transduction 
molecule, translocating to the nucleus and activating gene transcription 
(Okamoto et al., 2001) (Figure 1.8). 
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Figure 1.8: Shedding of CD44. CD44 is shed by cleavage of its ectodomain by 
MT1-MMP, ADAM-10 or ADAM-17, releasing soluble fragments (sCD44) to the 
extracellular milieu. The residual transmembrane (red) and cytoplasmic (blue) 
domains undergo further processing, resulting in the release of a CD44 
intracellular domain (ICD) fragment. The ICD fragment has been proposed to 
translocate to the nucleus and activate gene transcription. Modified from (Thorne 
et al., 2004). 
 
 
CD44 has been implicated in many biological processes, including 
lymphocyte homing and activation (Arch et al., 1992; Goldstein et al., 1989), cell 
adhesion, cell migration and invasion (Gunthert et al., 1991; Martin et al., 2003; 
Thomas et al., 1992). CD44-null mice were viable, developed normally and, if left 
unchallenged, showed few phenotypic abnormalities (Schmits et al., 1997). 
However, in models of inflammation or in tumour-prone mice, the effects of CD44 
gene knockout are more prominent. For instance, infection with Cryptosporidium 
pavrum caused exaggerated granuloma formation in animals that lacked CD44 
compared with their wild-type littermates (Schmits et al., 1997). SV40-
transformed CD44-deficient fibroblasts were highly tumorigenic in nude mice, 
whereas expression of CD44 in these fibroblasts resulted in a dramatic inhibition 
of tumour growth (Schmits et al., 1997). On the other hand, when the CD44-null 
mice were crossed with mice highly susceptible to tumors due to mutations in the 
Chapter 1  Introduction 
 
 52 
tumor suppressor genes p53 and APC, these mice have the same tumorigenesis, 
but metastasis was virtually absent (Weber et al., 2002).  
 
1.5.2.2 Cortactin 
Cortactin is a 63.3 kDa protein initially described as a major substrate of 
the oncogenic tyrosine kinase v-Src (Kanner et al., 1990; Wu et al., 1991). 
Because of its localisation to cortical actin, the protein was named cortactin (Wu 
and Parsons, 1993). Cortactin is encoded by the CTTN (formerly EMS1) gene 
present within the 11q13 chromosomal region (Ormandy et al., 2003; Patel et al., 
1996; Schuuring et al., 1993). The 11q13 region is frequently coamplified and 
overexpressed in human breast cancer and in squamous cell carcinomas of the 
head and neck (HNSCC) and its amplification has been associated with tumour 
metastasis and poor prognosis (Akervall et al., 1995; Meredith et al., 1995; 
Rodrigo et al., 2000; Williams et al., 1993).  
Cortactin is encoded by a single gene, however, when analysed by SDS-
PAGE, it migrates as two separate bands of 80 and 85 kDa (Wu and Parsons, 
1993). The relation between these two forms is not clear. The N-terminal half of 
cortactin comprises an N-terminal acidic domain (NTA), followed by 6.5 tandemly 
repeating segments, called cortactin repeats. The C-terminal half of the molecule 
is composed of an α-helical domain followed by a proline-serine-threonine-rich 
domain (PST); and a Src homology 3 (SH3) domain (Figure 1.9). The NTA 
domain contains a conserved DDW motif, which is involved in binding (Weaver et 
al., 2002) and the subsequent activation of the Arp2/3 complex (Uruno et al., 
2001; Weaver et al., 2001; Weed et al., 2000). Cortactin repeats comprise the 
actin binding region (ABR), which is involved in the direct binding of actin 
filaments (F-actin), with maximal binding activity centered on the fourth repeat 
(Weaver et al., 2001; Weed et al., 2000). 
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Figure 1.9: Domain organisation of cortactin. NTA, N-terminal acidic domain; 
helix, a α-helical domain; PST, a proline-serine-threonine-rich domain; SH3, a 
Src homology 3 domain. 
 
 
The α-helical domain has been shown to be a site of calpain cleavage (Huang et 
al., 1997b; Perrin et al., 2006). The PST-rich region of cortactin contains tyrosine 
and serine residues, which are targets of various serine/threonine and tyrosine 
kinases, including Src kinase. The major Src phosphorylation sites are Y421, Y466 
and Y482, although other tyrosine kinases, such as Fer and c-Met, have been also 
shown to phosphorylate these residues (Crostella et al., 2001; Huang et al., 
1997a; Kapus et al., 2000; Wu and Parsons, 1993). Mapping of phosphorylation 
sites within cortactin by mass spectrometry revealed the presence of 22 target 
residues (Martin et al., 2006). High level of phosphorylation has been reported to 
attenuate cortactin ability to cross-link filamentous actin and correlate with 
enhanced cell migration and invasion (Huang et al., 1998; Huang et al., 2003; Liu 
et al., 1999). In contrast, a more recent study showed that cortactin 
hyperphosphorylation suppressed cell migration	   of	   gastric cancer cell lines, 
possibly by inhibiting tyrosine phosphorylation of p130Cas (Jia et al., 2008). 
p130Cas (Crk-associated substrate) is an adaptor protein which, like cortactin, is 
phosphorylated by Src, following activation of integrins. Cortactin phosphorylation 
is believed to diminish phosphorylation of p130Cas, therefore suppressing 
p130Cas-mediated cell migration (Jia et al., 2008).  
The SH3 domain of cortactin mediates interaction with a number of 
cortactin binding partners, including N–WASP (Mizutani et al., 2002; Weaver et 
al., 2002) and the WASP-interacting protein (WIP) (Kinley et al., 2003), an 
endocytic GTPase dynamin-2 (McNiven et al., 2000), a missing in metastasis 
protein MIM (Lin et al., 2005), a Cdc42 activator guanine nucleotide exchange 
factor (GEF) (Hou et al., 2003) and many others.  
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In vitro studies have demonstrated that cortactin simultaneously binds to 
F-actin and Arp2/3 complex, promoting and stabilising actin network formation 
(Uruno et al., 2001; Weaver et al., 2001). Although cortactin is a weaker activator 
of the Arp2/3 complex than N-WASP, it can promote actin polymerisation 
indirectly by binding to and activating N-WASP (Mizutani et al., 2002), or by 
binding to WASP-activating protein WIP (Kinley et al., 2003) or by interaction with 
FGD1, which stimulates Cdc42, a direct activator of N-WASP (Kim et al., 2004). 
Cortactin accumulates in lamellipodia (Bryce et al., 2005; Weed et al., 
1998; Weed et al., 2000) in a mechanism presumably regulated by the activation 
of the small GTP-ase Rac1 (Weed et al., 1998). Tyrosine phosphorylation has 
been shown to follow the translocation of cortactin to lamellipodia and is not 
required for its lamellipodial localisation (Head et al., 2003). Although cortactin 
localises to lamellipodia, its exact function is not clear. It has been proposed to 
promote lamellipodia maintenance, but be non-essential for lamellipodia 
formation (Bryce et al., 2005).  
The strong localisation of cortactin to cell motility-associated structures such as 
lamellipodia and invadopodia suggests the role of cortactin in cell migration and 
invasion. Overexpression of cortactin has been reported to enhance 
motility/invasion of 3T3 fibroblasts (Patel et al., 1998) and spontaneously 
transformed human umbilical ECV304 endothelial cells (Huang et al., 1998). 
Conversely, cortactin knockdown has been shown to reduce cell motility/invasion 
of human fibrosarcoma HT-1080 cells (Bryce et al., 2005) and HBL100 breast 
epithelial cells (van Rossum et al., 2006). However, recently mice with cortactin 
floxed allele have been generated, from which MEFs have been isolated (Tanaka 
et al., 2009). Unexpectedly these MEFs showed normal actin organization and 
migration in comparison to wild-type MEFs, suggesting a non-essential role of 
cortactin in F-actin distribution and cell migration. This observation contradicts 
the previously published work performed using cortactin siRNA. The observed 
discrepancies may suggest cell type specific roles of cortactin. It is plausible that 
highly motile cells such as tumor cells utilize cortactin for their invasion differently 
than fibroblasts.  Indeed it has been suggested that the importance of cortactin in 
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cell migration is dependent on the original motile capacity of the cells (Tanaka et 
al., 2009). It is also possible that depletion of cortactin by genetic deletion 
activates the compensatory mechanisms. 
 
1.5.3 Mechanisms of MT1-MMP localisation to motility-associated 
 structures 
MT1-MMP localises to both lamellipodia and invadopodia of migrating and 
invading cells. In cells migrating through a 3D matrix, MT1-MMP is detected 
predominantly at the leading edge (Figure 1.10) (Itoh, 2006; Itoh and Seiki, 
2006). Localisation to lamellipodia has been shown to be facilitated by the 
association with CD44 (Mori et al., 2002). The Hpx domain of the enzyme has 
been reported to bind the stem region of CD44 (Mori et al., 2002; Suenaga et al., 
2005). The cytoplasmic tail of CD44 associates with ERM proteins that bind to F-
actin (Legg et al., 2002; Tsukita et al., 1994), indirectly linking MT1-MMP to the 
actin cytoskeleton (Mori et al., 2002). However, studies using fluorescence 
resonance energy transfer (FRET) microscopy have revealed that in MDA-MB-
231 and HT-1080 cells embedded in HA-containing three dimensional (3D) 
collagen-I matrices, MT1-MMP interacted with CD44 preferentially at the trailing 
edge of the invading cells (Marrero-Diaz et al., 2009). This suggests that 
localisation of MT1-MMP to leading edge of cells migrating through a 3D-matrix 
may not be regulated by the interaction with CD44. Further studies are required 
to give a better understanding of the mechanism that localises MT1-MMP to the 
leading edge in 3D and the role of CD44 in this process.  
MT1-MMP is well established to localise to invadopodia (Artym et al., 
2006; Clark and Weaver, 2008; Clark et al., 2007). The transmembrane domain 
and the cytoplasmic tail of MT1-MMP are reportedly involved in docking the 
enzyme to invadopodia in human melanoma cells (Nakahara et al., 1997). 
Although the mechanism of MT1-MMP localisation to these structures is not 
clear, the cortactin gene knockdown has been shown to decrease the 
invadopodial localisation of the enzyme and to inhibit matrix degradation (Artym 
et al., 2006; Clark and Weaver, 2008; Clark et al., 2007). Knockdown of the 
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cortactin gene in MDA-MB-231 cells resulted in a reduction of actin-positive 
invadopodia puncta and loss of invadopodia-associated matrix degradation 
(Artym et al., 2006). Silencing of the cortactin gene in HNSCC cells had little 
effect on invadopodia formation, but markedly decreased associated-matrix 
degradation, presumably by decreasing cell surface delivery of MT1-MMP to 
these structures (Clark and Weaver, 2008; Clark et al., 2007). Further studies are 
needed to assess the exact role of cortactin in MT1-MMP localisation to 
invadopodia. 
 
 
Figure 1.10: Localisation of MT1-MMP to motility-associated structures. (A) 
In cells cultured in a 2D culture system, MT1-MMP localises to lamellipodia and 
invadopodia. The lamellipodial localisation has been attributed to interaction with 
CD44. (B) In cells cultured in a 3D culture system, MT1-MMP is localised 
predominantly to the leading edge. 
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Recent studies have focused on intracellular vesicle trafficking as a major 
regulator of polarised localisation of MT1-MMP at the cell surface (Bravo-Cordero 
et al., 2007; Wiesner et al., 2010) (Section 1.4.7). Studies performed in Dr Itoh’s 
laboratory at the Kennedy Institute of Rheumatology, Imperial College London, 
have revealed that upon overexpression of exogenous MT1-MMP in mouse 
embryonic fibroblasts, the enzyme localised within intracellular vesicles 
(unpublished data) (Figure 1.11 A). The MT1-MMP-containing vesicles were 
aligned along microtubule filaments, suggesting the involvement of kinesin motor 
proteins in their translocation. Live cell imaging studies have demonstrated that 
MT1-MMP-containing vesicles moved bidirectionally and accumulated at the tip 
of growing protrusions (Figure 1.11 B). This indicates that the intracellular 
trafficking not only regulates the expression of the enzyme on the cell surface, 
but also its localisation. Therefore, identification of the mechanism that governs 
MT1-MMP trafficking is key to understanding the polarised localisation of MT1-
MMP to motility-associated structures. Since the kinesin-mediated intracellular 
trafficking is highly specific, identification of the kinesins which transport MT1-
MMP-containing vesicles will help to understand the temporal and spatial 
regulation of the enzyme during cell migration and invasion.  
 
 
Chapter 1  Introduction 
 
 58 
 
 
 
Figures 1.11: Intracellular trafficking of MT1-MMP-containing vesicles. (A) 
Transport of MT1-RFP-containing vesicles to lamellipodia along microtubules. 
Mouse embryonic fibroblasts expressing MT1-RFP (red) were fluorescently 
stained for microtubules (green). Left panel is a wide view of the image and right 
panel is an expanded view of marked area of the left panel where lamellipodia 
are extending. MT1-RFP-containing vesicles were present on the microtubules 
(yellow arrowheads). (B) Accumulation of MT1-RFP-containing vesicles in 
extending membrane structure. Mouse embryonic fibroblasts expressing MT1-
RFP were subjected to live cell imaging using confocal microscopy on RFP 
channel. Images taken at 20 seconds intervals. Time points are indicated in 
seconds in each image. Note that between 44 to 64 seconds time points, a new 
membrane structure was generated at the top of the cell, and MT1-RFP vesicles 
gradually accumulated to this structure (84 to 164 seconds). Yellow arrowheads 
indicate the region in which vesicles accumulated. Courtesy of Dr. Y. Itoh, 
Imperial College London. 
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1.6 AIMS OF THE THESIS 
In multicellular organisms, cell migration/invasion is observed during many 
physiological and pathological processes. MT1-MMP is a key enzyme that 
promotes cell migration/invasion in tissues. Polarised localisation of MT1-MMP 
on the cell surface is considered to be important for the focal degradation of the 
ECM in the direction of cellular movement. In cells cultured on a 2D matrix, the 
enzyme accumulates at lamellipodia and invadopodia structures. When cells are 
embedded into a 3D matrix, MT1-MMP is detected predominantly at the leading 
edge. Although the polarised localisation of MT1-MMP is thought to be important 
for cell invasion, the mechanism by which localisation is achieved is currently not 
known. Localisation of MT1-MMP to lamellipodia has been shown to be facilitated 
by interaction with CD44, but how association with CD44 allows MT1-MMP to 
reach particular membrane structures is not clear. It is also not known if the 
interaction with CD44 affects localisation of the enzyme to other areas of the 
plasma membrane. Localisation of MT1-MMP to substrate attachment sites has 
been linked to the formation of cortactin-rich invadopodia structures. However, 
the exact role of cortactin in localisation of the enzyme is not well understood. 
Live cell imaging studies performed in Dr Itoh’s laboratory suggest that 
localisation of MT1-MMP is regulated by targeted vesicular transport; however, 
the underlying regulatory mechanism still needs to be identified. Thus the aim of 
this thesis is to investigate the mechanisms that regulate polarised localisation of 
MT1-MMP on the cell surface. 
Aims of this thesis are to:  
Chapter 3: 
• Identify domains of MT1-MMP involved in enzyme localisation to 
lamellipodia and substrate attachment sites; 
• Investigate the role of CD44 in MT1-MMP localisation to substrate 
attachment sites and MT1-MMP-mediated cell migration; 
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Chapter 4: 
• Investigate the role of cortactin-driven invadopodia in localisation of MT1-
MMP to the substrate attachment sites and MT1-MMP-mediated cell 
migration; 
Chapter 5: 
• Identify kinesin motor proteins involved in intracellular vesicle trafficking of 
MT1-MMP to different areas of the plasma membrane. 
 
Understanding of the fundamental mechanisms that regulate localisation 
of MT1-MMP on the cell surface will provide novel insights into cellular invasion 
in tissues, and its role in cancer and other pathological processes.  
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2.1 REAGENTS 
 
2.1.1 Cells and cell culture reagents 
Cells were purchased from the following sources: human embryonic 
kidney 293 cells (HEK 293), African Green Monkey SV40-transformed kidney 
fibroblast cell line (COS-7) and human fibrosarcoma cells (HT-1080) were 
purchased from LGC Promochem; human epithelial carcinoma cells (A431) and 
human breast cancer cell line (MDA-MB-231) from ATTC Cultures; head and 
neck squamous cell carcinoma (HNSCC) cell line (TR131) from Cancer 
Research UK. 
Materials were obtained from the following sources: Dulbecco’s Modified 
Eagle’s Medium (DMEM), penicillin, streptomycin, 1 M HEPES buffer and 
versene/trypsin from Biowhittaker UK Ltd.; fetal bovine serum (FBS) from 
GIBCO; 1 x cell dissociation solution, 10 x RPMI-1640 media and sterile dimethyl 
sulphoxide (DMSO) from Sigma-Aldrich Company Ltd., Optimem I reduced 
serum medium with Glutamax I from Invitrogen Ltd; FuGENE 6 Transfection 
Reagent from F. Hoffman-La Roche Ltd.; Lipofectamine 2000, Lipofectamine 
RNAiMAX, Alexa 568- and Alexa 488-conjugated phalloidin from Invitrogen Ltd.; 
GM6001 (Ilomastat) from Elastin Products Company; protease inhibitor cocktail 
from Sigma-Aldrich Company Ltd.; type-I collagen (Cellmatrix type I-A) from Nitta 
Gelatin Inc.; PureCol collagen from Inamed Biomaterials; DQ collagen from type-I 
bovine skin fluorescein conjugate from Invitrogen Ltd.; type A gelatin from 
porcine skin from Sigma-Aldrich Company Ltd.; NH4Cl from Fisons Plc.; 
glutaraldehyde from BDH; albumin from bovine serum (lyophilised powder) from 
Sigma-Aldrich Company Ltd.; 12-well, 8 µm polyethylene terephthalate track-
etched membrane (PET) culture inserts from Falcon;  Cytodex 3 microcarrier 
beads from Sigma; Lab-Tec II chamber German Cover glass system from Nalge 
Nunc International; 8 chamber polystyrene vessel tissue culture treated glass 
slide from BD Biosciences; Falcon plates and Falcon flasks from Becton 
Dickinson UK Ltd. TIMP-1 and TIMP-2 were kindly provided by Dr. Hugh 
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Manning in this laboratory. proMMP-2 was kindly provided by Dr. Linda Troeberg 
in this laboratory. 
 
2.1.2 Antibodies 
Primary antibodies 
Primary antibodies were purchased from the following sources: anti-FLAG M1 
and M2 mouse monoclonal antibodies from Sigma-Aldrich Company Ltd. The 
anti-FLAG M1 antibody recognises the FLAG epitope (DYKDDDDK) located at 
the N-terminus of the protein in the presence of 1 mM Ca2+. Anti-FLAG M2 
antibody recognises the epitope anywhere in the molecule in the absence or 
presence of Ca2+. Anti-actin goat polyclonal antibody (clone I-19), anti-KIF3A 
rabbit polyclonal antibody (clone H-155), anti-cortactin rabbit polyclonal (clone H-
191) antibody, anti-HCAM mouse monoclonal antibody (clone F4) and anti-
HCAM rabbit polyclonal antibody (clone H-300) from Santa Cruz Biotechnology; 
anti-CD44S rat monoclonal antibody from Chemicon; anti-MMP14 mouse 
monoclonal antibody (clone LEM-2/15.8) from Millipore; anti-cortactin (p80/85) 
mouse monoclonal antibody (clone 4F11) from Upstate; anti-HA high affinity rat 
monoclonal antibody (clone 3F10) from Roche Applied Science; rabbit polyclonal 
antibody to KIF13A (ab72414) from Abcam. MMP-14 inhibitory antibody DX-2400 
was kindly provided by Dyax Corp. The mouse monoclonal anti-(human MT1-
MMP hemopexin domain) antibody (222-1D8) was a gift from Daiichi Fine 
Chemical Co. Ltd. 
 
Secondary antibodies 
 Secondary antibodies were purchased from the following sources: anti-
mouse alkaline phosphatase (AP)-linked secondary antibody and anti-rat AP-
linked secondary antibody from Sigma-Aldrich Company Ltd; anti-rabbit AP-
linked secondary antibody from Promega; Alexa 488- or 568-conjugated goat 
anti-mouse antibodies, Alexa 488-conjugated goat anti-rat antibody from 
Invitrogen Ltd.; goat anti-rat antibody, Cy5 conjugate from Millipore. 
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2.1.3 MT1-MMP and CD44 constructs 
All human MT1-MMP constructs were kindly provided by Dr Y. Itoh at the 
Kennedy Institute of Rheumatology, Imperial College London. The constructs 
contain a FLAG-tag (DYKDDDDK), inserted immediately downstream of the furin 
cleavage motif (RRRR111) at the end of the propeptide (Itoh et al., 1999). This 
allows for their identification by commercially available anti-FLAG M1 and M2 
antibodies.  
 All human CD44 constructs were kindly provided by Dr Y. Itoh. Full-length 
CD44 and the cytoplasmic domain deletion mutant (CD44-∆CP) were cloned into 
pSG5 vector, whereas a soluble form of CD44 (sCD44), lacking the cytoplasmic 
and transmembrane domain, was cloned into pCEP4 vector. All CD44 constructs 
were tag-free and detected using an anti-CD44 antibody raised against the 
extracellular domain.  
 
2.1.4 Molecular biology reagents 
 Materials were purchased from the following sources: Luria-Bertani (LB) 
media, LB agar, electrophoresis grade agarose from Invitrogen Ltd.; XL-1 Blue E. 
coli competent cells from Stratagene; QIAamp DNA Blood Mini Kit from QIAGEN; 
PureYield Plasmid Midiprep System from Promega; High Fidelity Prime Script 
RT-PCR Kit from TaKaRa Bio. Inc.; SuperScript III One-Step RT-PCR System 
with Platinum Taq DNA Polymerase from Invitrogen Ltd.; dNTP Mix (2 mM each), 
magnesium sulfate (MgSO4) and KOD Hot Start DNA polymerase from Novagen; 
EZ Load Molecular Rulers from Bio-Rad; deoxyribonucleic acid (DNA) grade 
ethanol (C2H5OH), carbenicillin and ethidium bromide (C21H20BrN3) from Merck 
Biosciences; restriction enzymes and CloneJET PCR Cloning Kit from 
Fermentas; calf interstinal alkaline phosphatase (CIP) from BioLabs. Target 
specific siRNAs were purchased from the following sources: ON-TARGETplus 
SMARTpool siRNA to KIF5B, KIF3A, KIF3B, KIF3C, KIF9, KIF15, KIF7, KIF13A, 
KIF13B, KIF1B, KIF1C, KIF21A, KIF21B, KIF7, KIF27 and non-targeting siRNA 
from Dharmacon; cortactin siRNA from Santa Cruz Biotechnology; CD44 siRNA 
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from Ambion. All reagents were of molecular biology grade. Water was 
autoclaved before use in order to destroy DNAses. 
 
2.1.5 Immunocytochemistry reagents 
Reagents were obtained from the following sources: paraformaldehyde 
(PFA) from Sigma-Aldrich, UK; goat serum from Dako UK Ltd.; ProLong Gold 
mounting solution from Invitrogen Ltd.; immersion oil fluorescence free from 
AppliChem., Ø 18 mm cover glass and 25 x 80 mm cover glass from VWR 
international; Menzel-Glaser microscope slides from Thermo Scientific.  
 
2.1.6 SDS-PAGE and Western blotting reagents 
 Materials were purchased from the following sources: sodium dodecyl 
sulfate (SDS), Tween, Trizma base, glycine, β-mercaptoethanol, formaldehyde 
(HCHO), glutaraldehyde (OHC(CH2)3CHO), bovine serum albumin (BSA) and 
amediol from Sigma-Aldrich Company Ltd.; 30 % (w/v) acrylamide/bis-acrylamide 
from Severn Biotech Ltd.; N,N,N',N'-Tetramethylethylenediamine (TEMED), 
hydrochloric acid (HCl), ethylenediaminetetraacetic acid (EDTA), Coomassie 
Brilliant Blue R-250, sodium azide (NaN3), sodium carbonate (Na2CO3), glycerol, 
calcium chloride (CaCl2), bromophenol blue, ammonium chloride (NH4Cl), 
methanol (CH3OH), butanol (C4H9OH), acetic acid (CH3COOH) and formic acid 
(HCOOH) from Merck Biosciences; ammonium persulfate (APS) from Acros 
Organics, Pre-stained Precision Protein Standards were purchased from Bio-
Rad;  polyvinylidene difluoride (PVDF) membrane from Invitrogen Ltd.; dry 
skimmed milk from Tesco; AP substrate (5-bromo-4-choloro-3-indolyl-1-
phosphate and nitroblue tetrazolium) from Promega UK. 
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2.2 CELL CULTURE    
 
2.2.1 Cell line culture 
Cells were cultured in DMEM supplemented with 100 U/mL penicillin, 100 
µg/mL streptomycin and 10 % (v/v) FBS (complete growth medium) at 37 ˚C in a 
humidified incubator with 5 % CO2. Cells were passaged every 3-4 days using 
trypsin-EDTA or cell dissociation solution. All cells were regularly screened for 
mycoplasma contamination by Mrs Parisa Amjadi at the Kennedy Institute of 
Rheumatology, Imperial College London. 
 
2.2.2 Cryopreservation and thawing of cells 
A confluent 10 cm2 cell culture dish was harvested using trypsin-EDTA 
and centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and 
the cell pellet was resuspended in 3 mL DMEM containing 50 % (v/v) FBS and 10 
% (v/v) DMSO. 1 mL aliquots were left overnight to freeze slowly in a cryovial at -
80 ˚C in a Nalgene cryo 1 ˚C freezing container, according to the manufacturer’s 
instructions. The next day, vials were transferred to liquid nitrogen storage.  
Cells were thawed by quickly transferring cryovials to a 37 °C water bath. 
Once thawed, cells were washed with 10 mL DMEM in order to remove DMSO.  
Next, cells were resuspended in 10 mL complete growth medium and cultured on 
a 10 cm2 culture dish. 
 
2.2.3 Transient transfection  
Transient transfection of COS-7 and A431 cells was performed with 
FuGene 6 transfection reagent according to the manufacturer’s instructions with 
some minor modifications. One day before transfection, COS-7 or A431 cells 
were seeded in a 6-well culture dish at a density of 2 x 105 cells per well. For 
transfection, 1 µg of DNA was pipetted into an autoclaved Eppendorf tube. In a 
separate tube, FuGene reagent (3 µL) was mixed with serum-free DMEM (100 
µL). FuGene/DMEM mix was then combined with the DNA and incubated at 
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room temperature for 20 minutes. At this point, media on cells were exchanged 
for 1 mL of pre-warmed DMEM containing 10 % (v/v) FBS. The FuGene/DNA mix 
was added to cells dropwise and left at 37 ˚C for at least 15 hours before cells 
were used in an experiment. If less than 1 µg of DNA was used for transfection, 
the amount of FuGene was decreased accordingly. 
Transient transfection of HT-1080 cells was performed using 
Lipofectamine 2000 reagent, according to the manufacturer’s instructions with 
some minor modifications. One day before transfection HT-1080 cells were 
seeded in a 6-well culture dish at a density of 2 x 105 cells per well in 2 mL of 
DMEM containing 10 % FBS (v/v) without antibiotics. For transfection, 1 µg of 
plasmid DNA was diluted in 50 µL of Opti-MEM medium. Lipofectamine 2000 
was mixed before use and 1.25 µL was diluted in 50 µL of Opti-MEM medium. 
After a 5-minute incubation at room temperature, diluted DNA was combined with 
diluted Lipofectamine 2000 and left for 20 minutes at room temperature. At this 
point, cells were washed once with Opti-MEM and 1 mL of Opti-MEM medium 
was added to each well. Lipofectamine 2000/DNA complex was added to the 
cells dropwise and left at 37 ˚C for 5-7 hours, before the medium was changed to 
DMEM containing 10 % (v/v) FBS without antibiotics. Cells were incubated for 
15-24 hours before they were used in an experiment.  
 
2.2.4 Gene silencing 
 Gene silencing was performed using Lipofectamine RNAiMAX reagent. 
For each reaction, 200 ng of siRNA was diluted in 50 µL of Opti-MEM medium in 
an autoclaved Eppendorf tube. In a separate tube, 1 µL of Lipofectamine 
RNAiMAX was diluted in 50 µL of Opti-MEM medium. Diluted siRNA was 
combined with diluted Lipofectamine RNAiMAX, mixed gently and incubated for 
20 minutes at room temperature. Next, the mix was added to a single well of a 
24-well plate. At this point, 3 x 104 cells in 500 µL of DMEM containing 10 % (v/v) 
FBS were added to the well and incubated for 48-72 hours before they were used 
in an experiment. Gene knockdown was confirmed either by Western blot 
analysis or RT-PCR.  
Chapter 2   Materials and Methods 
 
 68 
2.2.5 Establishment of stable HEK 293 cell line expressing sCD44 
A construct encoding a soluble form of CD44 (sCD44) in pCEP4 vector 
was kindly provided by Dr Y. Itoh. This construct was used to establish a stable 
sCD44-expressing cell line. pCEP4 vector contains a  hygromycin resistance 
gene, an Epstein-Barr virus nuclear antigen-1 gene and viral OriP. These allow 
for extrachromosomal replication of the plasmid under the cytomegalovirus 
(CMV) promoter. To establish a stable cell line expressing sCD44, human 
embryonic kidney 293 (HEK 293) cells were transfected with 1 µg of 
sCD44/pCEP4 construct or empty pCEP4 vector (mock), using FuGENE 6 
transfection reagent. Untransfected HEK 293 cells were used as a control. 
Transfected and control cells were cultured for two days, at which time the 
conditioned medium was removed and fresh DMEM containing 400 µg/mL 
hygromycin and 10 % (v/v) FBS was added. This was repeated every two days. 
By two weeks after transfection, control cells had perished. To test for protein 
expression in hygromycin-resistant cells, the media were changed to serum-free 
DMEM. After 48 hours, media were collected and spun to remove cell debris. 
Clear supernatants were collected and concentrated to approximately 750 µL. 
Total amounts of proteins in mock and sCD44-transfected samples were 
adjusted using the Bio-rad protein assay.   
 
2.3  MOLECULAR BIOLOGY 
 
2.3.1 General Solutions 
Tris - EDTA buffer (TE): 
 TE LPS-free buffer was used to store DNA and contained: 10 mM Tris-HCl 
and 1 mM EDTA, pH 8.0.   
LB agar and LB broth: 
 LB agar and LB broth were prepared according to the manufacturer’s 
instructions.  LB agar was allowed to cool down to about 50 °C, before adding a 
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selection antibiotic. The solution was then poured into 10 cm2 bacteriological petri 
dishes and left to set. These were then stored at 4 °C. 
Selection antibiotics: 
 Carbenicillin stock solution was made at 50 mg/mL in deionised water 
(dH2O) and used at the 50 µg/mL concentration. 
 
2.3.2 RT-PCR and cDNA synthesis 
 cDNA was synthesised from HT-1080 total cellular RNA or mRNA using 
High Fidelity PrimeScript RT-PCR Kit from TaKaRa, according to the 
manufacturer’s instructions.  
 To confirm silencing of KIF genes in HT-1080 cells SuperScript One-Step 
RT-PCR System with Platinum Taq was used. This system allows for the 
sensitive and reproducible detection and analysis of RNA molecules using RT-
PCR. Components for both, cDNA synthesis and PCR, are combined in one 
tube, so the PCR cycling follows reverse transcription without additional steps. 
Specific primers designed to confirm expression of the selected KIFs in HT-1080 
cells are listed in table 2.1.  
 
Table 2.1: List of primers used to confirm expression of selected KIFs in  
HT-1080 cells. 
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2.3.3 PCR reaction  
Polymerase chain reactions (PCR) were performed using KOD Hot start 
DNA polymerase from Novagen according to the standard reaction setup (Table 
2.2). 
 
Table 2.2: KOD Hot Start DNA Polymerase standard reaction setup. 
  
Component 
 
 
Volume 
(µL) 
 
Final  
concentration 
10x Buffer for KOD Hot Start DNA Polymerase 5 1X 
25 mM MgSO4 3 1.5 mM 
dNTPs (2 mM each) 5 0.2 mM 
PCR Grade Water 32 - 
Forward Primer (10 mM) 1.5 0.3 µM 
Reverse Primer (10 mM) 1.5 0.3 µM 
cDNA 1 - 
Kod Hot Start Polymerase (1U / µL) 1 0.02 U / µL 
Total reaction volume 50 
 
 
2.3.4 DNA electrophoresis 
 DNA electrophoresis was performed using 1 % (w/v) agarose gel in 0.5 x 
TAE buffer. Ethidium bromide was added at 0.1 µg/mL to agarose solution just 
before pouring into casting plates. Typically, DNA was electrophoresed at 130 V 
in 0.5 x TAE buffer.  A UV light was used to visualise DNA bands. 
 
2.3.5 DNA fragment purification 
DNA was analysed on a 1 % (w/v) agarose gel in the presence of SYBR 
green I (1/10,000) using a dark reader transilluminator, model DR88m BRI Ltd., 
Fragments of interest were excised with a minimal amount of agarose and 
purified using a QIAGEN plasmid purification kit, according to the manufacturer’s 
instructions.  DNA was eluted in 30 µL dH2O. 
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2.3.6 Restriction digestion 
Digestion reactions were carried out in 20 µL reaction volume, according 
to the manufacturer’s instructions. 
 
2.3.7 Ligation of DNA fragments  
Ligation of PCR-generated fragments to a pJET1.2 cloning vector was 
performed using CloneJET PCR Cloning Kit, according to the manufacturer’s 
instructions. pJET1.2 vector contains a lethal gene, which is disrupted by ligation 
of a DNA insert into the cloning site. As a result, only cells with recombinant 
plasmids are able to propagate. 
Ligation of the DNA insert into pSG5 expression vector required 
linearisation of the vector with appropriate restriction enzymes and its 
dephosphorylation to prevent self-ligation. Dephosphorylation was performed 
using calf intestinal alkaline phosphatase (CIP) from NEB, according to the 
manufacturer’s instructions. Gel-purified inserts were ligated into pSG5 vector in 
a 3:1 molar ratio using T4 DNA ligase. 
 
2.3.8 Colony PCR 
Colony PCR allows for a rapid screening for plasmid inserts directly from 
E. coli colonies. A single colony was resuspended in 20 µL LB medium. 10 µL of 
the suspension was kept at 4 °C, whereas the other half was boiled at 95 °C for 5 
minutes. After spinning, 5 µL of the supernatant was used as a PCR template. To 
confirm the presence and orientation of inserts in pJET1.2 cloning vector, the 
pJET1.2 specific reverse primer was used together with the insert specific 
forward primer. For the positive clones, the residual 10 µL of the bacteria/LB 
suspension was used to grow bugs for plasmid purification.  
 
2.3.9 Bacterial electroporation 
 Ligation mixture, 2 µL, was added to 50 µL of electrocompetent XL1-Blue 
E. coli competent cells. Bacteria/DNA mixture was pipetted into a cold 0.2 cm 
electroporation cuvette and pulsed in a BTX Electro Cell Manipulator (Qbiogene) 
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with 2100 V for 5 milliseconds. 400 µL LB media were added to the cuvette and 
the culture was grown at 37 °C for 1 hour with agitation. Cells were plated onto 
an LB plate containing 50 µg/mL carbenicillin and grown overnight at 37 °C. 
 
2.3.10  DNA plasmid purification 
A few colonies were picked with a P20 pipette tip from an LB plate and 
inoculated into liquid LB media containing 50 µg/mL carbenicillin. Transformed 
bacteria were cultured for 15 hours, before DNA was isolated and purified using 
QIAGEN plasmid purification kit or PureYield Plasmid Midiprep System, 
according to the manufacturer’s instructions. Plasmid DNA was separated from 
bacterial genomic DNA by alkaline lysis of bacteria. The lysate was then adjusted 
to a high salt concentration and adsorbed onto a silica gel matrix. Contaminants 
were washed off and DNA eluted in 50 µl dH2O or TE buffer. The yield of DNA 
was determined by measuring UV absorption at 260 nm on a UV/VIS 
spectrometer, Lambda Bio 20, Perkin Elmer LAS (UK) Ltd.   
 
2.3.11  Molecular cloning of KIF motorless mutants 
KIFs motorless mutants, KIF3A-∆M, KIF13A-∆M, KIF9-v1-∆M, KIF9-v2-∆M 
and KIF9-v3-∆M, were amplified by PCR reaction using proofreading KOD Hot 
Start DNA polymerase. cDNA synthesised from total cellular RNA or mRNA 
extracted from HT-1080 cells, was used as a template. An HA-tag sequence was 
introduced into forward primers (Table 2.3). PCR-generated specific blunt-end 
products were gel-purified and ligated into pJET1.2 blunt cloning vector. Four 
colonies of each construct were analysed for the presence of DNA insert using 
restriction enzyme digestion (Figure 2.1 B). A single positive clone of each 
mutant was sent for DNA sequencing to Eurofins MWG Operon, Germany. 
Clones with the correct DNA sequence were digested using restriction enzymes. 
The excised inserts were cloned into pSG5 expression vector. Colony PCR was 
used to assess the presence and orientation of the inserts (Figure 2.1 C). 
Positive clones were further analysed for protein expression by Western blot 
analysis using an anti-HA antibody (Figure 2.1 D). 
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Table 2.3: Primers used for amplification of KIFs motorless mutants. 
Sequence encoding HA-tag is shown in blue. Restriction sites are underlined: 
KpnI: GGTAC▼C; EcoRI: G▼AATTC; BamHI: G▼GA TCC. 
 
 
Construct 
 
 
Primer 
 
Sequence 
 
KIF13-∆M 
Forward 5’ TCA GGT ACC ACC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC GCT GGC ATA GAG GAC CGG GAA ACG C 3’  
Reverse 5’ TCA GGT ACC TCA TCA TTG ACA GCA CAG AAC CC 3’ 
 
KIF3-∆M 
Forward 5’ TCA GAA TTC C ACC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC GCT GGC GAG GAA GAT GAT GAT GAA GAG 3’ 
Reverse 5’ CGC GAA TTC TTA CTG CAG TAA AGA GTC AAT TA 3’ 
 
KIF9-v1-∆M 
Forward 5’ TCA GGA TCC ACC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC GCT GGC GTC AAG AAC CTG GAG AAG G 3’ 
Reverse 5’ TCA GGA TCC CTA CTA TTT TCT ATG TGC CTG CTG 3’ 
 
KIF9-v2-∆M 
Forward 5’ TCA GGA TCC ACC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC GCT GGC GTC AAG AAC CTG GAG AAG G 3’ 
Reverse 5’ TCA GGA TCC CTA CTA TTT TCT ATG TGC CTG CTG 3’ 
 
KIF9-v3-∆M 
Forward 5’ TCA GGA TCC ACC ATG TAC CCA TAC GAT GTT CCA 
GAT TAC GCT GGC GTC AAG AAC CTG GAG AAG G 3’ 
Reverse 5’ TCA GGA TCC TCA TCA TGG AAG CTG GCC TGG 3’ 
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Figure 2.1: Cloning and expression of motorless mutants of KIF3A, KIF13A 
and KIF9-v1, -v2, -v3. (A) Amplification of motorless mutants of KIF3A, KIF13A 
and KIF9 (splicing variants: -v1, -v2, -v3) from HT-1080 cDNA library by PCR 
reaction. Calculated sizes of PCR-generated inserts are shown in brackets. (B) 
Restriction digestion of the mutants cloned into pJET1.2 cloning vector. (C) 
Colony PCR of the mutants cloned into pSG5 expression vector. (D) Expression 
of the mutants in COS-7 cells. COS-7 cells were transiently transfected with 
mock vector or plasmid DNA encoding KIF3A-∆M, KIF13A-∆M, KIF9-v1-∆M, 
KIF9-v2-∆M or KIF9-v3-∆M. 48 hours later, cells were lysed and subjected to 
Western blot analysis using an anti-HA (clone 3F10) antibody (ab). Calculated 
molecular sizes of the mutants are shown in brackets.  
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2.4  SDS-PAGE GEL ELECTROPHORESIS  
 
2.4.1 Reagents 
 
 
Table 2.4: Reagent used for SDS-PAGE gel electrophoresis (Bury, 1981). 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis ( SDS-PAGE) 
Acrylamide solution 30 % acrylamide, 0.8 % (w/v) BIS (N, N’-methylene-bis-
acrylamide) 
4 x Lower gel buffer 110 mM amediol (2-amino-2-methyl-1,3-propanediol),   
47 mM HCl, 0.02% NaN3 
4 x Upper gel buffer 84 mM amediol, 62 mM HCl, 0.02 % NaN3 
50 % Sucrose solution  50 % (w/v) sucrose, 0.03 % (v/v) toluene, 0.02 % NaN3  
APS 10 % ammonium persulfate in dH2O 
Butanol solution 50 % (v/v) butanol in dH2O 
4 x Upper reservoir buffer 41 mM amediol, 40 mM glycine, 0.4 % SDS 
4 x Lower reservoir buffer 62.5 mM amediol, 50 mM HCl 
2 x Loading buffer 
(*reducing) 
0.2 g of SDS, 5 mL of 4 x upper gel buffer, 0.5 mL of 1 % 
bromophenol blue, 4 mL of glycerol, dH2O (up to 10.5 
mL) (* 0.4 mL of 0.5 M EDTA pH 8.0, 100 µL of β-
mercaptoethanol) 
Staining solution 0.5 g Coomassie Brilliant Blue R-250, 250 mL of 
methanol, 100 mL of acetic acid, 150 mL of dH2O 
Destaining solution  300 µL of methanol, 10 mL of formic acid, 700 µL of 
dH2O 
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2.4.2 SDS-PAGE gel composition 
 
Table 2.5: SDS-PAGE gel composition. Components of a 7.5 % resolving gel 
and stacking gel. 
 
Resolving, lower gel 
30 % acrylamide 1500 µL 
Lower gel buffer  1500 µL 
50 % sucrose 1290 µL 
dH2O 1710 µL 
APS 42.0 µL 
TEMED 4.5 µL 
Stacking, upper gel 
30 % acrylamide 320 µL 
Upper gel buffer  642 µL 
50 % sucrose 642 µL 
dH2O 963 µL 
APS 31.5 µL 
TEMED 6.75 µL 
 
 
2.4.3 SDS-PAGE procedure 
SDS-PAGE allows the separation of proteins by their individual molecular 
weights. SDS is an anionic detergent, which binds quantitatively to proteins, 
giving them linearity and uniform charge-to-mass ratio, so that they can be 
separated solely on the basis of their size. Gels of 1.5 mm thickness were 
prepared between glass plates. After pouring a resolving lower gel, a layer of 
butanol was applied to ensure a flat interface between lower and upper gels. 
After the gel had polymerised, the butanol layer was removed and the stacking 
upper gel was applied.  A 1.5 mm, 15-well comb was inserted to form the sample 
wells and the gel was allowed to set. The comb was then removed and wells 
washed with upper running buffer. Unless otherwise stated, cells were lysed 
using 1 x reducing SDS-PAGE sample buffer and boiled for 10 minutes at 95 oC.  
Samples were applied to wells, adding 6 µl prestained protein standard to one 
well.  Gels were electrophoresed at 150 V, until the dye front reached the bottom 
of the resolving gel (~55 minutes) and used for Western blotting.  
Chapter 2   Materials and Methods 
 
 77 
2.5 WESTERN BLOTTING 
 
2.5.1 Reagent 
Table 2.6: Western blotting reagents (Towbin et al., 1979). 
Western blotting reagents 
Transfer buffer 1.5 g of Trizma base, 7.2 g of glycine, 
200 mL of methanol, dH2O up to 1 L 
1 X Washing buffer (TTBS)  50 mM Trizma base (pH 7.5), 150 mM NaCl, 
0.02 % NaN3, 0.05 % (v/v) Tween 20 
10 % dry milk solution   50 g of dry milk, 10 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.02 % NaN3  
 
2.5.2 Procedure 
Following separation by SDS-PAGE electrophoresis, proteins were 
transferred onto a PVDF membrane. The Western blot was assembled and run 
according to the manufacturer’s instruction (Novex, Invitrogen Ltd.) for 90 
minutes at 25 V (constant voltage) in the transfer buffer. Prestained molecular 
weight markers were completely transferred in this time. Non-specific binding 
sites on the membrane were blocked using 10 % skimmed dry milk solution for 
20 minutes. After blocking, the membrane was washed three times for 5 min with 
the washing buffer and then incubated overnight with a primary antibody in 1 % 
(w/v) BSA in TBS at room temperature with agitation.  The membrane was 
washed three times with the washing buffer before an AP-linked secondary 
antibody in 1 % (w/v) BSA in TBS was added and incubated for 1 hour at room 
temperature. Finally, the membrane was washed with the washing buffer four 
times and the blot was incubated with AP substrate until bands appeared. 
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2.6 ZYMOGRAPHY  
 
2.6.1 Reagents 
 
Table 2.7: Zymography reagents. 
Zymography reagents 
Renaturing buffer  50 mM Tris-HCl pH 7.5, 5 mM CaCl2, 5 µM ZnCl2, 2.5 % (v/v) 
Triton X-100, 0.02 % (v/v) NaN3 
Incubation buffer 50 mM Tris-HCl pH 7.5, 5 mM CaCl2, 5 µM ZnCl2, 0.02 % NaN3 
Staining solution 0.125 % (w/v) Coomassie Brilliant Blue R-250, 62.5 % (v/v) 
methanol, 25 % (v/v) acetic acid   
Destain solution: 30 % (v/v) methanol, 1 % (v/v) formic acid  
 
2.6.2 Procedure 
Zymography is an electrophoretic technique enabling visualisation of 
proteinase activity in a sample on the basis of their hydrolysis of a gel-embedded 
protein substrate, such as gelatin. A 7.5 % SDS-PAGE gel was polymerised, as 
described in Table 2.5, but the lower gel was co-polymerised with gelatin at the 
final concentration 0.8 mg/mL. Cells were seeded at 3 x 104 in a 24-well plate 
and gene silencing was performed. 48 hours later, cells were washed with 
serum-free DMEM and incubated with 0.7 µg/mL proMMP-2 in a volume of 400 µl 
for 24 hours in serum-free DMEM. Medium was then recovered and a four times 
concentrated non-reducing SDS sample buffer was added to the supernatant in 
the (v/v) ratio 4:1. Samples were electrophoresed without heat denaturation. Gels 
were washed in 20 mL zymography renaturing buffer for 15 minutes, four times. 
After washing, the gel was incubated in 30 mL zymography developing buffer at 
37 °C. 6-12 hours later, the buffer was decanted and the gel stained in 
Coomassie Brilliant Blue R-250 protein stain for 30 minutes. Destain solution was 
then added (changing solution frequently) until clear, digested areas, were visible 
against a dark blue gelatin background. Gels were stored in destain solution. 
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2.7 IMMUNOCYTOCHEMISTRY  
 
2.7.1 Reagents 
Blocking solution:         
3 % (w/v) BSA, 5 % (v/v) goat serum, 1 mM CaCl2 in TBS  
 
3 % paraformaldehyde (PFA):  
To prepare a 3 % paraformaldehyde (3 % PFA) solution, 200 ml of PBS buffer 
was pre-heated in a microwave to boiling temperature. 6 g of paraformaldehyde 
was then added to the PBS and stirred until dissolved. If the PFA powder did not 
dissolve completely, the solution was incubated in a water bath at 60 ° C until 
clear.  
 
4 % formaldehyde: 
4 % formaldehyde solution was prepared by diluting 37 % formaldehyde solution 
with 1x PBS to adjust to the final concentration.  
 
2.7.2 Procedure 
Transfected or siRNA-treated cells were seeded onto coverslips coated 
with gelatin or a collagen film and incubated from 1 to 48 hours, depending on 
the assay. After the incubation, culture media were aspirated and cells fixed 
using 3 % PFA in PBS for 15 minutes. Cells were washed 3 times with 1x TBS 
and, when stated, permeabilised with 0.1 % Triton X-100 in TBS for 15 minutes. 
Cells were blocked for an hour with the blocking solution and then incubated with 
an appropriate primary antibody for an hour. After washing four times with 1x 
TBS, a fluorescently-conjugated secondary antibody diluted in blocking solution 
was added and incubated for one hour at room temperature. Samples were 
washed three times with TBS and, when stated, counter-stained with Alexa-568- 
or Alexa-488-conjugated phalloidin for 30 minutes at room temperature to 
visualise actin filaments. After removing unbound materials by washing with TBS, 
cells were mounted in ProLong Gold mounting solution on glass slides. Samples 
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were viewed under Nikon TE2000-U Ultraview confocal or Nikon TE2000-E 
Elipse microscopes. Images were analysed using Volocity (Improvision Ltd.) or 
ImageJ softwares. For colocalisation studies, a double immunofluorescence 
staining method was adopted using two primary antibodies from distinct species 
and species-specific secondary antibodies conjugated to different fluorophores. 
Immunofluorescent staining of HeLa cells in 3D collagen gel was 
performed as follows. Cells expressing wild-type FLAG-tagged MT1-MMP or the 
Hpx domain deletion mutant were cultured in 3D collagen. 15 hours later, cells 
were fixed with 3 % (w/v) PFA in PBS for 30 minutes, washed three times with 
TBS, 30 minutes per wash, and blocked in the blocking solution. After 2 hours of 
blocking, M1 anti-FLAG antibody diluted in blocking solution (5 µg/mL) was 
added and incubated for 15 hours at 4 °C. On the following day, cells were 
washed with 1 x TBS at least three times, 45 minutes per wash, and incubated 
with Alexa-568 conjugated-goat anti-mouse antibody, diluted 1:1000 in blocking 
solution for 15 hours. After washing with 1 x TBS for 3 times, cells were 
permeabilised and F-actin was visualised with Alexa-488-conjugated phalloidin. 
Cells were washed at least three times with 1 x TBS, 30 min per wash and 
viewed using an Ultraview confocal microscope. Image analysis was performed 
using ImageJ software. 
 
 
2.8 2D-GELATIN FILM DEGRADATION ASSAY  
 
2.8.1 Preparation of fluorescent gelatin 
Alexa Fluor-488 dye from Invitrogen was used to label gelatin as follows. 
20 mg of gelatin from porcine skin was dissolved in 1 mL of 0.1 M sodium 
bicarbonate by gently heating in a microwave. 250 µL of the gelatin solution was 
then mixed with 100 µg of Alexa-488 dye in 1.5 mL Eppendorf tube and vortexed 
well to dissolve dye completely. The mixture was stirred for one hour at room 
temperature. Next, 50 µL of 1 M ammonium chloride in dH2O was added and 
mixed well by vortexing. 50 µL of 10 x PBS and 150 µL of dH2O were then added 
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giving a concentration of 10 mg/mL of gelatin. The gelatin solution was dialysed 
against 1L PBS for 2-4 hours to remove unbound dye. After dialysis, the volume 
was measured and the gelatin solution diluted 10 times with 50 % glycerol in 
PBS. The final concentration of gelatin was 1 mg/mL. 1 mL aliquots were stored 
at – 20 ° C.  
 
2.8.2 Gelatin-coated coverslips 
To coat the glass surface, fluorescent gelatin stock solution (1 mg/mL) 
was diluted 1:20 in dH2O, adjusting the concentration to 50 µg/mL. Diluted gelatin 
was incubated at 60 °C for 20 minutes in a thermoblock. Glass coverslips (18 
mm in diameter) were coated with fluorescent gelatin for 20 minutes at room 
temperature. Excess gelatin solution was removed and gelatin-coated coverslips 
were fixed using 1 % (v/v) glutaraldehyde for 15 minutes at room temperature. 
Following fixation, the coverslips were incubated with 1 M NH4Cl for 15 minutes 
to block any free glutaraldehyde.  A single coverslip was placed into one well of a 
12-well plate and washed with 70 % (v/v) ethanol to sterilise. Coated coverslips 
were washed at least three times with DMEM containing 10 % (v/v) FBS before 
cells were added. 
 
2.9 DQ-COLLAGEN FILM DEGRADATION ASSAY  
Collagen gel was prepared by mixing ice-cold type-I collagen (Cellmatrix 
type I-A from Nitta Gelatin Inc.) at a final concentration of 2 mg/mL with DQ 
collagen (1 mg/mL) in volume ratio of 19:1. The mixture was supplemented with 
1/10th volume of RPMI. 1 M NaOH was used to adjust the solution to neutral pH. 
A glass coverslip (18 mm in diameter) was placed into one well of a 12-well plate, 
washed with 70 % (v/v) ethanol and coated with a thin layer of neutralised 
collagen. After 1 hour of incubation at 37 °C, 3.5 x 103 cells were seeded onto the 
polymerised collagen film and incubated for 36 hours at 37 °C. After incubation, 
cells and the collagen film were fixed using 3 % (w/v) PFA for 30 minutes. Actin 
cytoskeleton was stained with Alexa-568-conjugated phalloidin to visualise cells. 
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DQTM collagen is a fluorescence-quenched collagen which increases 
fluorescence upon proteolytic cleavage by collagen degrading enzymes, 
including MT1-MMP. The quenching of the signal is due to the close proximity of 
the fluorescein dye attached to the intact substrate. DQ collagen is generally 
used to detect collagenolytic activity. However, uncleaved DQ collagen emits 
basal fluorescence and thus can be also used to visualise intact collagen. In my 
experimental conditions degraded collagen was released into the medium and 
thus digested areas were visualized as fluorescence-negative areas against the 
green intact collagen background.  
 
2.10 COLLAGEN-FILM DEGRADATION ASSAY  
Nine portions of collagen gel were prepared using ice-cold PureCol 
collagen from Inamed Biomaterials. The mixture was supplemented with 1 
volume of RPMI and 0.02 M NaOH, to adjust the solution to neutral pH. The final 
concentration of collagen was 2.0 mg/mL. Wells within a 6-well dish were coated 
with a thin layer of neutralised collagen by adding 600 µL to each well, and 
removing the excess. Collagen-coated dishes were incubated at 37 ˚C. After one 
hour of incubation, cells were seeded onto the polymerised collagen. After a 
defined number of days, cells were removed from the well by trypsinisation and 
the collagen layer was fixed using 3 % (w/v) PFA in PBS for 30 minutes. 
Collagen was stained using a 1:1 mixture of Coomassie stain / destain for 30 
minutes. Wells were washed with destain solution and once with water and left to 
dry. Digested areas of collagen were visualised as white areas against blue 
collagen background.   
 
2.11 TRANSWELL INVASION ASSAY  
8 µm polyethylene terephthalate (PET) track-etched membrane culture 
transwells were inserted into wells of a 12-well plate and coated with neutralised 
Cellmatrix type I-A collagen at the concentration 2.5 mg/mL by adding 200 µL of 
the collagen per chamber and removing excess collagen with pipet set to 150 µL. 
Coated chambers were then incubated for 1 hour at 37 °C to let the collagen 
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polymerise. In the mean time, cells were trypsinised and counted. 3 x 104 cells 
were resuspended in 300 µL of serum-free DMEM and seeded onto the 
polymerised collagen. 1 mL of DMEM supplemented with 10 % (v/v) FBS was 
added to the bottom well. Cells were cultured for 20 hours, before the sample 
was fixed and collagen removed from the upper membrane surface with cotton 
buds. Cells which had invaded into the collagen and migrated to the other side of 
the membrane were stained with Alexa-488-conjugated phalloidin to visualise F-
actin and with DAPI (4',6-diamidino-2-phenylindole) to visualise cell nuclei 
(Figure 2.2). Invasive cells were viewed with a Nikon TE2000-E microscope with 
CCD-camera and counted using Volocity software.  
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Figure 2.2: Transwell invasion assay. PET culture inserts were coated with 
Cellmatrix type I-A collagen and inserted into a well of a 12-well plate. 3 x 104 
cells were resuspended in 300 µL of serum-free DMEM and seeded on top of the 
polymerised collagen. 1 mL of DMEM supplemented with 10 % (v/v) FBS 
(complete growth medium) was added to the bottom well. 20 hours later, the 
sample was fixed with 3 % (v/v) PFA and the collagen layer removed with a 
cotton swab. Cells that had migrated through the transwell were stained for F-
actin (green) and nuclei (blue) and counted using Volocity software. Modified 
from: (Palmisano and Itoh, 2009). 
 
 
 
2.12 MICROCARRIER BEAD INVASION ASSAY  
 
Bead invasion assay was performed as previously described (Palmisano and 
Itoh, 2009). 
Preparation of microcarrier beads 
1 g of gelatin-coated Cytodex 3 microcarrier beads were soaked in 50 mL 
Ca2+- and Mg2+- free PBS at room temperature for 15 hours. The next day, beads 
were allowed to settle on the bottom of the bottle and PBS was replenished. 
Beads were then autoclaved and from that point handled only in a culture hood to 
avoid contamination. Autoclaved beads were allowed to settle on the bottom of 
the bottle and the supernatant was removed and replaced with 50 mL of warm 
serum-free DMEM. The washing was repeated twice and finally beads were 
resuspended in 50 mL of serum-free medium and stored at 4 °C. The 
approximate concentration of beads in the suspension was 80 000 beads per 1 
mL.  
 
Attaching HT-1080 cells to beads 
In order to attach cells to microcarrier beads, HT-1080 cells were 
trypsinised and counted. 0.5 x 105 cells were mixed with 200 beads in 0.5 mL 
DMEM supplemented with 10 % (v/v) FBS, antibiotics and 10 mM HEPES. The 
cells/beads suspension was attached horizontally to a shaking platform with 
agitation in a 2 mL Eppendorf tube and incubated for 6-7 hours at 37 °C. A light 
microscope was used to assess if cells had attached to the beads. Beads were 
then allowed to settle on the bottom of the tube. The supernatant was removed to 
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a minimal volume of 50 µL and 450 µL of fresh growth medium were added. 
Beads were kept on ice for the next step. 
 
Mixing beads with collagen 
Nine portions of Cellmatrix type I-A collagen were mixed with one portion 
of 10x RPMI in a 50 mL pre-cooled Falcon tube. The pH of the collagen was 
adjusted to 8.0 and monitored with a pH strip. 250 µL of cell/beads suspension 
was mixed with 500 µL of neutralised collagen by gently pipetting and kept on 
ice. The surface of a single well of a 12-well plate was coated with the neutralised 
collagen by pouring 300 µL of the collagen per well and subsequently removing 
the excess. Immediately after that the collagen/cells/beads suspension was 
added to the coated well and incubated at 37 °C for 60 min to allow the collagen 
to polymerise. After incubation, 1.5 mL of DMEM supplemented with 10 % (v/v) 
FBS was added to the well and cells cultured for approximately 36 hours. After 
incubation, cells in the collagen were fixed with 3 % PFA in PBS. Images were 
acquired using a light microscope equipped with a CCD-camera. The distances 
between cells and beads were measured using ImageJ software (Figure 2.3).  
 
 
 
Figure 2.3: Quantification of bead invasion assay using ImageJ software. 
(A) Images were acquired using a light microscope equipped with a CCD-
camera. Only well-focused cells were included in quantification. (B) The line tool 
was used to measure the distance between a cell nucleus and the surface of a 
bead. Counted cells were highlighted in black to avoid recounting. 
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2.13 IMMUNOPRECIPITATION  
 
2.13.1    Reagents 
RIPA buffer 
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 % (v/v) Triton X-100, 0.02 % 
(w/v) NaN3, 0.1 % (w/v) SDS, 1 % (w/v) deoxycholic acid 
 
TNC buffer 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM CaCl2 and 0.02 % NaN3 
 
2.13.2 Procedure 
COS-7 cells were seeded in six 6-well culture dishes at 2 x 105 cells per 
well. The following day, cells were transiently transfected with mock vector or 
FLAG-tagged MT1-MMP constructs. 48 hours later, cells from a single well were 
lysed in 100 µL of 1x reducing SDS sample buffer and subjected to Western blot 
analysis. Cells from the other five wells were pooled and lysed with 5 mL RIPA 
buffer. The lysate was sonicated and spun in order to remove insoluble material. 
The supernatant was collected and incubated with 50 µL of a suspension of anti-
FLAG-M2 conjugated beads at 4 ˚C with rotation. 2 hours later, beads were 
washed three times with RIPA buffer and once with TNC buffer. Proteins were 
eluted from the beads by boiling at 95 °C with 50 µL of 1 x reducing SDS sample 
buffer for 10 minutes. The sample was then spun at 16,000 g for 10 minutes and 
the supernatant passed through a miniprep column to remove any remaining 
beads. Samples were separated on a 7.5 % SDS-polyacrylamide gel and 
subjected to Western blot analysis. 10 µM GM6001 and proteinases inhibitor 
cocktail (dilution 1/1000) were added in all incubation and wash steps. 
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2.14 FLOW CYTOMETRY  
 
2.14.1 Reagents: 
 
Washing buffer  
1 x PBS, 1% (v/v) FBS, 0.02% (v/v) NaN3 
Blocking solution 
3 % (w/v) BSA, 5 % (v/v) goat serum in TBS 
 
2.14.2 Procedure 
Flow cytometry is a commonly used technique to evaluate the presence of 
cell surface or intracellular proteins on a single cell basis. Cells labeled with 
fluorochrome-conjugated antibodies are able to scatter incident laser light and 
emit fluorescence as they move in a fluid stream through a beam of light. 
Consequently, the light scatter provides information regarding their relative size 
and granularity. At the same time, the amount of antigen present on a cell can be 
evaluated according to the fluorescence intensity.  
Flow cytometry was performed as follow. HT-1080 cells were transfected 
with non-targeting siRNA or siRNAs against KIF3A, KIF13A or KIF9. 72 hours 
later, cells were harvested using non-enzymatic cell dissociation solution, and 
fixed with 4 % formaldehyde in PBS for 10 minutes at room temperature. After 
washing 3 times with 1 x PBS, cells were blocked with blocking solution 
containing 3 % (w/v) BSA, 5 % (v/v) goat serum in TBS. After that, an anti-MT1-
MMP antibody (clone LEM 2/15.8) in blocking solution was added. One hour 
later, cells were washed 3 times with the washing buffer, followed by incubation 
with Alexa 488-conjugated secondary antibody. After 1 hour of incubation, cells 
were washed with 1 x PBS three times prior to acquisition using a BD LSR II 
Flow Cytometer (BD Biosciences). Subsequent analysis was carried out using 
the FlowJo (Treestar) software. Saturating amounts of primary and secondary 
antibodies were used for the MT1-MMP staining.  
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3.1 INTRODUCTION  
Cell surface localisation of MT1-MMP in a 2D culture system is highly 
polarised with the enzyme accumulating mainly at sites of substrate attachment 
and lamellipodia.  
The mechanism that localises MT1-MMP to substrate attachment sites is 
not known. Unpublished data from Dr Itoh’s laboratory indicate that the MT-Loop 
region of the catalytic domain of the enzyme is important for localisation to the 
basal surface of polarised epithelial MDCK cells cultured on 2D-collagen (Bird 
and Itoh, 2006). An initial study using COS-7 cells has suggested that the MT-
Loop may also be responsible for localisation of MT1-MMP to substrate 
attachment sites of transformed cells (Bird and Itoh, 2006). To further explore this 
observation, domain dependent-localisation of MT1-MMP to the substrate 
attachment sites was investigated using the fluorescent gelatin film degradation 
assay.  
One previously described mechanism by which MT1-MMP localises to 
lamellipodia is association of the enzyme with CD44 (Mori et al., 2002). Mori et 
al. (2002) demonstrated that when cell surface Myc-tagged CD44 was forced to 
move by addition of anti-Myc-conjugated beads to cells, MT1-MMP molecules 
were translocated with CD44 (Mori et al., 2002). The stem region of CD44 was 
shown to bind to the Hpx domain of the enzyme (Mori et al., 2002; Suenaga et 
al., 2005), and the cytoplasmic tail was shown to associate with ERM proteins 
(Legg et al., 2002; Tsukita et al., 1994), indirectly linking MT1-MMP to the actin 
cytoskeleton (Mori et al., 2002). Although, CD44 has been implicated in MT1-
MMP localisation to lamellipodia, its effect on localisation to other areas of the 
plasma membrane is not known. The Hpx domain has been shown to be required 
for lamellipodia localisation of MT1-MMP (Mori et al., 2002), but the role of other 
domains in this localisation still needs to be investigated.  
In this chapter, a series of domain deletion mutants of MT1-MMP were 
used to identify domain(s) responsible for enzyme localisation to substrate 
attachment sites and lamellipodia. Next, the effect of CD44 on MT1-MMP 
localisation to substrate attachments sites was analysed using the fluorescent 
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gelatin film degradation assay. Finally, the effect of CD44 on MT1-MMP-
dependent cell invasion was examined using the microcarrier bead invasion 
assay.  
 
 
3.2 RESULTS  
 
3.2.1 MT1-MMP-dependent fluorescent gelatin film degradation assay  
  In order to investigate MT1-MMP localisation to substrate attachment 
sites, a fluorescent gelatin film degradation assay was employed. To confirm that 
degradation of gelatin film is mediated by MT1-MMP, COS-7 cells, which do not 
endogenously express this enzyme, were transiently transfected with mock 
vector or plasmid DNA encoding wild type MT1-MMP fused with red fluorescent 
protein (MT1-RFP). After 15 hours of incubation, cells were seeded on a 
fluorescently labeled gelatin film and incubated in DMEM supplemented with 10 
% (v/v) FBS and containing TIMP-2, GM6001 (a broad spectrum MMP inhibitor), 
anti-MT1-MMP inhibitory antibody (DX-2400), DMSO (a vehicle control for 
GM6001) or buffer that the DX-2400 antibody was supplied in. After one hour of 
incubation, cells were fixed with 3 % (w/v) PFA in PBS for 15 minutes. Mock cells 
were permeabilised and stained for F-actin with Alexa-568-conjugated phalloidin. 
MT1-RFP-expressing cells were visualised by fluorescent microscopy without 
need of staining. Gelatin degradation was detected using a confocal microscope 
as black areas against a green gelatin background.  
As shown in Figure 3.1, no degradation was observed in mock cells. MT1-
RFP expressing cells, untreated or incubated with DMSO or DX-2400 buffer, 
extensively degraded the underlying matrix. In contrast, TIMP-2, GM6001 and 
DX-2400 antibody completely inhibited gelatin degradation by MT1-RFP 
expressing cells, indicating that the degradation in this experimental system is a 
direct result of MT1-MMP proteolytic activity.  
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Figure 3.1: MT1-MMP-dependent fluorescent gelatin film degradation assay. 
COS-7 cells were transiently transfected with 1 µg of mock vector or plasmid 
DNA encoding MT1-RFP. After 15 hours of incubation, cells were seeded on 
Alexa-488-gelatin-coated coverslips and incubated in DMEM supplemented with 
10 % (v/v) FBS and containing 0.5 µM TIMP-2, 10 µM, 0.5 µM anti-MT1-MMP 
inhibitory antibody DX-2400, DMSO (vehiscle control for GM6001) or the 
antibody storage buffer (1:200). After 1 hour of incubation, cells were fixed with 3 
% (w/v) PFA in PBS for 15 minutes. Mock cells were permeabilised and stained 
for F-actin using Alexa-568-conjugated phalloidin. Images were captured using 
an Ultraview confocal microscope. In the merged image, MT1-RFP and actin are 
shown in red. Areas of gelatin degradation are shown as dark areas against the 
green background. Scale bar represents 300 µm. 
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3.2.2 Domain-dependent localisation of MT1-MMP to substrate attachment 
sites 
 
3.2.2.1 Deletion of MT-Loop decreases MT1-MMP-dependent gelatin film 
 degradation by COS-7 cells 
Domain-dependent localisation of MT1-MMP to the substrate attachment 
sites was assessed by analysing degradation of the fluorescent gelatin film by 
cells transfected with different FLAG-tagged MT1-MMP domain deletion mutants 
(Figure 3.2 A). 
Western blot analysis using the anti-FLAG M2 antibody revealed 
comparable expression levels of all MT1-MMP constructs (Figure 3.2 B).  
COS-7 cells transiently transfected with mock vector or constructs 
encoding full-length enzyme (MT1F wt) or MT1-MMP domain deletion mutants 
were seeded on a fluorescent gelatin film. After one hour of incubation, cells were 
fixed with 3 % (w/v) PFA in PBS for 15 minutes and stained with an anti-FLAG 
M1 antibody without permeabilisation. The anti-FLAG M1 antibody recognises the 
FLAG-tag only if it is located at the N-terminus of molecule, thus only active form 
of the enzyme is stained with this procedure. 
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Figure 3.2: Deletion of MT-Loop decreases MT1-MMP-dependent gelatin 
film degradation by COS-7 cells. COS-7 cells were transiently transfected with 
1 µg of mock vector, or expression plasmids encoding FLAG-tagged full-length 
MT1-MMP (MT1F wt) or MT1-MMP domain deletion mutants, as indicated. 15 
hours later, 0.5 x 105 cells were seeded on Alexa-488-gelatin-coated coverslips, 
while residual cells were lysed and subjected to Western blot analysis. After 1 
hour of incubation, cells seeded on gelatin film were fixed and stained for cell 
surface FLAG-tag. (A) Schematic representation of constructs used in this 
experiment and their calculated molecular weights (MW). MT1F (wt), full-length 
FLAG-tagged MT1-MMP; SP, signal peptide; Pro, prodomain; FLAG, FLAG-tag; 
Cat, catalytic domain; MT-Loop, MT-Loop; L1, linker-1; Hpx, hemopexin domain; 
L2, linker-2; Tm, transmembrane domain; CP, cytoplasmic tail; MT1F-NGFRTm, a 
chimera mutant in which Tm domain of MT1-MMP was replaced with the 
corresponding region of nerve growth factor receptor (NGFR). (B) Western blot 
analysis using mouse anti-FLAG M2 antibody with an anti-mouse AP-linked 
secondary antibody. (C) Degradation of Alexa-488-gelatin film by cells 
expressing MT1F or its domain deletion mutants. Cell surface staining of FLAG-
tagged proteins was performed with mouse anti-FLAG M1 primary and Alexa-
568-conjugated goat anti-mouse secondary antibodies. In the merged image 
fluorescent gelatin is shown in green and MT1F and its domain deletion mutants 
are shown in red. Areas of gelatin degradation are shown as dark areas against 
the green background. Representative images of each transfectant were 
captured using an Ultraview confocal microscope using the same exposure and 
laser intensity. BF, bright field. Scale bar represents 25 µm. 
 
 In order to compare efficiency of gelatin degradation by the full-length 
enzyme and its domain deletion mutants, only cells with the similar fluorescence 
intensity of FLAG-tag staining were analysed. Among all MT1-MMP mutants 
tested, only removal of the MT-Loop, a region of 8 amino acids 163PYAYIREG170 
in the catalytic domain, markedly decreased degradation of underlying gelatin.  
To further examine this phenomenon, a time course of gelatin degradation 
was carried out (Figure 3.3). COS-7 cells were transiently transfected with mock 
vector or expression plasmids encoding MT1F, MT1F-∆Hpx or MT1F-∆Loop. 15 
hours later, cells were seeded on Alexa-488-gelatin-coated coverslips. After 30, 
60 or 120 minutes, cells were fixed and stained with an anti-FLAG M1 antibody 
without permeabilisation  
As shown in Figure 3.3, fluorescence intensities of the FLAG-tag staining 
were comparable between MT1F, MT1F-∆Hpx and MT1F-∆Loop, suggesting 
similar cell surface expression levels of the active forms of these constructs. 
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Mock cells did not show FLAG-tag staining and did not degrade gelatin. After 30 
minutes, cells expressing MT1F or MT1F-∆Hpx showed small areas of 
degradation, which were clearly increased at one hour. In contrast, cells 
expressing MT1F-∆Loop showed very weak degradation even after one hour.  
After two hours, differences in gelatin degradation between cells expressing 
MT1F and MT1F-∆Loop started to diminish due to the non-linearity of the assay. 
Taken together, the time-course experiment confirmed that deletion of the MT-
Loop delays MT1-MMP-dependent gelatin film degradation.  
As MT-Loop deletion did not affect the amount of active enzyme on the 
cell surface, the observed decrease in gelatin degradation is likely to be a result 
of reduced localisation of the enzyme to substrate attachment sites.  
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Figure 3.3:  Gelatin degradation by MT1F-∆Loop is slower than by MT1F or 
MT1F-∆Hpx. COS-7 cells transfected with mock vector or constructs encoding 
MT1F, MT1F-∆Hpx or MT1F-∆Loop were seeded on Alexa-488-gelatin. After 30, 
60 or 120 minutes, cells were fixed and stained for cell surface FLAG-tag using 
mouse anti-FLAG M1 primary and Alexa-568-conjugated goat anti-mouse 
secondary antibodies. Representative images were captured with an Ultraview 
confocal microscope using the same exposure and laser intensity. In the merged 
image, cell surface MT1F, MT1F-∆Hpx and MT1F-∆Loop are shown in red. Areas 
of gelatin degradation are shown as dark areas against the green background. 
BF, bright field. Scale bar, 25 µm.  
 
 
 
3.2.2.2 Deletion of MT-Loop decreases MT1-MMP-dependent gelatin film 
degradation by HT-1080 and A431 cells 
COS-7 cells are derived from simian kidneys. They are very easy to 
transfect and thus often used in laboratory practice. Although, the removal of MT-
Loop had such a striking effect on gelatin degradation by COS-7 cells, the finding 
had to be confirmed in other cell lines. Human fibrosarcoma cells (HT-1080) and 
human epithelial carcinoma cells (A431) were transiently transfected with mock 
vector or plasmid DNA encoding MT1F, MT1F-∆Cat, MT1F-∆Hpx, MT1F-
NGFRTm, MT1F-∆CP, MT1F-∆Loop or MT1F-∆Hpx∆Loop. 15 hours later, cells 
were seeded on Alexa-488-gelatin-coated coverslips. After one hour of 
incubation, cells were fixed and stained with the anti-FLAG M1 antibody without 
permeabilisation. Representative images were taken using a confocal 
microscope. 
As seen in Figure 3.4, mock cells and cells expressing MT1F-∆Cat were 
unable to digest the gelatin film. In contrast, cells expressing MT1F, MT1F-∆Hpx, 
MT1F-NGFRTm or MT1F-∆CP efficiently degraded the underlying matrix, 
generating large dark areas against the green gelatin background. Only deletion 
of the MT-Loop region markedly decreased gelatin degradation in comparison to 
the full-length enzyme. Immunofluorescent staining using the anti-FLAG M1 
antibody confirmed comparable cell surface expression levels of the active 
mutants. This result indicates that the effect of MT-Loop deletion on gelatin film 
degradation is consistent in different cells. 
 
Chapter 3   MT-Loop and CD44 
 
 98 
 
Chapter 3   MT-Loop and CD44 
 
 99 
 
Chapter 3   MT-Loop and CD44 
 
 100 
Figure 3.4: Deletion of MT-Loop decreases MT1-MMP-dependent gelatin 
film degradation by HT-1080 and A431 cells. HT-1080 (A) and A431(B) cells 
were transiently transfected with mock vector or plasmid DNA encoding MT1F, 
MT1F-∆Cat, MT1F-∆Hpx, MT1F-NGFRTm, MT1F-∆CP, MT1F-∆Loop or MT1F-
∆Hpx∆Loop. 15 hours later, cells were seeded on Alexa-488-gelatin. After one 
hour of incubation, cells were fixed and stained for cell surface FLAG-tag using 
mouse anti-FLAG M1 primary and Alexa-568-conjugated goat anti-mouse 
secondary antibodies. Representative images were captured with an Ultraview 
confocal microscope using the same exposure and laser intensity. In the merged 
image, cell surface FLAG-tag staining is shown in red and areas of gelatin 
degradation are shown as dark areas against the green background. BF, bright 
field. Scale bars represent: 25 µm (A) or40 µm (B).  
 
 
 
3.2.3 Domain-dependent localisation of MT1-MMP to lamellipodia 
 
3.2.3.1 Hpx domain is not required for lamellipodial localisation of MT1-
MMP in a 2D-culture system 
Previous studies have demonstrated that localisation of MT1-MMP to 
lamellipodia is facilitated by interaction with CD44 (Mori et al., 2002). The Hpx 
domain of the enzyme has been reported to bind the stem region of CD44 (Mori 
et al., 2002; Suenaga et al., 2005). The cytoplasmic tail of CD44 associates with 
ERM proteins that bind to the F-actin (Legg et al., 2002; Tsukita et al., 1994), 
indirectly linking MT1-MMP to the actin cytoskeleton. Deletion of the Hpx domain 
prevented localisation of the enzyme to lamellipodia in in vitro studies using HT-
1080 cells (Mori et al., 2002). In order to investigate if any other domain of MT1-
MMP was involved in lamellipodial localisation, a series of MT1-MMP domain 
deletion mutants was expressed in HT-1080 cells and their cell surface 
localisation was assessed by immunofluorescence.  
HT-1080 cells were transfected with mock vector or expression plasmids 
for MT1F, MT1F-∆Hpx, MT1F-∆Hpx∆Cat, MT1F-∆Hpx∆Loop, MT1F-
∆HpxNGFRTm or MT1F-∆Hpx∆CP (Figure 3.5 A). After 24 hours, cells were 
seeded on gelatin-coated coverslips and incubated for 5 hours to allow cells to 
spread. Next, the cells were fixed and stained without permeabilisation. FLAG-
tagged MT1-MMP mutants were stained with mouse anti-FLAG M1 primary and 
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Alexa-568-conjugated goat anti-mouse secondary antibodies. HT-1080 cells 
express a high level of endogenous CD44, which was stained with anti-CD44 rat 
primary and Alexa-488-conjugated goat anti-rat secondary antibodies.  
As seen in Figure 3.5 B, mock transfected cells did not show FLAG-tag staining, 
confirming the specificity of the M1 antibody. HT-1080 cells formed clear 
lamellipodia, where full-length MT1F and endogenous CD44 accumulated. 
Unexpectedly, all MT1-MMP mutants localised to lamellipodia and colocalised 
with CD44. Removal of the MT-Loop did not affect lamellipodial localisation, 
indicating its specific role in localisation of the enzyme to the substrate 
attachment sites. Surprisingly, deletion of the Hpx domain, a reported interface 
with CD44, did not disturb MT1-MMP localisation to lamellipodia or colocalisation 
with CD44. Thus, these data may suggest a non-essentail role of the Hpx domain 
in the lamellipodial localisation of the enzyme. However, as the analysis was 
performed on merged images, it is possible that the observed co-localization of 
CD44 and mutants of MT1-MMP was only apparent due to ruffling of membrane 
at the leading edge of cells. To examine this possibility co-localization of these 
molecules should be analyzed in a single confocal section. Alternatively, cell 
membrane can be stained to correct for membrane ruffling. In addition, these 
observations should be confirmed in fibroblasts that form thin lamellipodia without 
ruffling.  
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Figure 3.5: Domain-dependent localisation of MT1-MMP to lamellipodia. (A) 
Schematic representation of MT1-MMP constructs used in this experiment. 
MT1F, full-length FLAG-tagged MT1-MMP; SP, signal peptide; Pro, prodomain; 
FLAG, FLAG-tag; Cat, catalytic domain; MT-Loop, MT-Loop; L1, linker-1; Hpx, 
hemopexin domain; L2, linker-2; Tm, transmembrane domain; CP, cytoplasmic 
tail. MT1F-NGFRTm is a chimera mutant in which Tm domain of MT1-MMP was 
replaced with the corresponding region of NGFR. (B) HT-1080 cells transfected 
with mock vector or MT1F constructs indicated above were seeded on gelatin-
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coated coverslips. After 5 hours of incubation, cells were fixed and stained 
without permeabilisation. Cell surface staining of FLAG-tagged mutants was 
performed with mouse anti-FLAG M1 primary and Alexa-568-conjugated goat 
anti-mouse secondary antibodies. Endogenous CD44 was stained with anti-
CD44 rat monoclonal primary and Alexa-488-conjugated goat anti-rat secondary 
antibodies. Confocal images were captured with an Ultraview confocal 
microscope. In the merged image, FLAG-tag staining is shown in red, CD44 in 
green, and colocalisation of MT1-MMP constructs with CD44 is shown in yellow. 
Arrows indicate lamellipodia. Scale bar represents 25 µm. 
 
 
3.2.3.2 Hpx domain deletion does not impair association of MT1-MMP 
 with actin cytoskeleton 
The finding that the Hpx domain was not required for lamellipodial 
localisation of MT1-MMP was different from the previous report by Mori et al. 
(2002), who have found that this localisation was facilitated by the association of 
the Hpx domain with the stem region of CD44. Furthermore, Mori et al. (2002) 
showed that CD44 indirectly linked MT1-MMP to actin filaments. Disruption of the 
actin cytoskeleton with cytochalasin D (CyD) caused aggregation of actin-bound 
CD44, and subsequent aggregation of CD44-bound MT1-MMP. Deletion of the 
Hpx domain was shown, however, to prevent the CyD-induced aggregation of the 
enzyme (Mori et al., 2002). To closely examine the interaction between MT1-
MMP and CD44, HT-1080 cells transiently transfected with mock vector, or 
plasmid DNA encoding MT1F or MT1F-∆Hpx were seeded on gelatin-coated 
coverslips. Five hours later, CyD in DMSO (1 µg/mL) or DMSO alone (control 
treatment) were added to the culture media. After 30 minutes of incubation, cells 
were fixed and stained for FLAG-tag and endogenous CD44 without 
permeabilisation. F-actin was visualised by Alexa-488-conjugated phalloidin 
staining with permeabilisation. Colocalisation of MT1F or MT1F-∆Hpx with the 
actin cytoskeleton was analysed using an Ultraview confocal microscope. 
As shown in Figure 3.6, DMSO-treated control cells extended clear 
lamellipodia structures, where MT1F and MT1F-∆Hpx accumulated and 
colocalised with endogenous CD44. During incubation with CyD, cells became 
round, but remained attached to the gelatin. As expected, CyD treatment 
disturbed the actin cytoskeleton and caused translocation of MT1F and CD44 to 
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the sites of actin aggregation. Surprisingly, the MT1-∆Hpx mutant also 
aggregated with actin and CD44 in CyD-treated cells.  
This experiment confirmed that the Hpx was not required for the 
lamellipodial localisation of the enzyme and revealed that it was dispensable for 
association of the enzyme with actin filaments. This suggests that either the Hpx 
domain is not the only interface with CD44, or CD44 is not the only molecule that 
links MT1-MMP to the actin cytoskeleton. 
 
 
 
 
Figure 3.6: MT1F-∆Hpx localises with actin aggregates in cytochalasin D 
(CyD) treated cells. HT-1080 cells expressing MT1F or MT1F-∆Hpx constructs 
were seeded on gelatin-coated coverslips and incubated for 5 hours to allow cells 
to spread and form lamellipodia. Next, CyD in DMSO (final concentration 1 
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µg/mL) or DMSO alone (control treatment) were added to the DMEM 
supplemented with 10 % FBS. After 30 minutes of incubation, cells were fixed 
and stained with anti-FLAG M1 primary and Alexa-568-conjugated goat anti-
mouse secondary antibodies without permeabilisation. Cell surface staining of 
endogenous CD44 was performed with anti-CD44 rat monoclonal primary and 
Cy5-conjugated goat anti-rat secondary antibodies. After permeabilisation, the 
actin cytoskeleton was visualised using Alexa-488-conjugated phalloidin. 
Representative images were captured with an Ultraview confocal microscope. 
 
 
3.2.3.3 Hpx domain is not required for polarised localisation of MT1-MMP 
in cells cultured in 3D-collagen  
To examine the role of Hpx domain in localisation of MT1-MMP in a 3D-
culture system, human cervical cancer (HeLa) cells were transfected with mock 
vector or constructs encoding MT1F or MT1F-∆Hpx, and embedded in a 3D-
collagen gel (2 mg/mL). HeLa cells do not express MT1-MMP endogenously, but 
they form a clear leading edge, where exogenously expressed MT1-MMP is 
localised. Immunofluorescent staining of transfected HeLa cells cultured in 3D-
collagen was performed using anti-FLAG M1 antibody. After permeabilisation 
with 0.1 % Triton X-100 in TBS, actin was stained with Alexa-488-conjugated 
phalloidin. Cells were viewed using an Ultraview confocal microscope. Image 
analysis was performed with ImageJ software. 
Mock transfected cells were round and negative for FLAG-tag staining. 
MT1F and MT1F-∆Hpx transfected cells had elongated shapes and localised the 
enzyme to the protrusive structures (Figure 3.7 A). Although the Hpx domain is 
important for the MT1-MMP-mediated collagenolysis (Itoh et al., 2006; Itoh et al., 
2008), the MT1F-∆Hpx mutant was shown to retain some collagenolytic activity 
(Li et al., 2008). This may explain the ability of HeLa cells expressing MT1F-∆Hpx 
to extend membrane protrusions in 3D type-I collagen. 
 In order to compare localisation of MT1F and MT1F-∆Hpx, mean 
fluorescence intensity (MFI) of FLAG-tag staining was measured for a cell body 
and protrusions and the ratio taken (Figure 3.7 B). Quantification of fluorescence 
intensity of FLAG-tag staining revealed that there were no apparent differences in 
localisation of MT1F and MT1F-∆Hpx to protrusive structures, suggesting that the 
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Hpx domain is not required for polarised MT1-MMP localisation in a 3D-culture 
system. 
 
 
 
 
Figure 3.7: Hpx domain is not required for polarised localisation of mMT1-
MMP in a 3D-culture system. HeLa cells transiently transfected with mock 
vector or constructs encoding MT1F or MT1F-∆Hpx were embedded in 3D-
collagen (2 mg/mL). After overnight incubation, cells were fixed and stained. Cell 
surface FLAG-tagged proteins were stained with mouse M1 anti-FLAG primary 
antibody, followed by staining with Alexa-568 anti-mouse secondary antibody. 
After permeabilisation with 0.1 % (v/v) Triton X-100 in TBS, the actin cytoskeleton 
was visualised with Alexa-488-conjugated phalloidin. (A) Representative images 
were captured using an Ultraview confocal microscope. In the merged image, cell 
surface MT1F and MT1F-∆Hpx are shown in red and actin is shown in green. 
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Scale bar represents 25 µm. (B) Mean fluorescence intensities (MFI) of FLAG-
tag staining for a cell body and cell protrusions were calculated according to the 
formula shown, and the ratio taken. Fluorescence intensities of a cell body (CB) 
and protrusions (P1, P2) as well as intensity of background fluorescence (B) 
were measured using ImageJ software. Statistical significance was evaluated 
using t test. Number of cells analysed was: MT1F, n=30; MT1F-∆Hpx, n=31. 
 
 
3.2.3.4 Immunoprecipitation of MT1F, MT1F-∆Hpx and MT1F-∆Hpx∆L2 
The finding that the Hpx is not required for lamellipodial localisation of 
MT1-MMP was different from the previous report by Mori et al. (2002). The 
observed discrepancy may be a result of different design of the constructs. To 
study the interaction between MT1-MMP and CD44, Mori et al. (2002) used a 
construct which lacked not only the Hpx domain, but also the linker-2 (MT1F-
∆Hpx∆L2). In contrast, in this thesis, MT1F-∆Hpx was used. To test the 
hypothesis that linker-2 may be important for the MT1-MMP-CD44 interaction, an 
immunoprecipitation (IP) experiment was performed. Full-length CD44 binds to 
actin filaments through its cytoplasmic domain. To exclude the possibility that 
during immunoprecipitation CD44 will accumulate together with actin filaments in 
the insoluble fraction, a cytoplasmic domain deletion mutant (CD44-∆CP) of a 
standard form of CD44 was used.  
CD44-negative COS-7 cells were seeded in 6-well culture dishes at 2 x 
105 cells per well. The following day, the cells were transiently transfected with 
mock vector or expression plasmids for CD44-∆CP, MT1F, MT1F-∆Hpx, MT1F-
∆Hpx∆L2, MT1F + CD44-∆CP, MT1F-∆Hpx + CD44-∆CP or MT1F-∆Hpx∆L2 + 
CD44-∆CP. 48 hours later, cells in one well each were recovered in 1 x reducing 
SDS sample buffer and subjected to Western blot to check transfection 
efficiency. Cells from the other 5 wells were pooled and lysed with RIPA buffer 
and subjected to immunoprecipitation using anti-FLAG M2-conjugated beads. 
Precipitated material was analysed for the presence of FLAG-tagged proteins 
and CD44-∆CP by Western blotting. 
As shown in Figure 3.8 Western blot of the cell lysates revealed that 
bands corresponding to MT1F-∆Hpx and MT1F-∆Hpx∆L2 were of similar 
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intensities, indicating the comparable expression levels. In comparison to the 
mutants, the expression of MT1F was lower. 
The sequence of CD44-∆CP predicts a theoretical molecular weight of 37 
kDa; however, the estimated weight of the protein by SDS-PAGE is 80-90 kDa, 
due to extensive glycosylation. In cells transfected with MT1F + CD44-∆CP or 
MT1F-∆Hpx + CD44-∆CP, multiple bands corresponding to CD44-∆CP were 
visible, but showed a similar pattern with a major 80-90 kDa band, a faint 50 kDa 
band and two additional bands of molecular weight about 37 kDa.  Bands 
corresponding to CD44-∆CP in cells transfected with MT1F-∆Hpx∆L2 + CD44-
∆CP showed a pattern similar to cells expressing CD44-∆CP only, and lacked the 
low molecular bands. These differences may reflect different shedding potential 
of the MT1-MMP mutants. All bands were specific as no bands were observed in 
mock transfected cells.  
The precipitated material was probed for FLAG-tagged proteins and 
CD44-∆CP. Bands corresponding to MT1F, MT1F-∆Hpx and MT1F-∆Hpx∆L2 
showed similar intensities, indicating that all constructs were immunoprecipitated 
with the comparable efficiency. The 55 kDa band present in the precipitated 
material represents antibody heavy chain and originates from the M2-conjugated 
beads. The 37 kDa species of CD44-∆CP was precipitated by anti-FLAG 
antibody when co-expressed with MT1F or MT1F-∆Hpx, but not when expressed 
alone or co-expressed with MT1F-∆Hpx∆L2. It is not clear why full-length CD44-
∆CP was not detected in precipitated samples, although it was present in the 
beads unbound fraction (data not shown). It is possible that the weak interaction 
between MT1-MMP and CD44 (Kd approximately 64 nM (Mori et al., 2002)) was 
not sustained in the harsh conditions of the IP procedure. The different pattern of 
CD44-∆CP bands in cells expressing MT1F-∆Hpx∆L2 + CD44-∆CP may suggest 
a role for linker-2 in CD44 shedding and in interaction of MT1-MMP with CD44. 
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Figure 3.8: Immunoprecipitation of MT1F, MT1F-∆Hpx and MT1F-∆Hpx∆L2. 
COS-7 were seeded in 6-well culture dishes at 2 x 105 cells per well and 
transiently transfected with mock vector or expression plasmids for CD44-∆CP, 
MT1F, MT1F-∆Hpx, MT1F-∆Hpx∆L2, MT1F + CD44-∆CP, MT1F-∆Hpx + CD44-
∆CP or MT1F-∆Hpx∆L2 + CD44-∆CP. 48 hours later, cells from one well each 
were recovered with 1 x reducing SDS sample buffer and subjected to Western 
blot to assess transfection efficiency. Cells from the other 5 wells were pooled 
and lysed with 5 mL RIPA buffer, containing proteinase inhibitor cocktail (dilution 
1/1000) and 10 µM GM6001. The lysates were subjected to immunoprecipitation 
using anti-FLAG M2-conjugated beads. Precipitated material was released from 
the beads by boiling with SDS sample buffer and analysed for the presence of 
FLAG-tagged proteins and CD44-∆CP. (A) Schematic illustration of constructs 
used in this experiment. MT1F, full-length FLAG-tagged MT1-MMP; SP, signal 
peptide; Pro, prodomain; FLAG, FLAG-tag; Cat, catalytic domain; MT-Loop, MT-
Loop; L1, linker-1; Hpx, hemopexin domain; L2, linker-2; Tm, transmembrane 
domain; CP, cytoplasmic tail; CD44-∆CP, cytoplasmic domain deletion mutant of 
a standard form of CD44. (B) Transfection efficiency of FLAG-tagged MT1-MMP 
constructs and CD44-∆CP was confirmed by Western blot analysis using mouse 
anti-FLAG M2 and mouse anti-CD44 (clone F4) antibodies, respectively. (C) 
Precipitated samples were analysed for the presence of FLAG-tag proteins and 
CD44-∆CP by Western blotting. Western blots of precipitated samples contain a 
55 kDa band, which represents antibody (IgG) heavy chain and originates from 
M2-conjugated beads. 
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3.2.4 Effect of CD44 on MT1-MMP localisation to substrate attachment 
sites 
 
3.2.4.1 Knockdown of CD44 enhances localisation of MT1-MMP to matrix 
attachment sites 
 CD44 has been shown to localise MT1-MMP to lamellipodia (Mori et 
al., 2002); however, its role in localisation of the enzyme to substrate attachment 
sites is not known. Here, the effect of CD44 gene knockdown on MT1-MMP-
dependent fluorescent-gelatin film degradation was investigated. HT-1080 cells 
were used in this experiment, because they express high level of endogenous 
CD44 and MT1-MMP and utilise the enzyme to degrade the underlying matrix. 
 First, it was confirmed that gelatin degradation by HT-1080 cells 
depended on proteolytic activity of endogenous MT1-MMP (Figure 3.9). HT-1080 
cells were seeded on an Alexa-488-gelatin film and incubated in DMEM 
supplemented with 10 % (v/v) FBS and containing TIMP-2, GM6001 in DMSO, 
anti-MT1-MMP inhibitory antibody (DX-2400) or DMSO. Control cells were left 
untreated. After 15 hours of incubation, cells were fixed and visualised by F-actin 
staining with Alexa-568-phalloidin. Gelatin degradation was detected using a 
confocal microscope as black areas against the green gelatin background.  
 As shown in Figure 3.9, control cells or cell treated with DMSO 
extensively degraded the underlying gelatin. In contrast, cells treated with 
GM6001, TIMP-2 or DX-2400 antibody lost the ability to digest the underlying 
matrix. This result clearly suggests that endogenous MT1-MMP is responsible for 
gelatin degradation by HT-1080 cells in this system. 
 Next, the effect of CD44 gene silencing on MT1-MMP-dependent 
gelatin film degradation by HT-1080 cells was examined. HT-1080 cells were 
seeded in 24-well culture dishes at 3 x 104 cells per well and transfected with 200 
ng of non-targeting siRNA or CD44 siRNA using Lipofectamine RNAiMAX 
reagent. 60 hours later, 1.5 x 104 cells were seeded on an Alexa-488-gelatin film 
and incubated for 15 hours.  
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Figure 3.9: Degradation of fluorescent-gelatin film by HT-1080 cells 
depends on proteolytic activity of endogenous MT1-MMP. HT-1080 cells 
were seeded on Alexa 488-gelatin film and incubated in DMEM supplemented 
with 10 % FBS and containing 0.5 µM TIMP-2, 10 µM GM6001 in DMSO, 0.5 µM 
anti-MT1-MMP inhibitory antibody (DX-2400) or DMSO (dilution 1/1000). Control 
cells were left untreated. After 15 hours of incubation, cells were fixed and 
stained with Alexa-568-phalloidin with permeabilisation. Gelatin degradation was 
detected using a confocal microscope as black areas against the green gelatin 
background. Actin staining is shown in red. Scale bars represent 300 µm. 
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 To check the efficiency of CD44 knockdown, residual cells were lysed and 
subjected to Western blot analysis (Figure 3.10 A), or seeded on gelatin-coated 
coverslips and stained for CD44 without permeabilisation (Figure 3.10 B).  
 As shown in Figure 3.10 A, an apparent decrease in CD44 expression was 
detected in cells transfected with CD44 siRNA. In contrast, non-transfected HT-
1080 cells (Control) or cells transfected with non-targeting siRNA (Non-target) 
showed high levels of CD44 expression. A Western blot for actin was used as a 
loading control. The effect of CD44 gene silencing on MT1-MMP expression level 
was analysed by Western blotting using mouse anti-MT1-MMP (222-1D8) 
antibody. There were no apparent changes in MT1-MMP expression level upon 
CD44 knockdown. 
 Immunofluorescence staining of CD44 was performed to further confirm 
the efficiency of CD44 knockdown. Untreated HT-1080 cells (control) or cells 
transfected with non-targeting siRNA or CD44 siRNA were seeded on gelatin-
coated coverslips and, after 15 hours of incubation, fixed and stained. Cell 
surface CD44 was visualised by staining with anti-CD44 rat monoclonal antibody. 
F-actin was stained with Alexa-488-conjugated phalloidin with permeabilisation. 
Representative confocal images were captured with an Ultraview confocal 
microscope using the same exposure and laser intensity. As seen in Figure 3.10 
B, in control cells or cells treated with non-targeting siRNA, CD44 localised 
mainly to lamellipodia. In contrast, only a faint staining of CD44 was detected in 
HT-1080 cells transfected with CD44 siRNA, suggesting high efficiency of 
knockdown.  
 Next, the effect of CD44 knockdown on gelatin degradation was analysed. 
As shown in Figure 3.10 C, after 15 hours of incubation on the gelatin film, 
control cells moderately degraded the underlying matrix. Treatment with non-
targeting siRNA slightly increased the ability of HT-1080 cells to degrade gelatin 
compare to the control. Interestingly, in comparison to non-targeting siRNA, 
silencing of the CD44 gene resulted in an apparent enhancement in gelatin film 
degradation.  
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Figure 3.10: Silencing of CD44 gene enhances MT1-MMP-dependent gelatin 
film degradation by HT-1080 cells. HT-1080 cells were transfected with non-
targeting siRNA or CD44 siRNA. Control cells were left untreated. (A) 72 hours 
after silencing, cells were lysed with 1 x SDS reducing sample buffer and 
analysed by Western blotting, using anti-CD44 (F4) primary antibody with anti-
mouse AP-linked secondary antibody. The effect of CD44 silencing on MT1-MMP 
expression was analysed by Western blotting using mouse anti-Hpx domain 222-
ID8 primary antibody with anti-mouse AP-linked secondary antibody. Scale bar 
represents 25 µm. (B) 60 hours after silencing, cells were seeded on gelatin-
coated coverslips. After 15 hours of incubation, CD44 silencing was confirmed by 
immunofluorescent staining of cell surface CD44 using anti-CD44 rat primary 
antibody with Alexa-568-conjugated goat anti-rat secondary antibody. Actin 
staining was performed with Alexa-488 conjugated phalloidin. In the merged 
image, CD44 is shown in red and actin is shown in green. (C) 60 hours after 
silencing, cells were seeded on Alexa-488 gelatin film. After 15 hours of 
incubation, cells were permeabilised and stained with Alexa-568 phalloidin. In the 
merged image, actin is shown in red and gelatin is shown in green. Gelatin 
degradation is shown as dark areas against the green background. Scale bars 
represent 150 µm. 
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3.2.4.2 Knockdown of CD44 increases collagen-film degradation by HT-
1080 cells 
 To investigate the effect of CD44 silencing on collagen degradation, HT-
1080 cells were transfected with non-targeting siRNA or CD44 siRNA. After 48 
hours, cells were seed on fluorescein-conjugated type-I collagen-coated 
coverslips (final concentration of 2 mg/mL collagen) and incubated in DMEM 
supplemented with 2 % FBS. 36 hours later, cells and the collagen layer were 
fixed and cells were stained with Alexa-568-conjugated phalloidin to visualise the 
actin cytoskeleton. Digested areas of collagen were visualised as black holes 
against the green collagen background. The control sample did not contain cells. 
A Nikon TE2000-E microscope was used to capture representative pictures. As 
shown in Figure 3.11, in the absence of cells, the collagen surface was smooth. 
Cells treated with non-targeting siRNA degraded the collagen film, generating 
fluorescence-negative dark areas in the collagen layer. Interestingly, silencing of 
the CD44 gene markedly enhanced collagen degradation in comparison to non-
targeting siRNA, as observed for gelatin degradation (Section 3.2.4.1).  
 
 
 
Figure 3.11: Silencing of CD44 gene increases collagen-film degradation by 
HT-1080 cells. HT-1080 cells were transfected with non-targeting siRNA or 
CD44 siRNAs. 48 hours after silencing, cells were seeded on fluorescein-
conjugated type-I collagen-coated coverslips (final concentration of 2 mg/mL 
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collagen) and incubated in DMEM supplemented with 2 % FBS. 36 hours latter, 
cells and the collagen layer were fixed using 3 % (w/v) PFA for 30 minutes and 
stained with Alexa-568-conjugated phalloidin. The control sample did not contain 
cells. Digested areas of collagen are shown as black areas against the grey 
collagen background.  
 
3.2.4.3 Overexpression of CD44 decreases MT1-MMP-dependent gelatin 
film degradation 
 To further investigate role of CD44 in MT1-MMP-dependent gelatin film 
degradation, the effect of CD44 overexpression was analysed. COS-7 cells were 
chosen for this experiment, because they have an undetectable level of 
expression of endogenous CD44 (Franzmann et al., 2005; Jiang et al., 2002) and 
are very easy to transfect. MT1F, MT1F-∆Hpx and MT1F-∆Loop constructs were 
overexpressed in COS-7 cells alone or together with a standard form of CD44 
(CD44) in a DNA ratio of 1:5. Mock cells and cells expressing CD44 alone were 
used as controls. After 15 hours of incubation, transfected cells were seeded on 
an Alexa-488 gelatin film. 1 hour later, the cells were fixed and stained with anti-
FLAG M1 antibody without permeabilisation (Figure 3.12 A). Residual cells were 
lysed and subjected to Western blot analysis using anti-FLAG M2 or anti-CD44 
(H-300) antibodies. A Western blot for actin was used as a loading control 
(Figure 3.12 B). 
As seen in Figure 3.12 B, Western blots confirmed expression of all 
transfected constructs. The faint band of about 80 kDa detected in COS-7 cells 
not transfected with CD44 plasmid, is considered to be unspecific, as 
endogenous CD44 was not detected in COS-7 cells either by Western blotting 
using an anti-CD44 F4 antibody (Figure 3.14) or immunofluorescence (Figure 
3.12 A). As shown in Figure 3.12 A, COS-7 cells expressing MT1F or MT1F-
∆Hpx extensively degraded the underlying gelatin film. As expected, deletion of 
the MT-Loop markedly decreased the degradation. No degradation was detected 
in mock or CD44-transfected cells. Interestingly, coexpression of CD44 with 
MT1F or its mutants markedly decreased gelatin degradation. The already weak 
degradation by MT1F-∆Loop transfected cells was even further reduced upon 
CD44 overexpression. As CD44 has been shown to be involved in the 
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localisation of MT1-MMP to lamellipodia (Mori et al., 2002), the observed 
decrease in gelatin degradation may be a result of enhanced localisation of the 
enzyme to these structures, causing fewer molecules to be delivered to the 
substrate attachment sites.  
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Figure 3.12: Overexpression of CD44 decreases MT1-MMP–dependent 
gelatin-film degradation. (A) COS-7 cells expressing MT1F, MT1F-∆Hpx or 
MT1F-∆Loop alone or together with exogenous CD44 were seeded on an Alexa-
488-gelatin film. 1 hour later, cells were fixed and stained with anti-FLAG M1 
antibody without permeabilisation. Representative images were captured with a 
Nikon TE2000-E microscope. In the merged image, FLAG-tag staining is shown 
in red and gelatin in green. Scale bar represents 300 µm. (B) Expression of 
CD44 and MT1-MMP constructs was confirmed by Western blotting using anti-
CD44 (H-300) and anti-FLAG M2 antibodies. A Western blot for actin was used 
as a loading control.  
 
 To further investigate the effect of CD44 overexpression on gelatin film 
degradation, COS-7 cells were transiently transfected with an MT1F expression 
plasmid and with increasing amounts of a CD44 expression plasmid. 24 hours 
later, cells were seeded on a fluorescent gelatin film. After 1 hour of incubation, 
cells were fixed and stained with anti-FLAG M1 and anti-CD44 antibodies without 
permeabilisation. Representative images were captured using an Ultraview 
confocal microscope. The same exposure and laser intensity were used for all 
images. Expression of MT1F and CD44 was confirmed by Western blotting using 
anti-FLAG M2 and anti-CD44 (H-300) antibodies (Figure 3.13 B). 
As seen in Figure 3.13 A, all cells expressing MT1-MMP degraded the 
underlying matrix; however, the degradation decreased with increasing 
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expression of CD44. Cells transfected with MT1F and 1 µg of CD44 plasmid 
degraded the underlying gelatin mainly at the cell periphery. No degradation was 
observed in mock cells or cells expressing CD44 alone, confirming that 
degradation of the gelatin film was a direct result of MT1F activity. No staining 
was detected in mock cells, indicating the specificity of the antibodies. The 
intensity of CD44 staining correlated with the increasing amount of CD44 plasmid 
used for the transfection. 
Taken together, this experiment demonstrated that overexpression of 
CD44 in COS-7 cells reduces MT1-MMP-dependent gelatin degradation in a 
dose-dependent manner.  
 
 
Chapter 3   MT-Loop and CD44 
 
 121 
 
 
 
 
  
Figure 3.13: Overexpression of CD44 decreases MT1–MMP-dependent 
gelatin degradation in a dose-dependent manner. (A) COS-7 cells were 
transiently transfected with mock vector or expression plasmids for CD44 and 
MT1F as indicated above. 24 hours later, cells were seeded on an Alexa-488 
gelatin film. After one hour of incubation, cells were fixed and stained with anti-
FLAG M1 and anti-CD44S rat monoclonal antibodies without permeabilisation. 
Images were captured using an Ultraview confocal microscope. The same 
exposure and laser intensity were used for all images. In the merged image, 
MT1F is shown in red, CD44 in blue and colocalisation of MT1F and CD44 is 
shown in pink. Scale bar represents 25 µm. (B) Expression of MT1F and CD44 
was confirmed by Western blotting using anti-FLAG M2 and anti-CD44 (H-300) 
antibodies, respectively. Actin staining was used as a loading control. 
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3.2.4.4 Overexpression of CD44-∆CP decreases MT1-MMP-dependent 
gelatin film degradation 
Previous studies have shown that CD44 undergoes ectodomain shedding 
mediated by MT1-MMP (Kajita et al., 2001; Suenaga et al., 2005). This is 
followed by further proteolytic processing of the residual transmembrane and 
cytoplasmic domains, resulting in the release of a CD44 intracellular domain 
(ICD) fragment (Murakami et al., 2003; Okamoto et al., 2001). The ICD fragment 
has been shown to act as a signal transduction molecule, translocating to the 
nucleus and activating gene transcription (Okamoto et al., 2001). To test the 
possibility that CD44-mediated signaling was responsible for the observed 
decrease in MT1-MMP-dependent gelatin film degradation upon CD44 
overexpression (Section 3.2.4.3), a cytoplasmic domain deletion mutant of CD44 
(CD44-∆CP) was next examined.  
COS-7 cells were transfected with mock vector or expression plasmids for 
CD44-∆CP, MT1-RFP and MT1-RFP + CD44-∆CP. 24 hours after transfection, 
cells were seeded on Alexa-488 gelatin. 1 hour later, cells were fixed and 
representative images captured using an Ultraview confocal microscope. The 
same exposure and laser intensity were used for all images. To visualise cells in 
mock and CD44-∆CP samples, bright field images were taken using a CCD-
equipped microscope with 10 x objective lens (Figure 3.14 A). Expression of the 
transfected constructs was confirmed by Western blotting (Figure 3.14 B). 
As seen in Figure 3.14 A, no degradation of the underlying gelatin was 
detected in mock or CD44-∆CP expressing cells. In contrast, cells expressing 
MT1-RFP alone efficiently degraded gelatin, generating black areas against the 
green background. Interestingly, cells coexpressing MT1-RFP together with 
CD44-∆CP showed a reduced ability to digest the underlying matrix in 
comparison to cells expressing MT1-RFP alone.  
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Figure 3.14 Overexpression of CD44-∆CP in COS-7 cells decreases MT1–
MMP-dependent gelatin film degradation. (A) COS-7 cells were transiently 
transfected with mock vector or constructs encoding CD44-∆CP, MT1-RFP or 
MT1-RFP + CD44-∆CP. 24 hours after transfection, cells were seeded on Alexa-
488-gelatin. After one hour of incubation, cells were fixed and representative 
images captured using an Ultraview confocal microscope. The same exposure 
and laser intensity were used for all images. Bright field images were taken using 
a CCD-equipped microscope with 10 x objective lens to visualise cells 
transfected with mock vector or CD44-∆CP construct. In the merged image, MT1-
RFP is shown in red, gelatin in green and gelatin degradation is shown as black 
areas against the green background. (B) Expression of transfected constructs 
was confirmed by Western blotting using anti-FLAG M2 and anti-CD44 (F4) 
antibodies.  
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The effect of CD44-∆CP overexpression on gelatin film degradation was 
also confirmed using MT1F. COS-7 cells were transiently transfected with mock 
vector or expression plasmids for CD44-∆CP, MT1F or MT1F + CD44-∆CP. 24 
hours later, cells were seeded on Alexa-488 gelatin. After 1 hour of incubation, 
cells were fixed and stained with anti-FLAG M1 and anti-CD44 antibodies without 
permeabilisation to visualise MT1-F and CD44-∆CP, respectively. Images were 
captured using an Ultraview confocal microscope. The same exposure and laser 
intensity were used for all images.  
As shown in Figure 3.15 A, the cell surface level of the active MT1F was 
not affected by CD44-∆CP overexpression. Cells expressing MT1F extensively 
degraded the underlying gelatin. In comparison to MT1F, cells coexpressing 
MT1F together with CD44-∆CP showed decreased gelatin degradation, detected 
mainly at the cell periphery. No degradation was observed in mock or CD44-∆CP 
expressing cells.  
 Taken together, these data demonstrated that the effect of CD44-∆CP 
overexpression on MT1-MMP-dependent gelatin film degradation was similar to 
the full-length CD44. This suggests that a CD44-mediated signaling pathway is 
unlikely to be involved in the observed phenomenon. 
 
 
 
Chapter 3   MT-Loop and CD44 
 
 125 
 
Chapter 3   MT-Loop and CD44 
 
 126 
Figure 3.15 Overexpression of CD44-∆CP decreases MT1-MMP–dependent 
gelatin degradation. (A) COS-7 cells were transiently transfected with mock 
vector or expression plasmids for CD44-∆CP, MT1F or MT1F + CD44-∆CP. 24 
hours after transfection, cells were seeded on Alexa-488-gelatin. After one hour 
of incubation, cells were fixed and stained with anti-FLAG M1 and anti-CD44S 
antibodies, to visualise cell surface MT1F and CD44-∆CP, respectively. 
Representative images were captured using an Ultraview confocal microscope. 
The same exposure and laser intensity were used for all images. In the merged 
image, MT1F is shown in red, CD44-∆CP in blue and colocalisation of MT1F and 
CD44-∆CP is shown in pink. Gelatin degradation is shown as black areas against 
the green background. Scale bar represents 25 µm. (B) Expression of 
transfected constructs was confirmed by Western blotting using anti-FLAG M2 
and anti-CD44 (F4) antibodies.  
 
 
3.2.4.5 Soluble CD44 (sCD44) does not inhibit MT1-MMP-dependent gelatin 
film degradation 
CD44 is a substrate for MT1-MMP. Therefore, it is possible that CD44 
overexpression decreases gelatin film degradation simply by competing with 
gelatin for binding to MT1-MMP. It is likely that MT1-MMP engaged in CD44 
shedding may show lower proteolytic potential towards the underlying matrix. To 
test this hypothesis, human embryonic kidney 293 (HEK-293) cells were stably 
transfected with mock vector or expression plasmid for a soluble form of CD44 
(sCD44). Untransfected HEK-293 cells were used as a control. Two days after 
transfection, condition media were removed and fresh DMEM, containing 400 
µg/mL hygromycin and 10 % (v/v) FBS, was added. This was repeated every two 
days. By two weeks after transfection, the control cells had perished. To test for 
sCD44 expression in the hygromycin-resistant cells, the media were changed to 
serum-free conditions. 48 hours later, the media were collected and spun to 
remove cell debris. The clear supernatants were collected and concentrated. The 
total amount of proteins in the medium of transfected mock cells (mock-medium) 
and cells stably expressing sCD44 (sCD44-medium) was comparable. 10 µL of 
concentrated mock-medium or sCD44-medium was mixed in ratio 1:1 with 2 x 
SDS reducing sample buffer and analysed by Western blotting using an anti-
CD44 (F4) antibody. HT-1080 cell lysate was used as a positive control. As seen 
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in Figure 3.16 A, high amount of sCD44 had accumulated in the medium of cells 
stably expressing sCD44. No sCD44 was detected in the medium of mock 
transfected cells. 
Next, COS-7 cells were transiently transfected with mock vector or MT1-
RFP. 24 hours after transfection, cells were seeded on Alexa-488 gelatin and 
cultured in the sCD44-medium or mock-medium, supplemented with 2 % FBS. 
After a 2.5-hour incubation, cells were fixed and gelatin degradation analysed 
using a Nikon TE2000-E microscope. As shown in Figure 3.16 B, mock cells did 
not degrade the underlying matrix, confirming that the degradation in this system 
depended on MT1-RFP activity. MT1-RFP-transfected cells incubated in the 
mock-medium or sCD44-medium digested gelatin with comparable efficiency, 
suggesting that CD44 does not inhibit proteolytic activity of cell surface MT1-
MMP against gelatin.  
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Figure 3.16: Soluble CD44 (sCD44) does not inhibit MT1-MMP-dependent 
gelatin degradation. (A) HEK-293 cells were transfected with mock vector 
(pCEP4) or construct encoding a soluble CD44 (sCD44). Non-transfected HEK-
293 cells were used as a control. Construct encoding sCD44 in pCEP4 vector 
was kindly provided by Dr Y. Itoh. Transfected and control cells were cultured for 
two days after transfection, at which time the conditioned medium was removed 
and fresh DMEM, containing 400 µg/mL hygromycin and 10 % (v/v) FBS, was 
added. By two weeks after transfection, the control cells had perished. The 
medium on mock and sCD44 transfected cells was changed to serum-free. 48 
hours later, the media were collected and spun to remove cell debris. The clear 
supernatants were collected and concentrated. The total amount of proteins in 
mock- and sCD44-medium was adjusted using Bio-rad protein assay. 10 µL of 
concentrated mock-medium or sCD44-containing medium was mixed in ratio 1:1 
with 2 x SDS sample buffer and subjected to Western blotting using mouse anti-
CD44 (F4) antibody. HT-1080 cell lysate was used as a positive control. (B) 
COS-7 cells were transiently transfected with mock vector or expression plasmid 
for MT1-RFP. 24 hours after transfection, cells were seeded on Alexa-488 gelatin 
in the medium containing sCD44 (sCD44-medium) or mock-medium. After a 2.5 
Chapter 3   MT-Loop and CD44 
 
 129 
hours of incubation, cells were fixed and gelatin degradation was analysed using 
a Nikon TE2000-E microscope. In the merged image MT1-RRP is shown in red 
and gelatin in green. Bright-field (BF) images were taken using CCD-equipped 
microscope with 10 x objective lens to visualise cells transfected with mock 
vector.  
 
 
3.2.5 Activation of proMMP-2 is not impaired by CD44 knockdown  
Next, the effect of CD44 on MT1-MMP-mediated proMMP-2 activation was 
investigated by gelatin zymography. HT-1080 cells were seeded at 3 x 104 in a 
24-well plate and transfected with non-targeting siRNA or CD44 siRNA. The 
control sample did not contain cells. 48 hours later, media were changed to 150 
µL serum-free DMEM, containing exogenous proMMP-2 (0.7 µg/mL), and where 
indicated, 10 µM GM6001 was added. After 36 hours of incubation, the media 
were recovered, mixed with 4 x non-reducing SDS sample buffer and subjected 
to gelatin zymography. Digested areas were visible as transparent bands against 
the dark blue gelatin background.  
MT1-MMP processes 72-kDa proMMP-2 to a 68-kDa intermediate form, 
which can be further activated by intermolecular cleavage to a 66-kDa end 
product (Atkinson et al., 1995). As seen in Figure 3.17, the control sample 
incubated with GM6001 showed some proMMP-2 conversion, which probably 
took place during proMMP-2 purification or storage. In comparison to the control, 
cells transfected with non-targeting siRNA efficiently activated proMMP-2, which 
could be observed as an apparent increase of the active form with the 
concomitant decrease of the proform. In comparison to non-targeting siRNA, 
CD44 gene silencing did not affect proMMP-2 activation. Addition of GM6001 
completely inhibited proMMP-2 activation to a basal level observed in the control 
sample treated with GM6001. 
This result suggests that CD44 silencing does not affect MT1-MMP-
mediated proMMP-2 activation and further implies that silencing of the receptor 
does not affect cell surface activity of the enzyme.  
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Figure 3.17: Knockdown of CD44 in HT-1080 cells does not impair MT1-
MMP-mediated proMMP-2 activation. HT-1080 cells were seeded at 3 x 104 in 
a 24-well plate and transfected with non-targeting siRNA (non-target) or CD44 
siRNA. The control sample did not contain cells. After 48 hours of incubation, 
media were changed to 150 µL serum-free DMEM containing 0.7 µg/mL 
proMMP-2 and, where indicated, 10 µM GM6001 in DMSO was added. 36 hours 
later, media were recovered, mixed with 4 x non-reducing SDS sample buffer and 
subjected to gelatin zymography. Cell lysates were recovered with 1 x reducing 
SDS sample buffer and subjected for Western blot analysis. (A) Western blot 
analysis was performed using anti-CD44 (F4) antibody to confirm CD44 
knockdown. Arrowheads indicate bands of interests. (B) Zymography of condition 
media harvested after 36 hours incubation with exogenous proMMP-2 (0.7 
µg/mL). Digested areas are visible as transparent bands against the dark gelatin 
background. 
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3.2.6 CD44 gene silencing inhibits HT-1080 cell invasion  
Role of CD44 in MT1-MMP-dependent cell invasion was investigated 
using the microcarrier bead invasion assay. HT-1080 cells transfected with non-
targeting siRNA or CD44 siRNA were attached to microcarrier beads and 
embedded in 3D type-I collagen (final concentration of 2 mg/mL collagen). In the 
bead invasion assay, cells have to degrade 3D-collagen in order to migrate from 
the bead surface, thus MT1-MMP is absolutely required. Cells were cultured in 
DMEM supplemented with 10 % (v/v) FBS in the presence or absence of 10 µM 
GM6001. After 36 hours, cells in the collagen gel were fixed and images acquired 
under a light microscope.  
As shown in Figure 3.18, HT-1080 cells attached to microcarrier beads 
invaded from the beads into the collagen gel. The distances between cells and 
beads were measured using ImageJ software. The invasion into collagen was 
completely inhibited by GM6001. Silencing of the CD44 gene markedly 
decreased HT-1080 cell invasion compare to non-targeting siRNA. These data 
suggest that CD44 plays an important role in MT1-MMP-dependent cell invasion.  
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Figure 3.18: CD44 gene silencing inhibits HT-1080 cell invasion. HT-1080 
cells transfected with non-targeting or CD44 siRNAs were attached to 
microcarrier beads and embedded in 3D type-I collagen (final concentration of 2 
mg/mL collagen). Cells were cultured in DMEM supplemented with 10 % FBS in 
the presence or absence of 10 µM GM6001. After 36 hours of incubation, cells in 
the collagen were fixed with 3 % PFA in PBS. (A) Western blot using anti-CD44 
(F4) antibody was performed to confirm CD44 knockdown. (B) and (C) 
Representative images acquired under a light microscope with CCD-camera and 
scatterplot representation of the migration distance from the bead surface. 
Number of cells analysed for each treatment was as follow: non-targeting siRNA, 
n=39; CD44 siRNA, n=36; non-targeting siRNA + GM6001, n=40; CD44 siRNA + 
GM6001, n=41. Bars in scatterplots show the median. The asterisks (*) indicates 
statistically apparent differences: ***= P <0.001. P values were calculated using 
one-way ANOVA analysis of variances, followed by Bonferroni’s multiple 
comparison test. Scale bar represents 150 µm. 
 
 
3.3 DISCUSSION  
In this chapter, the domains of MT1-MMP responsible for localisation of 
the enzyme to substrate attachment sites and lamellipodia were investigated 
using FLAG-tagged MT1-MMP domain deletion mutants.  
The mechanism that localises the enzyme to substrate attachment sites is 
not clear. This localisation has been associated with invadopodia formation and 
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is believed to be important for breaching of the basement membrane by invasive 
tumour cells. Unpublished results from Dr Itoh’s laboratory have revealed that in 
MDCK epithelial cells cultured on type-I collagen, MT1-MMP was preferentially 
localised to the apical surface. However, upon stimulation with HGF (hepatocyte 
growth factor), an apparent amount of the enzyme was detected at the basal 
surface, which resulted in degradation of the underlying collagen. This HGF-
dependent localisation of MT1-MMP to the basal surface of cells was mediated 
by the MT-Loop, an eight amino acid sequence in the catalytic domain of the 
enzyme. An initial experiment in non-polarised COS-7 cells has demonstrated 
that cells expressing the MT-Loop deletion mutant of MT1-MMP showed 
markedly less gelatin film degradation, even though the cell surface expression 
levels and in vitro catalytic activity of this mutant were similar to the full-length 
enzyme (Bird and Itoh, 2006). In this chapter, a series of MT1-MMP domain 
deletion mutants was employed to examine localisation of the enzyme to the 
substrate attachment sites using an MT1-MMP-dependent gelatin film 
degradation assay. Among all the mutants tested, only deletion of the MT-Loop 
region decreased the degradation of the underlying gelatin by COS-7, HT-1080 
and A431 cells. Taken together, these findings suggest the existence of the 
common mechanism that depends on the MT-Loop region and directs 
localisation of MT1-MMP to the substrate attachment sites. Interestingly, the 
transmembrane and cytoplasmic domains were not required for gelatin 
degradation at the substrate attachment sites. This finding is consistent with the 
report published by Itoh et al. (2008), but differs from the report by Nakahara et 
al. (1997), who showed that removal of these domains decreased degradation of 
the underlying matrix by melanoma cells, presumably due to loss of MT1-MMP 
localisation to invadopodia.  
One of the mechanisms that localises MT1-MMP to lamellipodia has been 
shown to be association of the Hpx domain of the enzyme with CD44 (Mori et al., 
2002). CD44 was reported to direct lamellipodial localisation of MT1-MMP and 
indirectly link the enzyme to the actin cytoskeleton (Mori et al., 2002). 
Surprisingly, deletion of the Hpx domain, the interface of CD44 interaction, did 
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not affect localisation of the enzyme either in 2D or 3D culture systems. 
Furthermore, in cytochalasin D-treated HT-1080 cells, MT1F-∆Hpx colocalised 
with aggregated actin, suggesting that the Hpx domain deletion does not 
dissociate MT1-MMP from the actin cytoskeleton. This indicates that either the 
Hpx domain is not the only interface with CD44, or CD44 is not the only molecule 
that links MT1-MMP to the actin cytoskeleton. The current finding that the Hpx 
domain was not required for lamellipodial localisation of the enzyme differs from 
the previous report by Mori et al. (2002). However, in their study, Mori et al. 
(2002) used an MT1-MMP construct which lacked not only the Hpx domain, but 
also the linker-2 (MT1F-∆Hpx∆L2), whereas in this thesis, only the region 
corresponding to the Hpx domain (MT1F-∆Hpx) was removed. Linker-2 has been 
proposed to provide flexibility, and thus proper arrangement of the MT1-MMP 
molecule and its deletion was shown to inhibit proMMP-2 activation and gelatin 
film degradation (Itoh et al., 2008). Interestingly, a mutant that lacked most of the 
linker-2 region except for the last three glycine residues activated proMMP-2 and 
degraded underlying gelatin as efficiently as the wild type enzyme (Itoh et al., 
2008). To investigate if deletion of the linker-2 was responsible for the observed 
discrepancies, both constructs (MT1F-∆Hpx∆L2 and MT1F-∆Hpx) were 
coexpressed together with CD44-∆CP and subjected to immunoprecipitation 
using anti-FLAG M2-conjugated beads. Interestingly, in cells coexpressing CD44-
∆CP together with MT1F-∆Hpx∆L2, bands corresponding to CD44-∆CP had a 
different pattern to bands corresponding to CD44-∆CP in cells cotransfected with 
MT1F or MT1F-∆Hpx, suggesting that linker-2 may be involved in MT1-MMP-
mediated shedding of CD44. Both constructs, MT1F-∆Hpx and MT1F-∆Hpx∆L2, 
were immunoprecipitated with similar efficiency, but a 37 kDa species derived 
from CD44-∆CP was coprecipitated with MT1F or MT1F-∆Hpx, but not with 
MT1F-∆Hpx∆L2. Surprisingly, full-length CD44-∆CP was not detected in the 
precipitated samples, although it was present in the unbound bead fraction. One 
possible explanation is that MT1-MMP interaction with CD44-∆CP may be too 
weak (Kd approximately 64 nM (Mori et al., 2002)) to sustain interaction in the 
harsh conditions used for the IP procedure. However, precipitation of full-length 
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CD44 by MT1-MMP has been demonstrated by others (Mori et al., 2002; 
Suenaga et al., 2005).  
Although, CD44 has been shown to be involved in MT1-MMP localisation 
to lamellipodia (Mori et al., 2002), its effect on the localisation to the substrate 
attachment site is not known. In this chapter, it was shown that silencing of the 
CD44 gene in HT-1080 cells enhanced MT1-MMP-mediated gelatin- and 
collagen-film degradation; however, it did not affect either expression of the 
endogenous enzyme, or proMMP-2 activation. Conversely, overexpression of 
CD44 in COS-7 cells resulted in reduced gelatin-film degradation. A cytoplasmic 
domain deletion mutant of CD44 (CD44-∆CP) also decreased MT1-MMP-
dependent gelatin film degradation, suggesting that CD44-mediated signaling is 
not involved in the observed phenomenon. Addition of the soluble form of CD44 
(sCD44) to cells expressing MT1-RFP did not affect gelatin film degradation, 
indicating that CD44 does not inhibit proteolytic activity of the enzyme against 
gelatin. Neither knockdown of CD44 nor its overexpression affected cell surface 
expression of the active enzyme analysed by immunofluorescence. Taken 
together, these results suggest that a CD44-mediated mechanism decreases 
localisation of the enzyme to matrix attachment sites, potentially by directing 
MT1-MMP to lamellipodia.   
 The effect of CD44 knockdown on MT1-MMP mediated cell invasion was 
investigated using microcarrier bead invasion assay. Interestingly, knockdown of 
CD44 markedly decreased invasiveness of HT-1080 cells embedded into 3D-
collagen. This may be the result of decreased localisation of the enzyme to the 
leading edge in the absence of CD44. However, further studies are required to 
assess if the CD44-dependent mechanism that localises MT1-MMP to 
lamellipodia is also responsible for enzyme localisation to the leading edge in a 
3D environment. This is particularly important given that in invasive cells 
embedded in HA-containing 3D collagen-I matrices, MT1-MMP and CD44 were 
shown to interact mainly at the trailing edge, although interaction at the leading 
edge was also detected (Marrero-Diaz et al., 2009).   
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Taken together, the data in this chapter indicate that localisation of MT1-
MMP to substrate attachment sites is regulated by the MT-Loop region in the 
catalytic domain (Figure 3.19). A CD44-dependent mechanism seems to 
decrease MT1-MMP localisation to the matrix attachment sites, potentially by 
enhancing lamellipodial localisation. These findings suggest that MT1-MMP 
localisation to different areas of the plasma membrane may be regulated by 
multiple mechanisms, which may be necessary to enable the enzyme to promote 
cellular invasion in different microenvironments.  
 
 
 
 
 
Figure 3.19: Cell surface localisation of MT1-MMP is regulated by multiple 
mechanisms. The MT-Loop region is necessary for efficient localisation of MT1-
MMP to the substrate attachment sites. CD44-mediated localisation of MT1-MMP 
decreases enzyme localisation to substrate attachment sites, presumably by 
directing MT1-MMP molecules to lamellipodia. 
Chapter 4   Cortactin 
 
 
 
 
 
 
 
CHAPTER 4 
 
ROLE OF CORTACTIN IN LOCALISATION  
OF MT1-MMP TO SUBSTRATE ATTACHMENT 
SITES AND HT-1080 CELL INVASION 
 
 
 
 
 
 
 
 
Chapter 4   Cortactin 
 
 138 
4.1 INTRODUCTION  
During metastasis, cancer cells have to breach the basement membrane 
(BM), a 50- to 100-µm thick and highly cross-linked meshwork, composed mainly 
of type-IV collagen and laminin. MT1-MMP has been shown to be a critical 
enzyme involved in BM remodeling (Hotary et al., 2006). The observations that 
tumor cells assemble specialised ECM-degrading membrane protrusions, named 
invadopodia, when cultured on 2D matrix, and that MT1-MMP mediates focal 
degradation in these structures have provided a widely accepted model of BM 
breaching (Poincloux et al., 2009). Although many researchers speculate that 
invadopodia are crucial for BM degradation, the conclusive evidence supporting 
this hypothesis is still missing, as the structures have been almost exclusively 
observed in 2D culture systems.  
Cortactin has been shown to be essential for the formation of invadopodia 
and is used as a marker for these structures. Although the exact function of 
cortactin is not clear, its depletion has been shown to decrease invadopodia 
associated matrix degradation in different cells (Artym et al., 2006; Bowden et al., 
1999; Clark et al., 2007). This suggests that cortactin-mediated invadopodia may 
regulate localisation of MT1-MMP to substrate attachment sites.  
In this chapter, the effect of cortactin knockdown on enzyme localisation to 
substrate attachment sites was investigated using MT1-MMP-dependent gelatin 
and collagen film degradation assays. Next, the effect of cortactin knockdown on 
HT-1080 cell invasion was examined using transwell invasion and 3D 
microcarrier bead invasion assays.  
 
4.2 RESULTS 
 
4.2.1 HT-1080 cells generate invadopodia-associated degradation cavities 
in fluorescent gelatin films 
 The gelatin film degradation assay is widely used to visualise active 
invadopodia (Artym et al., 2006; Bowden et al., 1999; Chen et al., 1985; Clark et 
al., 2007; Linder, 2007). Degradation of underlying matrix by these structures 
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results in the formation of fluorescence-negative cavities, which can be visualised 
by fluorescence microscopy.  Here, the formation of invadopodia-associated 
degradation cavities by HT-1080 cells was examined. HT-1080 cells transiently 
transfected with mock vector or plasmid encoding MT1F were seeded on an 
Alexa-488 gelatin film and cultured for 30 minutes in DMEM supplemented with 
10 % FBS. After incubation, cells were fixed and stained with anti-FLAG M1 
antibody without permeabilisation. As shown in Figure 4.1, mock cells did not 
degrade the underlying matrix within a 30-minute incubation. In contrast, MT1F- 
expressing cells degraded the underlying gelatin, generating fluorescence-
negative cavities in the fluorescent gelatin film. This result suggests the formation 
of invadopodia structures by HT-1080 cells. The puncta-like degradations could 
be detected only after a short incubation (up to 45 minutes). When cells were 
incubated on the gelatin film for more than an hour, the degradation cavities were 
replaced by vast degradation areas, due to prolonged activity of MT1F (Figure 
3.4 A).  
To examine if non-transfected HT-1080 cells utilise endogenous MT1-
MMP to generate invadopodia-associated degradation cavities, HT-1080 cells 
were seeded on a fluorescently-labeled gelatin film and incubated in DMEM 
supplemented with 10 % (v/v) FBS in the presence of TIMP-2 or anti-MT1-MMP 
inhibitory antibody (DX-2400). After 4 hours of degradation, cells were fixed with 
3 % (w/v) PFA for 15 minutes, permeabilised and stained for F-actin with Alexa-
568-conjugated phalloidin. As shown in Figure 4.1 B, untreated HT-1080 cells 
degraded the underlying gelatin, generating fluorescence-negative cavities in the 
fluorescent gelatin film. In contrast, TIMP-2 and DX-2400 antibody completely 
inhibited gelatin degradation, indicating that the degradation was a direct result of 
MT1-MMP proteolytic activity. 
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Figure 4.1: HT-1080 cells generate invadopodia-associated degradation 
cavities in fluorescent gelatin film. (A) HT-1080 cells transfected with mock 
vector or plasmid encoding MT1F were seeded on Alexa-488 gelatin. After 30 
minutes of incubation, cells were fixed and stained for cell surface FLAG-tag 
using mouse anti-FLAG M1 primary and Alexa-568-conjugated goat anti-mouse 
secondary antibodies. Images were captured with an Ultraview confocal 
microscope. Areas of gelatin degradation are shown as dark cavities against the 
green gelatin background. In the merged image, cell surface FLAG-tag staining is 
shown in red and gelatin is shown in green. Scale bar represents 25 µm. BF, 
bright field. (B) HT-1080 cells were seeded on a fluorescently labeled gelatin film 
and incubated in DMEM supplemented with 10 % (v/v) FBS in the presence of 
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0.5 µM TIMP-2 and 0.5 µM anti-MT1-MMP inhibitory antibody (DX-2400). After 4 
hours of incubation, cells were fixed, permeabilised and stained with Alexa-568-
conjugated phalloidin. Representative images were captured using an Ultraview 
confocal microscope. Left panel is a wide view of the image and right panel is a 
5.5x expanded view of marked area of the left panel. 
 
4.2.2 MT1-RFP colocalises with endogenous cortactin in HT-1080 cells  
 Localisation of exogenously expressed MT1-RFP and endogenous 
cortactin in HT-1080 cells was analysed. HT-1080 cells transfected with mock 
vector or construct encoding MT1-RFP were seeded on gelatin-coated 
coverslips. After two hours of incubation, cells were fixed, permeabilised and 
stained with anti-cortactin (p80/85) mouse monoclonal primary antibody (clone 
4F11) and Alexa-488-conjugated goat anti-mouse secondary antibody.  
 As shown in Figure 4.2, endogenous cortactin seemed to accumulate 
mainly in lamellipodia, where it co-localised with MT1-RFP. However, the 
possibility cannot be excluded that the apparent co-localization of cortactin and 
MT1-RFP at lamellipodia was due to membrane ruffling, as has been discussed 
in Chapter 3.2.3.1. Apart from in lamellipodia, MT1-RFP was also detected in the 
Golgi apparatus.  
 
 
Figure 4.2: MT1-RFP colocalises with endogenous cortactin in HT-1080 
cells. HT-1080 cells transfected with mock vector or construct encoding MT1-
RFP were seeded on gelatin-coated coverslips. After two hours of incubation, 
cells were fixed, permeabilised and stained with anti-cortactin (p80/85) mouse 
monoclonal primary antibody (clone 4F11) and Alexa-488-conjugated goat anti-
mouse secondary antibody. Representative images were captured using an 
Ultraview confocal microscope. In the merged image, MT1-RFP is shown in red 
and cortactin is shown in green. Colocalisation of MT1-RFP and cortactin is 
shown in yellow. Arrows indicate lamellipodia. 
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4.2.3 Silencing of cortactin gene enhances MT1-MMP-dependent gelatin 
film degradation and changes morphology of HT-1080 cells  
 The effect of cortactin gene silencing on MT1-MMP-dependent gelatin 
film degradation was examined. HT-1080 cells were used, because they express 
high level of endogenous cortactin and MT1-MMP and utilise the enzyme to 
degrade underlying gelatin (Figure 3.9).  
 HT-1080 cells were seeded in 24-well culture dishes at 3 x 104 cells per 
well and transfected with 200 ng of non-targeting siRNA or cortactin siRNA, using 
Lipofectamine RNAiMAX reagent. Control cells were incubated with transfection 
reagent without siRNA. 60 hours after silencing, cells were seeded on an Alexa-
488-gelatin film and incubated for 15 hours in the presence or absence of 
GM6001. To check the efficiency of cortactin knockdown, residual cells were 
lysed and subjected to Western blot analysis (Figure 4.3 C). When analysed by 
SDS-PAGE, cortactin migrates as two separate bands of 80 and 85 kDa. 
Cortactin siRNA decreased expression of cortactin by 79 % when compared to 
non-targeting siRNA relative to actin. This result confirmed that a high efficiency 
of cortactin gene knockdown was achieved in HT-1080 cells.  
 As shown in Figure 4.3 A, the MT1-MMP-dependent gelatin film 
degradation assay revealed that control cells and cells transfected with non-
targeting siRNA efficiently degraded the underlying gelatin, generating black 
distinct areas of degradation against green gelatin background. Surprisingly, 
cortactin knockdown enhanced gelatin degradation, with many cells generating 
extensive round degradation areas. Interestingly, cortactin knockdown also 
changed the cell morphology, from spindle-shaped to a larger and flatter shape. 
Cells transfected with cortactin siRNA were on average 29 % larger than cells 
transfected with non-targeting siRNA, formed clear lamellipodia and clustered 
when cultured at high density (Figure 4.3 B).  
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Figure 4.3: Silencing of cortactin gene enhances MT1-MMP-dependent 
gelatin film degradation and changes morphology of HT-1080 cells. HT-
1080 cells were seeded in a 24-well culture dish at 3 x 104 cells per well and 
transfected with 200 ng of non-targeting siRNA or cortactin siRNA, using 
Lipofectamine RNAiMAX reagent. Control cells were incubated with transfection 
reagent without siRNA. (A) Effect of cortactin gene silencing on MT1-MMP-
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dependent gelatin film degradation. 60 hours after silencing, cells were seeded 
on an Alexa-488 gelatin film and incubated in the presence or absence of 10 µM 
GM6001. 15 hours later, cells were fixed, permeabilised and stained with Alexa-
568 phalloidin. The merged panel shows actin (red) and gelatin (green) images 
merged. Scale bar represents 300 µm. (B) Effect of cortactin gene silencing on 
morphology of HT-1080 cells. HT-1080 cells transfected with non-targeting or 
cortactin siRNA were seeded on gelatin-coated coverslips. After 15 hours of 
incubation, cells were permeabilised and stained with Alexa-568 phalloidin. 
Representative images were taken with a Nikon TE2000-E microscope. The 
indicated number of cells were encircled and their area measured using ImageJ 
software. Statistical significance was evaluated using t test. The asterisk (*) 
indicates statistically apparent differences. (*)= P <0.05. (C) Cortactin knockdown 
was confirmed by Western blot using anti-cortactin rabbit polyclonal (H-191) 
primary antibody with anti-rabbit AP-linked secondary antibody. Actin staining 
was used as a loading control. Quantification of cortactin knockdown was 
performed using Adobe Photoshop. (D) Cortactin knockdown in HT-1080 was 
confirmed by immunostaining, using anti-cortactin (p80/85) mouse monoclonal 
primary antibody (clone 4F11) and Alexa-488-conjugated goat anti-mouse 
secondary antibody. Actin was visualised with Alexa-568 phalloidin. In the 
merged image, cortactin is shown in green and actin is shown in red. 
Colocalisation of cortactin and actin is shown in yellow. Scale bar represent 20 
µm.  
 
 
4.2.4 Fibronectin coating does not affect gelatin degradation by cortactin-
knockdown HT-1080 cells  
 The finding that cortactin silencing increases gelatin degradation 
contradicts the previous reports by Artym et al. (2006) and Clark et al. (2007), 
who showed that cortactin knockdown decreased gelatin degradation in MDA-
MB-231 and HNSCC cells, respectively. To coat coverslips with gelatin Clark et 
al. (2007) used a slightly different technique, which involved incubation of gelatin-
coated coverslips with 50 µg/mL FITC-fibronectin. Therefore, the effect of 
fibronectin coating on gelatin degradation by cortactin-knockdown HT-1080 cells 
was examined. HT-1080 cells were seeded in a 24-well culture dish and 
transfected with non-targeting siRNA or cortactin siRNA, using Lipofectamine 
RNAiMAX reagent. Glass coverslips were coated with Alexa-488 gelatin (Section 
2.8.2), and subsequently incubated with fibronectin for 30 minutes to allow 
fibronectin to bind to gelatin on the surface of the coverslip. 48 hours after the 
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silencing, cells were seeded on the Alexa-488-gelatin/fibronectin film and 
incubated for 15 hours in the presence or absence of GM6001.  
 As shown in Figure 4.4 A, cortactin-knockdown cells still showed 
enhanced degradation of the underlying matrix and still were bigger and flatter 
than parental cells (Figure 4.4 B). This experiment indicates that fibronectin 
coating does not affect MT1-MMP-dependent gelatin film degradation by 
cortactin-knockdown HT-1080 cells.  
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Figure 4.4 Fibronectin coating does not affect MT1-MMP-dependent gelatin 
film degradation by cortactin-knockdown HT-1080 cells. HT-1080 cells were 
seeded in a 24-well culture dish at 3 x 104 cells per well and transfected with 200 
ng of non-targeting siRNA or cortactin siRNA, using Lipofectamine RNAiMAX 
reagent. Glass coverslips were coated with Alexa-488 gelatin (Section 2.8.2), 
followed by incubation with fibronectin (50 µg/mL in PBS) for 30 minutes. 48 
hours after silencing, 1.5 x 104 cells were seed on Alexa-488-gelatin/fibronectin 
coated coverslips and incubated for 15 hours in the presence or absence of 10 
µM GM6001. Next, cells were fixed, permeabilised and stained with Alexa-568 
phalloidin. Representative images were taken with a Nikon TE2000-E 
microscope using lower (A) or higher (B) magnification to analyse gelatin 
degradation and cell morphology, respectively.  In the merge image, actin is 
shown in red and gelatin is shown in green. Gelatin degradation is shown as dark 
areas against the green gelatin background. 
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4.2.5 Effect of cortactin knockdown on MT1-MMP-dependent gelatin film 
degradation by MDA-MB231 and TR131 cells  
 Next, I examined if the discrepancy between my data and the previous 
reports was due to differences in cell types. The effect of cortactin knockdown on 
gelatin film degradation was examined in a human breast cancer cell line (MDA-
MB-231) and a head and neck squamous cell carcinoma (HNSCC) cell line 
TR131. Both cell lines express cortactin and MT1-MMP endogenously and have 
been used to investigate the role of cortactin in invadopodia formation and 
function (Artym et al., 2006; Bowden et al., 1999; Clark et al., 2007).   
 MDA-MB-231 or TR131 cells were seeded in a 24-well culture dish and 
transfected with cortactin siRNA or non-targeting siRNA, using Lipofectamine 
RNAiMAX reagent. 60 hours after silencing, cells were seeded on an Alexa-488-
gelatin film and incubated for 15 hours in the presence or absence of GM6001. 
After incubation, cells were fixed, permeabilised and stained with Alexa-568-
phalloidin to visualise actin cytoskeleton.  
 As shown in Figure 4.5 A, in comparison to non-targeting siRNA, 
cortactin knockdown noticeably increased gelatin degradation in TR131 and 
MDA-MB-231 cells, but did not change the pattern of degradation or morphology 
of these cells. The efficiency of cortactin knockdown was analysed by Western 
blotting, using anti-cortactin rabbit polyclonal (H-191) antibody. Although, the 
silencing markedly decreased cortactin expression, when compared to non-
targeting siRNA (Figure 4.5 C), a relatively high amount of the protein was still 
detected.  
 The effect of cortactin knockdown on MT1-MMP expression was 
analysed by Western blotting using anti-MT1-MMP (Hpx) (222ID8) or anti-MT1-
MMP (Cat) (clone LEM-2/15.8) antibodies. As shown in Figure 4.5 D, cortactin 
knockdown did not affect expression level of the endogenous enzyme. 
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Figure 4.5: Silencing of cortactin gene enhances MT1-MMP-dependent 
gelatin film degradation by MDA-MB-231 and TR131, but does not change 
the pattern of degradation or cell morphology. MDA-MB-231 or TR131 cells 
were seeded in a 24-well culture dish at 3 x 104 cells per well and transfected 
with 200 ng of non-targeting siRNA or cortactin siRNA using Lipofectamine 
RNAiMAX reagent. 60 hours after silencing, cells were seeded on an Alexa-488 
gelatin film and incubated in DMEM supplemented with 10 % FBS in the 
presence or absence of 10 µM GM6001. After 15 hours of incubation, cells were 
fixed, permeabilised and stained with Alexa-568 phalloidin. Representative 
images of TR131 (A) or MDA-MB-231 cells (B) were taken with a Nikon TE2000-
E microscope. In the merged image, actin is shown in red and gelatin is shown in 
green. Gelatin degradation is shown as dark areas against the green gelatin 
background. (C) Efficiency of cortactin knockdown was confirmed by Western 
blotting using anti-cortactin polyclonal (H-191) antibody. (D) Effect of cortactin 
knockdown on MT1-MMP expression was analysed by Western blotting using 
anti-MT1-MMP (Hpx) (222ID8) or anti-MT1-MMP (Cat) (clone LEM-2/15.8) 
antibodies. Arrows indicate bands of interest. 
 
 
4.2.6 Cortactin gene silencing enhances collagen film degradation by HT-
1080 cells  
 Next, the effect of cortactin gene silencing on collagen film degradation 
was examined. HT-1080 cells were transfected with non-targeting or cortactin 
siRNA. 48 hours after silencing, cells were counted and seeded on a collagen 
film. Cells were cultured in DMEM supplemented with 2 % FBS in the presence 
or absence of GM6001. 36 hours later, cells were removed from the collagen by 
trypsinisation. The collagen layer was fixed and stained using a 1:1 mixture of 
Coomassie stain: destain for 30 minutes.  After staining, wells were washed and 
analysed under a light microscope.  Digested areas of collagen were visible as 
white areas against the blue collagen background.  
 As shown in Figure 4.6, cells transfected with non-targeting siRNA 
moderately digested the underlying collagen. Cortactin knockdown markedly 
enhanced collagen degradation, with cells generating large areas depleted of the 
collagen matrix. GM6001 completely inhibited the degradation.  
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Figure 4.6: Cortactin gene silencing enhances collagen film degradation by 
HT-1080 cells. HT-1080 cells were transfected with non-targeting (non-target.) 
siRNA or cortactin siRNA. 48 hours after silencing, cells were counted and 
seeded on a collagen film (final concentration of 2.0 mg/mL collagen). Cells were 
cultures in DMEM supplemented with 2 % FBS in the presence or absence of 10 
µM GM6001. 36 hours later, cells were removed from the collagen by 
trypsinisation. The collagen layer was fixed using 3 % (w/v) PFA for 30 minutes 
and stained using a 1:1 mixture of Coomassie stain: destain for 30 minutes. After 
staining, wells were washed and left to dry. Representative images were 
acquired under a light microscope using a 10 x objective lens. Digested areas of 
collagen are shown as white areas against the grey collagen background.  
 
 
 
4.2.7 Cortactin knockdown does not affect MT1-MMP-mediated proMMP-2 
activation  
The effect of cortactin gene silencing on MT1-MMP-mediated proMMP-2 
activation was investigated by gelatin zymography. HT-1080 cells were seeded at 
3 x 104 in a 24-well plate and transfected with non-targeting siRNA or cortactin 
siRNA. The control sample did not contain any cells. After 2 days, media were 
changed to 150 µL serum-free DMEM containing exogenous proMMP-2 (0.7 
µg/mL) and, where indicated, 10 µM GM6001. After 36 hours, media were 
collected and mixed with 4 x non-reducing SDS sample buffer and subjected to 
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gelatin zymography. Digested areas were visible as transparent bands against 
the dark blue gelatin background. MT1-MMP processes 72-kDa proMMP-2 to a 
68-kDa intermediate form, which can be further activated by intermolecular 
cleavage to a 66-kDa end product (Atkinson et al., 1995).  
As shown in Figure 4.7 A, control sample treated with GM6001 (Control + 
GM6001) showed partial conversion of exogenous proMMP-2. This conversion 
most likely took place during proMMP-2 purification and storage. Control sample 
(Control) showed increased proMMP-2 conversion compared with the control 
sample incubated with GM6001 (Control + GM6001) due to MMP-2 
autoactivation. In comparison with the control sample, cells transfected with non-
targeting siRNA efficiently activated proMMP-2, which could be observed as an 
apparent increase in the active form, with concomitant decrease of the proform. 
Cortactin silencing did not affect proMMP-2 activation, when compared to non-
targeting siRNA. Addition of GM6001 completely inhibited proMMP-2 activation to 
the basal level observed in control sample treated with GM6001. This result 
indicates that cortactin knockdown does not impair MT1-MMP-mediated 
proMMP-2 activation, and further suggests that it does not affect cell surface 
expression of MT1-MMP. 
Western blot using anti-cortactin (F411) antibody confirmed a high 
efficiency of cortactin knockdown (Figure 4.7 B).  
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Figure 4.7: Cortactin knockdown does not impair MT1-MMP-mediated 
proMMP-2 activation. (A) HT-1080 cells were seeded at 3 x 104 in a 24-well 
plate and transfected with non-targeting siRNA or cortactin siRNA. The control 
sample did not contain any cells. After 2 days, media were changed to 150 µL 
serum free DMEM containing exogenous proMMP-2 (0.7 µg/mL) and, where 
indicated, 10 µM GM6001. 36 hours later, media were recovered and mixed with 
4 x non-reducing SDS sample buffer and subjected to gelatin zymography. 
Digested areas were visible as transparent bands against a dark blue gelatin 
background. Arrows indicate bands of interest. (B) The efficiency of cortactin 
gene silencing was confirmed by Western blotting using mouse anti-cortactin 
(F411) primary and anti-mouse AP-linked secondary antibodies. HT-1080 cell 
lysate was used as a control. Arrows indicate bands of interest. 
 
 
4.2.8 Cortactin gene silencing enhances HT-1080 cell invasion in transwell 
assay  
HT-1080 cell invasion was measured using transwells with 8 µm- pore 
PET membrane coated with a thin layer of type I collagen on the upper surface 
(final concentration of 2.5 mg/mL collagen). The collagen-coated transwells were 
inserted into wells of a 12-well plate filled with 1 mL of DMEM supplemented with 
10 % (v/v) FBS as an attractant. Control HT-1080 cells or cells transfected with 
non-targeting or cortactin siRNA were resuspended in serum-free DMEM and 
seeded on top of the polymerised collagen. After 20 hours of culture, the upper 
surface containing collagen was removed and the cells that had invaded into the 
collagen and migrated to the other side of the membrane were fixed and stained 
with Alexa-488-conjugated phalloidin to visualise the actin cytoskeleton and with 
DAPI to visualise cell nuclei. Invasive cells were viewed with a TE2000-E Nikon 
microscope and counted using Volocity software.  
As shown in Figure 4.8, invasion of control cells (defined as 100%) was 
almost completely inhibited by GM6001. Non-targeting siRNA decreased 
transwell invasion compared to control cells; however, the difference was not 
statistically apparent. Cortactin silencing markedly increased cell invasion by 2 
fold when compared to non-targeting siRNA.  
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Figure 4.8: Cortactin gene silencing enhances HT-1080 cell invasion in 
transwell assay. Cell migration was measured using transwells coated with a 
thin layer of type-I collagen (2.5 mg/mL). Collagen coated transwells were 
inserted into wells of a 12-well plate filled with 1 mL of DMEM supplemented with 
10 % (v/v) FBS as attractant. Serum starved control cells and cells transfected 
with non-targeting or cortactin siRNA were plated on the upper sides of transwell 
filters (3 × 104 cells/well). Cells were allowed to migrate for 20 hours, before non-
migratory cells were removed together with the collagen using a cotton swab. 
Cells migrated to the other side of the membrane were stained with Alexa-488-
phalloidin and DAPI. Number of nuclei was then counted using Velocity software. 
Data are the means ± SEM of three independent experiments in relation to the 
control, which is set at 100 % migration. Statistical significance was evaluated 
with analyses of variance (ANOVA), followed by Bonferroni’s multiple comparison 
test. The asterisks (*) indicate statistically apparent differences: *= P <0.05; **= P 
<0.01. 
 
 
4.2.9 Cortactin gene silencing impairs 3D-invasion of HT-1080 cells  
The effect of cortactin gene silencing on 3D-invasion of HT-1080 cells was 
investigated using the microcarrier bead invasion assay. HT-1080 cells 
transfected with non-targeting siRNA or cortactin siRNA were attached to the 
surface of gelatin-coated beads and embedded into 3D type-I collagen (final 
concentration of 2 mg/mL collagen). After 36 hours of incubation, cells in the 
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collagen were fixed and images acquired using a light microscope with a CCD-
camera. The distance that cells had migrated from the bead surface was 
measured using ImageJ software. Cortactin knockdown was confirmed by 
Western blotting (Figure 4.9 C).  
As seen in Figure 4.9 A and B, HT-1080 cells transfected with non-
targeting siRNA invaded from the beads into the collagen gel. Invasion was 
completely inhibited by GM6001. Knockdown of cortactin markedly decreased 
HT-1080 cell invasion when compare to non-targeting siRNA. These data 
suggest that cortactin plays an important role in HT-1080 cell invasion in a 3D-
matrix.  
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Figure 4.9: Cortactin gene silencing impairs 3D-invasion of HT-1080 cells. 
HT-1080 cells transfected with non-targeting siRNA or cortactin siRNA were 
attached to microcarrier beads and embedded in a 3D type-I collagen (final 
concentration of 2 mg/mL collagen). Cells were cultured in DMEM supplemented 
with 10 % (v/v) FBS in the presence or absence of 10 µM GM6001. After 36 
hours of incubation, cells in the collagen were fixed with 3 % PFA in PBS. (A) 
Representative images were acquired under a light microscope with a CCD-
camera. (B) Scatterplot representation of the migration distance from the bead 
surface. Number of cells analysed for each treatment was as follows: non-
targeting siRNA, n=326; cortactin siRNA, n= 280; non-targeting siRNA + 
GM6001, n=231; cortactin siRNA + GM6001, n=199.  Bars in scatterplots show 
the median. The asterisks (*) indicate statistically apparent differences: **= P 
<0.01; ***= P <0.001. P values were calculated using one-way ANOVA analysis 
of variances, followed by Bonferroni’s multiple comparison test. (C) Western blot 
of cell lysates was performed using anti-cortactin (H-191) antibody. 
 
 
4.3 DISCUSSION 
 
Cortactin is a multifunctional protein involved in assembly and stabilisation 
of the branched actin network, which provides structural support for the plasma 
membrane, regulates formation of motility structures such as lamellipodia and 
invadopodia, and determines cell shape and the formation of cell-cell junctions 
(Goley and Welch, 2006; Weaver, 2008). Among the diverse functions of 
cortactin, its role in invadopodia has been extensively investigated. Invadopodia 
are ECM-degrading membrane protrusions formed by invasive tumour cells 
cultured on a 2D matrix. They are believed to promote basement membrane 
breaching during tumor cell invasion, however their relevance in vivo has not 
been confirmed yet. The proteolytic potential of invadopodia is provided by MT1-
MMP (Artym et al., 2006; Bowden et al., 1999; Clark et al., 2007; Nakahara et al., 
1997). Depletion of cortactin has been shown to decrease invadopodia-
associated matrix degradation (Artym et al., 2006; Bowden et al., 1999; Clark et 
al., 2007), suggesting that cortactin may be involved in localisation of MT1-MMP 
to substrate attachment sites.  
In this chapter, the effect of cortactin knockdown on localisation of MT1-
MMP to substrate attachment sites and MT1-MMP-mediated cell invasion was 
examined. Silencing of the cortactin gene in HT-1080 cells markedly affected cell 
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morphology. HT-1080 cells transfected with cortactin siRNA were larger than 
control cells, formed clear lamellipodia and clustered when cultured at high 
density. A similar effect of cortactin knockdown on cell morphology has been 
previously reported in HBL100 breast epithelial cells (van Rossum et al., 2006). 
Interestingly, silencing of the cortactin gene in MDA-MB-231 and TR131 cells did 
not change the morphology of these cells. This could be due to differences in the 
efficiency of cortactin knockdown in the different cell types, but it is also possible 
that cortactin function may be cell-type specific. 
The effect of cortactin knockdown on MT1-MMP localisation to substrate 
attachment sites was examined using a fluorescent gelatin film degradation 
assay. HT-1080 cells seeded on the gelatin film generated degradation cavities 
typical of invadopodia at an early stage of gelatin degradation, and these were 
replaced by larger areas of degradation after longer periods of incubation. 
Unexpectedly, knockdown of cortactin in HT-1080 cells markedly enhanced 
degradation of underlying gelatin and collagen films and changed the pattern of 
gelatin film degradation. Cortactin depletion did not affect MT1-MMP-mediated 
proMMP-2 activation in HT-1080 cells, suggesting that the cell surface 
expression level of the enzyme was not affected by the knockdown.  The effect of 
cortactin knockdown in MDA-MB-231 and TR131 cells was less striking, but a 
noticeable increase in gelatin film degradation was also observed.  
Taken together, these results indicate that cortactin is dispensable for 
localisation of MT1-MMP to substrate attachment sites. As cortactin was shown 
to be crucial for the formation of functional invadopodia (Artym et al., 2006; Clark 
and Weaver, 2008; Clark et al., 2007), these results strongly suggest that 
cortactin-mediated invadopodia structures are not required for the localisation of 
MT1-MMP to substrate attachment sites and potentially they are not essential for 
the cancer cells to initiate invasion. These results also indicate that invadopodia 
may not be the sole membrane structures at substrate attachment sites of the 
cells where MT1-MMP is localised.   
Our findings contradict the previous reports which have shown that 
silencing of the cortactin gene in MDA-MB-231 (Artym et al., 2006) and SCC61 
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HNSCC cells (Clark et al., 2007) markedly inhibited MT1-MMP-mediated gelatin 
degradation at substrate attachment sites. In the former report, cortactin depleted 
MDA-MB-231 cells were incubated on a fluorescent gelatin film for 3 hours, 
before the degradation of underlying matrix was analysed. Within 3 hours of 
incubation, control cells were shown to generate few degradation cavities in the 
underlying gelatin, whereas knockdown of cortactin almost completely inhibited 
the degradation (Artym et al., 2006). In the later report, cortactin depleted SCC61 
HNSCC cells were seeded on a fluorescent gelatin film and incubated for 20 
hours. When the degradation of underlying matrix was analysed, few degradation 
cavities were detected in the control cells, whereas no degradation was detected 
in cortactin knockdown sample (Clark et al., 2007). 
The reports described above investigated the effect of cortactin knockdown on 
invadopodia-associated degradation cavities and thus the experiments were 
terminated at a very early stage of gelatin degradation, when only few 
degradation cavities could be detected in the underlying matrix. In contrast, in our 
study, cortactin-knockdown cells where incubated on a gelatin film until clear 
areas of degradation were detectable. Under this condition, knockdown of the 
cortactin gene in HT-1080, MDA-MB-231 and TR131 cells enhanced gelatin film 
degradation, suggesting that invadopodia-associated degradation cavities may 
not reflect the degradative potential of the cells against the underlying matrix 
upon prolonged incubation.  
 We found that cortactin knockdown increased collagen invasion in HT-
1080 cells measured by transwell invasion assays, corresponding with the 
observed increase in degradation of gelatin and collagen films. However, in the 
microcarrier bead invasion assay, cortactin knockdown unexpectedly inhibited 
invasion of HT-1080 cells. These discrepancies may be explained by the different 
conditions of these two assays. In the transwell invasion assay, HT-1080 cells 
were seeded on a thin layer of collagen coating the membranes of the transwells. 
It is therefore possible that the cortactin-depleted HT-1080 cells extensively 
degraded the underlying matrix at substrate attachment sites, generating holes in 
the collagen layer sufficient to allow migration to the other side of the membrane. 
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In the bead invasion assay, the process of invasion is more complex than in the 
transwell assay and under these conditions the global effect of cortactin 
knockdown on cell invasion is examined. As cortactin has been shown to localise 
to lamellipodia and promote their persistence (Bryce et al., 2005), it is likely that 
the reduced invasion of cortactin-depleted HT-1080 cells in 3D collagen was at 
least partially a result of impaired lamellipodia maintenance. The different results 
observed with the transwell and microcarrier bead invasion assays may thus 
reflect differences in the requirement for invadopodia and lamellipodia for cell 
migration in the two systems.  
Taken together, the results in this chapter strongly indicate that cortactin is 
not required for localisation of MT1-MMP to substrate attachment sites. This 
further suggests that invadopodia may not be required for cancer cells to invade 
the underlying matrix. Although cortactin depletion decreased HT-1080 cell 
invasion in 3D collagen, the effect is unlikely to be a result of invadopodia 
downregulation.   
In future experiments, it will be important to confirm our findings by 
analysing the effect of cortactin overexpression on MT1-MMP-mediated gelatin 
and collagen film degradation and cellular invasion in 2D and 3D culture systems. 
It will be also interesting to investigate localisation of cortactin and MT1-MMP in 
cells invading through a 3D matrix. 
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5.1 INTRODUCTION 
Recent studies have focused on intracellular transport as a major regulator 
of polarised localisation of MT1-MMP on the cell surface (Bravo-Cordero et al., 
2007; Steffen et al., 2008; Wiesner et al., 2010). As described in Section 1.5.3, 
live cell imaging studies in Dr Itoh’s laboratory have demonstrated that MT1-MMP 
is transported to the cell surface inside intracellular vesicles that are targeted to 
extending membrane protrusions. These vesicles have been shown to align 
along microtubules, suggesting involvement of kinesin motor proteins (KIFs) in 
their translocation. 
The aim of this chapter is to investigate the molecular mechanism of 
intracellular vesicle trafficking of MT1-MMP by identification of the responsible 
KIFs. In this study, 17 human KIFs, including splice variants, were analysed for 
they involvement in intracellular trafficking of the enzyme. The effects of silencing 
of these KIFs in HT-1080 cells were analysed by evaluating MT1-MMP-
dependent gelatin and collagen film degradation, proMMP-2 activation and flow 
cytometry. To confirm the siRNA data a kinesin-dominant negative approach was 
employed. 
 
5.2 RESULTS 
 
5.2.1 Selection of KIFs to study intracellular trafficking of MT1-MMP-
containing vesicles  
There are 45 KIFs genes identified in the human genome (Miki et al., 
2001). Among them, there are 39 N-type KIFs, which possess the motor domain 
at their N-terminus and translocate cargoes towards the cell periphery. These 
KIFs are the most likely to be involved in intracellular trafficking of MT1-MMP. 
However, some of these KIFs are expressed exclusively in neurons or are 
involved in cell division, so they are not likely to traffic MT1-MMP-containing 
vesicles. Based on this consideration, 17 KIFs, including splicing forms, were 
chosen for further study. A list of the selected KIFs and their reported functions is 
shown in Table 5.1 A.  A list of excluded KIFs is shown in Table 5.1 B. 
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Table 5.1: Selection of KIFs. There are 45 KIFs genes in the human genome. 
Based on literature, 17 KIFs were chosen, including splicing forms, to be tested 
for their involvement in intracellular trafficking of MT1-MMP. (A) Chosen KIFs and 
their reported functions. (B) Excluded KIFs. 
 
A.  
 
 
Selected 
KIFs 
 
 
Reported functions 
 
 
KIF5B 
 
 
 
 
 
 
Transport of organelles (Nakata and Hirokawa, 1995; Tanaka et al., 
1998); Post Golgi-transport of apical proteins in epithelial cells (Jaulin et 
al., 2007); Transport of oligomeric tubulin (Terada et al., 2000); 
Transport of apolipoprotein E receptor 2 for Reelin (Verhey et al., 
2001), Transport of RNA (Kanai et al., 2004). 
 
 
KIF3A, KIF3B, 
KIF3C 
 
 
 
Transport of organelles (Yamazaki et al., 1995); Transport of fodrin 
associated vesicles (Takeda et al., 2000); Transport of PAR-3 
(Nishimura et al., 2004); Intraflagellar transport (Nonaka et al., 1998; 
Takeda et al., 2000). 
 
KIF1B_v-1, -2 
 
Transport of mitochondria (Nangaku et al., 1994) 
 
KIF1C 
 
Regulation of podosome dynamics in macrophages (Kopp et al., 2006) 
 
KIF13A 
 
 
Transport of mannose-6-phosphate receptor to plasma membrane 
(Nakagawa et al., 2000) 
 
KIF13B 
 
 
 
 
 
 
Transport of DLG, a human homologue of D. melanogaster disc 1 
tumour suppressor gene 113 to tips of projections in epithelial cells 
(Asaba et al., 2003) 
 
Transport of PIP3 (phosphatidylinositol-(3,4,5) to the tip of neurons 
(Horiguchi et al., 2006) 
 
KIF21A 
KIF21B 
 
Involvement in congenital fibrosis of the extraocular muscles and 
Marcus Gunn jaw-winking phenomenon (Yamada et al., 2005) 
 
KIF7, KIF27 
 
 
Involvement in hedgehog signaling pathway (Katoh and Katoh, 2004a, 
b, 2005) 
 
KIF9-v1, -v2 
and -v3 
 
Interaction with Ras-like GTPase GEM involved in cell shape 
remodeling (Piddini et al., 2001) 
 
KIF15  
 
Involvement in neuronal migration and development (Buster et al., 
2003) 
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B. 
 
 
KIF 
 
 
Reasons for being excluded 
Kinesin-1 
 KIF5A, KIF5C 
 
Neuron specific (Kanai et al., 2000) 
Kinesin-2 
KIF17 
 
Neuron specific (Guillaud et al., 2003; Setou et al., 2000) 
Kinesin-3 
KIF1A; KIF14; KIF16A; 
KIF16B; KIF28 
 
Neuron specific (Okada et al., 1995); Mitotic kinesins 
(Gruneberg et al., 2006); or function unknown 
Kinesin-4 
KIF4A, KIF4B 
 
 
Chromokinesins, expressed mostly in the juvenile brain 
(Kurasawa et al., 2004; Sekine et al., 1994) 
Kinesin-5 
KIF11 (Eg5) 
 
Mitotic kinesin (Kapitein et al., 2005; Sawin et al., 1992) 
Kinesin-6 
KIF20A; KIF20B; KIF23   
(-v1,-v2)  
 
Mitotic kinesin involved in cytokinesis (Fontijn et al., 2001; 
Liu and Erikson, 2007) 
Kinesin-7 
KIF10 (CENP-E) Mitotic kinesin (Ma et al., 2006) 
Kinesin-8 
KIF19A, KIF19B, KIF18A, 
KIF18B 
 
Unknown function (Miki et al., 2001; Stumpff et al., 2008); 
Mitotic kinesin (Mayr et al., 2007) 
Kinesin-9 
KIF6 
Testis-specific 
(Nakagawa et al., 1997) 
Kinesin-10 
KIF22 (Kid) 
 
Chromokinesin (Ohsugi et al., 2008) 
Kinesin-11 
KIF26A,  KIF26B 
 
Microtubule-independent (Lillie and Brown, 1998) 
Kinesin-12 
KIF12,  
 
Mitotic kinesin involved in cytokinesis (Lakshmikanth et al., 
2004);  
Kinesin-13 
KIF2A,  KIF2B, KIF2C 
 
M-type kinesin with microtubule-depolymerising activity 
(Homma et al., 2003) 
Kinesin-14A 
KIFC1,  KIFC2, KIFC3, 
KIF25 (v-1,-2) 
 
C-type kinesin which moves towards the minus end of 
microtubule; implicated in acrosome formation (Yang et 
al., 2006; Yang and Sperry, 2003) 
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5.2.2 Expression of selected KIFs in HT-1080 cells 
Expression of the selected KIFs in HT-1080 was analysed by RT-PCR. 
HT-1080 cells were used in this experiment, because they express MT1-MMP 
endogenously and thus are likely to express KIFs involved in trafficking of the 
enzyme. Primers amplifying short, specific fragments of each KIF were designed 
and PCR reactions performed using HT-1080 cDNA as a template. As shown in 
Figure 5.1, mRNA for all selected KIFs was detected in HT-1080 cells, indicating 
that they are all expressed. 
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Figure 5.1: Expression of selected KIFs in HT-1080 cells. Specific pairs of 
primers were designed for all selected KIFs. PCR reactions were performed 
using HT-1080 cDNA as a template to confirm expression of the selected KIFs on 
an mRNA level. Expected sizes of the PCR products are shown in brackets.  
 
 
5.2.3 MT1-MMP-dependent gelatin film degradation by HT-1080 cells is 
inhibited by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9 and KIF1C  
In order to identify KIFs involved in MT1-MMP vesicle trafficking to 
substrate attachment sites, gene silencing studies were carried out for all of the 
selected KIFs. Specific siRNAs were purchased from Dharmacon. HT-1080 cells 
were transfected with non-targeting siRNA or siRNAs against the selected KIFs. 
60 hours later, cells were seeded on Alexa-488 gelatin. After 15 hours of 
incubation, cells were fixed and stained for F-actin with Alexa 568-conjugated 
phalloidin.  
As shown in Figure 5.2 A, silencing of four KIFs genes resulted in notable 
changes in gelatin film degradation. Silencing of KIF3A or KIF13A markedly 
decreased gelatin degradation, with KIF13A knockout having the greater effect. 
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In contrast, silencing of the KIF9 and KIF1C genes greatly enhanced degradation 
of the underlying matrix. The efficiency of silencing was confirmed by one-step 
RT-PCR. DNA gels were quantified by Phoretix software.  
As shown in Figure 5.2 B, silencing of KIF13A and KIF9 genes was almost 
complete, whereas KIF3A mRNA was decreased by approximately 75%. The 
efficiency of KIF1C knockdown was relatively low, with almost half of the mRNA 
still detected after siRNA treatment.  
To confirm that the decrease in mRNA level reflects a decrease at the 
protein level, cell lysates of HT-1080 cells transfected with non-targeting siRNA 
or siRNAs against KIF3A or KIF13A were subjected to Western blot analysis. 
Unfortunately, there was no commercially available antibody to KIF9. As shown 
in Figure 5.3 C, Western blotting using anti-KIF3A and anti-KIF13A antibodies 
confirmed high efficiency of knockdown. Importantly, silencing of KIF13B gene 
did not affect expression of KIF13A and silencing of KIF3C did not affect 
expression of KIF3A.  
Chapter 5   Kinesin motor proteins (KIFs) 
 
 170 
 
 
 
 
 
Chapter 5   Kinesin motor proteins (KIFs) 
 
 171 
 
 
 
 
Chapter 5   Kinesin motor proteins (KIFs) 
 
 172 
 
 
 
 
 
Chapter 5   Kinesin motor proteins (KIFs) 
 
 173 
 
 
 
 
 
 
 
 
  
Chapter 5   Kinesin motor proteins (KIFs) 
 
 174 
 
 
 
 
 
 
 
Chapter 5   Kinesin motor proteins (KIFs) 
 
 175 
 
 
 
 
 
 
 
Figure 5.2: MT1-MMP-dependent gelatin film degradation by HT-1080 cells 
is inhibited by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9 and KIF1C (A) HT-1080 cells were transfected with non-
targeting siRNA or siRNAs against the KIFs indicated. Control cells were left 
untreated. 60 hours later, cells were seeded on an Alexa-488 gelatin film. After 
15 hours of incubation, cells were fixed and stained with Alexa-568 phalloidin 
with permeabilisation. Representative images were taken with a Nikon TE2000-E 
microscope with a CCD-camera attached. In the merged images, gelatin has 
been shown in green and F-actin in red. (B) Efficiency of KIF knockdown was 
confirmed by one-step RT-PCR. Comparison of the intensity of bands 
corresponding to non-targeting siRNA and KIFs siRNA in relative to GAPDH 
mRNA was performed using Phoretix software. (C) Knockdown of KIF3A and 
KIF13A was confirmed by Western blotting using anti-KIF3A (H-155) and anti-
KIF13A (72414) antibodies. Arrows indicate bands of interest. Expected 
molecular weights of KIF3A and KIF13A are shown in brackets.  
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5.2.4 MT1-MMP-dependent collagen film degradation by HT-1080 cells is 
inhibited in by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9  
Effect of KIF3A, KIF13A and KIF9 gene silencing on collagen film 
degradation was examined. Unfortunately, I did not have sufficient time to 
analyse KIF1C in more detail, but this will be done in the future.  
HT-1080 cells transfected with non-targeting siRNA or siRNAs against 
KIF3A, KIF13A or KIF9 were seeded on a fluorescein-conjugated type-I collagen 
film and incubated for 36 hours in DMEM supplemented with 2% (v/v) FBS. 
Control sample did not contain cells. After incubation, cells and the collagen layer 
were fixed and stained with Alexa-568-conjugated phalloidin.   
As shown in Figure 5.3, silencing of KIF13A markedly decreased collagen 
film degradation when compared to non-targeting siRNA. Although, the effect of 
KIF3A silencing was not as striking as that of KIF13A, degradation was 
detectably decreased. In contrast, silencing of KIF9 enhanced degradation of the 
underlying collagen.  
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Figure 5.3: MT1-MMP-dependent collagen film degradation by HT-1080 cells 
is inhibited by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9. HT-1080 cells transfected with non-targeting siRNA or 
siRNAs against KIF3A, KIF13A or KIF9 were seeded on fluorescein-conjugated 
type-I collagen-coated coverslips (final concentration of 2 mg/mL collagen) and 
incubated for 36 hours in DMEM supplemented with 2% (v/v) FBS. After 
incubation, cells were fixed and stained for F-actin using Alexa-568-conjugated 
phalloidin. A control sample did not contain cells. A widefiled Nikon microscope 
attached with CCD-camera was used to capture representative pictures. In the 
merged image, F-actin is shown in red and collagen in green. Areas of collagen 
degradation are shown as black areas against the green collagen background. 
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5.2.5 Effect of KIF3A, KIF13A and KIF9 gene silencing on processing of 
endogenous MT1-MMP  
Effect of KIF3A, KIF13A and KIF9 silencing on processing of endogenous 
MT1-MMP was analysed by Western blotting. HT-1080 cells were transfected 
with non-targeting siRNA or siRNAs against KIF3A, KIF13A, KIF9 or KIF5B. 
Untreated cells were used as a control. After 72 hours of incubation, cells were 
lysed and subjected to Western blot analysis using anti-MT1-MMP (Hpx) 222-
1D8 antibody.  
 
 
 
 
 
 
Figure 5.4: Effect of KIF3A, KIF13A and KIF9 gene silencing on processing 
of endogenous MT1-MMP. HT-1080 cells were transfected with non-targeting 
siRNA or siRNAs against KIF3A, KIF13A, KIF9 or KIF5B. Untreated HT-1080 
cells were used as a control. 72 hours later, cells were lysed and subjected to 
Western blot analysis using anti-MT1-MMP (Hpx) 222-1D8 antibody, which 
recognises a proform (~65 kDa) of the enzyme, an active form (~55 kDa) and an 
autolytic product (~40 kDa). Arrows indicate bands of interest. 
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As shown in Figure 5.4, the 222-ID8 antibody against the Hpx domain of 
MT1-MMP recognises three forms of the enzyme: a proform, an active form and 
a product of enzyme autolysis, which lacks the catalytic domain. Silencing of KIF 
genes did not considerably change the total amount of the active enzyme, when 
compared to non-targeting siRNA. Interestingly, the amount of the autolytic 
product was reduced by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9. 
 
 
5.2.6 MT1-MMP-mediated proMMP-2 activation in HT-1080 cells is 
decreased by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9  
In Section 5.2.5, it was found that the amount of the autolytic product of 
MT1-MMP was reduced by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9. As increased autolysis of MT1-MMP has been shown to 
coincide with proMMP-2 activation (Stanton et al., 1998), the effect of KIF3A, 
KIF13A and KIF9 knockdown on MT1-MMP-mediated proMMP-2 activation was 
analysed by gelatin zymography. HT-1080 cells were transfected with non-
targeting siRNA or siRNA against KIF3A, KIF13A, KIF9 or KIF5B (negative 
control). 48 hours later, media were changed to serum-free DMEM. After 36 
hours of incubation, media were recovered using 4 x non-reducing SDS sample 
buffer and subjected to gelatin zymography.  
As shown in Figure 5.5, MT1-MMP processed 72-kDa endogenous 
proMMP-2 to a 68-kDa intermediate form, which was further activated by 
intermolecular cleavage to a 66-kDa active MMP-2. Silencing of KIF5B did not 
affect proMMP-2 activation when compared to non-targeting siRNA. Silencing of 
KIF3A or KIF13A gene markedly inhibited proMMP-2 activation, whereas that of 
KIF9 accelerated MT1-MMP-mediated conversion of proMMP-2 to the 
intermediate form. Interestingly, silencing of KIF9 resulted in an apparent 
increase in MMP-9 level, whereas silencing of KIF3A and KIF13A had an 
opposite effect. These results may suggest a potential role of KIF3A, KIF13A and 
KIF9 in intracellular trafficking of MMP-9.  
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Figure 5.5: MT1-MMP-mediated proMMP-2 activation in HT-1080 cells is 
decreased by knockdown of KIF3A and KIF13A, and enhanced by 
knockdown of KIF9. HT-1080 cells were transfected with non-targeting siRNA 
or siRNA against KIF3A, KIF13A, KIF9 or KIF5B. 48 hours after transfection, 
media on cells were changed to serum free DMEM. After 36 hours of incubation, 
media were recovered using 4 x non-reducing SDS sample buffer and subjected 
to gelatin zymography. Digested areas were visible as transparent bands against 
the dark blue gelatin background. Arrows indicate bands of interest.  
 
 
5.2.7 Effect of KIF3A, KIF13A or KIF9 gene silencing on cell surface 
expression of MT1-MMP  
The effect of KIF3A, KIF13A or KIF9 gene silencing on cell surface 
expression of MT1-MMP was analysed by flow cytometry. HT-1080 cells were 
treated with non-targeting siRNA or siRNAs against KIF3A, KIF13A or KIF9. 72 
hours later, cells were harvested using non-enzymatic cell dissociation solution, 
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fixed and stained without permeabilisation with an anti-MT1-MMP antibody (clone 
LEM-2/15.8), which recognises the catalytic domain of the enzyme. Incubation 
with the primary antibody was followed by incubation with Alexa-448 labeled 
secondary antibody. Stained cells were subjected to flow cytometric analysis. 
Unstained HT-1080 cells, or HT-1080 cells stained only with secondary antibody, 
were used as negative controls.  
As shown in Figure 5.6, non-targeting siRNA slightly increased cell surface 
expression of the enzyme when compared to cells stained but not treated with 
siRNA. In comparison to non-targeting siRNA, silencing of KIF3A or KIF13A gene 
slightly increased cell surface expression of MT1-MMP. This was quite 
unexpected as silencing of these KIFs led to apparent reduction in MT1-MMP-
mediated gelatin film degradation. Interestingly, silencing of KIF9, which was 
shown to enhance gelatin-film degradation, had no effect on enzyme cell surface 
expression.  
Although LEM-2/15.8 antibody has been widely used for FACS analysis of 
MT1-MMP (Wiesner et al., 2010), it will be important to confirm the validity of the 
data by including the appropriate isotype control.  
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Figure 5.6: Effect of KIF3A, KIF13A or KIF9 gene silencing on cell surface 
exposure of MT1-MMP. HT-1080 cells were treated with non-targeting siRNA or 
siRNAs against KIF3A, KIF13A or KIF9. 72 hours later, cells were stained for cell 
surface MT1-MMP without permeabilisation using anti-MT1-MMP (Cat) (clone 
LEM-2/15.8) primary and Alexa-488 labeled secondary antibodies. HT-1080 cells 
unstained or stained only with secondary antibody were used as negative 
controls. HT-1080 cells stained, but not treated with siRNA, were used as a 
positive control. The experiment was performed twice with a similar outcome. 
Representative results from one experiment are shown. Data were analysed 
using FlowJo Software. 
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5.2.8 Effect of dominant negative forms of KIF3A, KIF13A and KIF9 on 
MT1-MMP-mediated gelatin film degradation 
As reported in Section 5.2.3, silencing of KIF3A or KIF13A genes 
decreased, whereas that of KIF9 enhanced MT1-MMP-mediated gelatin film 
degradation. To confirm these results by another approach, dominant negative 
forms of these KIFs were cloned.  
KIFs with their motor domain deleted work as dominant negative forms 
(Gelfand et al., 2001). These mutants cannot translocate along microtubules, 
however they can still bind to specific cargo. Thus the mutants compete with the 
endogenous KIF for cargo binding and overexpression of the mutants inhibits 
trafficking mediated by that KIF. The concept of KIF dominant negative forms is 
summarised in Figure 5.7 A.  
Using HT-1080 cDNA as a template, dominant negative forms of KIF3A, 
KIF13A and three splice variants of KIF9 were cloned. The mutants lacked the 
motor domain, were tagged with an HA-epitope at their N-terminus, and named 
as followed: KIF3A-∆M; KIF13A-∆M; KIF9-v1-∆M; KIF9-v2-∆M; KIF9-v3-∆M. The 
effect of their overexpression on MT1-MMP localisation to the substrate 
attachment sites was investigated using the gelatin film degradation assay. HT-
1080 cells were transiently transfected with 1 µg of mock vector or plasmid DNA 
encoding KIF3A-∆M, KIF13A-∆M or KIF9-∆M (0.33 µg of each splice variant). 24 
hours later, cells were seeded on a fluorescent gelatin-film. After 15 hours of 
incubation, cells were fixed and stained with an anti-HA antibody (clone 3F10) 
with permeabilisation.  
As shown in Figure 5.7 B, mock cells were negative for HA-staining, 
confirming the specificity of the antibody. In comparison to mock cells, 
overexpression of KIF3A-∆M or KIF13A-∆M decreased MT1-MMP-mediated 
gelatin film degradation, confirming the effect of KIF3A and KIF13A siRNA. 
Unexpectedly, overexpression of KIF9-∆M also decreased gelatin film 
degradation, with this observation being opposite to that obtained using KIF9 
siRNA. It is possible that binding of overexpressed KIF9 mutants to MT1-MMP-
containing vesicles prevents the binding of other KIFs, e.g. KIF3A and KIF13A 
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(Figure 5.7 A, right panel). As a result the MT1-MMP vesicles would be released 
from the microtubule and trapped in the cytosol and the total amount of the 
enzyme on the cell surface would be decreased.  
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Figure 5.7: Effect of dominant negative forms of KIF3A, KIF13A and KIF9 on 
MT1-MMP-mediated gelatin film degradation. (A) Diagram representation of 
the concept of dominant negative approach to study the role of KIFs. Dominant 
negative KIF mutants lack their motor domain and cannot bind to microtubules. In 
the absence of kinesin-dominant negative form (left panel), cargo is transported 
by a specific endogenous KIF (KIF-X). The overexpressed dominant negative 
form of KIF-X (middle and right panel) binds to the cargo, resulting in inhibition of 
vesicle transport mediated by KIF-X. In this condition, the cargo may be 
transported by other KIFs (KIF-Y) (middle panel), or if the dominant negative form 
prevents other kinesins from binding, the cargo may dissociate from the 
microtubule and be trapped in the cytosol (right panel). (B) HT-1080 cells were 
transfected with 1 µg of mock vector or plasmid DNA encoding KIF3A-∆M, 
KIF13A-∆M or KIF9-∆M (0.33 µg of each splice variant). 24 hours later, cells 
were seeded on Alexa488-labelled gelatin-film-coated coverslips. After 15 hours 
of incubation, cells were fixed and stained with an anti-HA antibody (clone 3F10). 
Images were captured using an Ultraview confocal microscope and 
representative images are shown. In the merged image, gelatin is shown in green 
and HA-tag staining is shown in red. Areas of gelatin degradation are shown as 
dark areas against the green background.   
 
 
5.3 DISCUSSION 
Intracellular transport governs spatial and temporal organisation of 
macromolecules and organelles within the cell (Hirokawa and Takemura, 2004). 
We and others have demonstrated that intracellularly MT1-MMP molecules are 
present in vesicles that dynamically accumulate at extending membrane 
protrusions (Section 1.5.3) (Bravo-Cordero et al., 2007; Wiesner et al., 2010). 
This strongly suggests that polarised localisation of MT1-MMP on the cell surface 
is achieved by targeted vesicle transport. Studies presented in this Chapter 
aimed to understand the molecular mechanisms mediating intracellular trafficking 
of MT1-MMP by identification of kinesins involved in transport of MT1-MMP-
containing vesicles to different areas of the plasma membrane.  
Among the 17 KIFs studied, knockdown of four KIFs (KIF3A; KIF13A; KIF9 
and KIF1C) resulted in apparent changes in MT1-MMP-mediated gelatin film 
degradation. KIF3A is a ubiquitously expressed kinesin which forms a 
trimolecular complex with KIF3B and a kinesin superfamily-associated protein 3 
(KAP3), and was shown to associate with membranous organelles in neurons 
(Yamazaki et al., 1995). The KIF3A/KIF3B dimer has been shown to be involved 
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in transport of a polarity complex PAR-3–PAR-6–atypical protein kinase C 
(aPKC) to the tip of growing axons. The PAR-2-PAR-6-aPKC complex 
determines polarity of different cells and its mislocalisation in neurons by 
overexpression of a dominant-negative mutant of KIF3A was shown to abolish 
neuron polarity (Nishimura et al., 2004).  KIF13A has been shown to transport a 
mannose-6-phosphate receptor (M6PR) from the Golgi network to the plasma 
membrane through direct interaction with a β1 subunit of adaptor protein 1 (AP-1) 
and its overexpression in MDCK cells induced accumulation of M6PR and AP-1 
at the tip of long extending processes (Nakagawa et al., 2000). Since KIF3A and 
KIF13A have been shown to be involved in trafficking of vesicles to extending 
membrane protrusions, they are good potential candidates for trafficking of MT1-
MMP vesicles.  
KIF1C has been shown to regulate the maintenance of podosomes in 
primary human macrophages (Kopp et al., 2006). As podosomes are similar 
structures to invadopodia, the role of KIF1C in both structures may be similar. 
The trafficking route of KIF9 is poorly characterised. KIF9 has been 
reported to interact with a Ras-like GTPase Gem, overexpression of which was 
shown to induce elongation and sprouting of HUVEC (human umbilical vein 
endothelial cells) and COS cells. The function of the KIF9-Gem interaction is not 
clear, but it is possible that Gem binding may induce trafficking via a pathway 
mediated by KIF9 (Piddini et al., 2001). Involvement in cell sprouting and 
elongation make KIF9 a potential candidate for MT1-MMP vesicle trafficking. 
Knockdown of KIF3A and KIF13A genes markedly decreased MT1-MMP-
mediated degradation of gelatin and collagen films, suggesting their potential 
involvement in localisation of MT1-MMP to substrate attachment sites. 
Conversely, silencing of KIF9 and KIF1C genes enhanced degradation of 
underlying gelatin and, in the case of KIF9, also collagen. These results indicate 
a potential involvement of KIF1C and KIF9 in localisation of MT1-MMP to areas 
of the plasma membrane other than substrate attachment sites, e.g., 
lamellipodia. Unfortunately, I did not have sufficient time to analyse KIF1C in 
more detail, but this will be done in the future.   
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Knockdown of KIF3A and KIF13A genes decreased proMMP-2 activation 
and processing of MT1-MMP to inactive ~40 kDa species, whereas knockdown 
of KIF9 had the opposite effect. These changes can not be explained by 
differences in the cell surface expression level of MT1-MMP, since knockdown of 
KIF3A and KIF13A slightly enhanced, whereas that of KIF9 had no effect on 
enzyme cell surface expression level as measured by flow cytometry. As 
proMMP-2 activation requires TIMP-2, which acts as a receptor for proMMP-2 
(Butler et al., 1998; Kinoshita et al., 1998; Strongin et al., 1995), it is possible that 
knockdown of KIF3A, KIF13A and KIF9 may have affected trafficking of TIMP-2 
and therefore affected proMMP-2 activation. Generation of an inactive ~40 kDa 
autolytic species of MT1-MMP was concomitant with proMMP-2 activation, as 
has been previously reported (Hernandez-Barrantes et al., 2000; Stanton et al., 
1998). 
It should be noted that silencing of KIF3A or KIF13A genes, which 
decreased gelatin film degradation, did not reduced the cell surface level of the 
MT1-MMP. On the other hand, knockdown of KIF9 enhanced degradation of 
underlying matrix, but it did not affect the cell surface level of MT1-MMP. These 
data suggest that trafficking of MT1-MMP vesicles involves multiple kinesins, 
which may compete with each other and when one kinesin is depleted other 
kinesins may take over. 
Data from kinesin silencing studies were confirmed by a dominant 
negative approach. This approach has been successfully used to study the 
function of kinesin proteins (Gelfand et al., 2001). To generate a kinesin 
dominant negative mutant, the motor domain was deleted. A motorless mutant of 
kinesin cannot bind to microtubules or hydrolyse ATP, but it can still bind its 
cargo. Upon overexpression, the mutant competes with endogenous kinesins for 
cargo binding, resulting in inhibition of the specific transport mediated by this 
kinesin. Overexpression of motorless mutants of KIF3A and KIF13A decreased 
gelatin film degradation, indicating their role in MT1-MMP localisation to substrate 
attachment sites. Unexpectedly, overexpression of the motorless mutant of KIF9 
inhibited gelatin film degradation, which was opposite to the result obtained by 
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KIF9 knockdown. It is, however, possible that overexpression of the motorless 
mutant of KIF9 not only prevented endogenous KIF9 from binding to MT1-MMP 
vesicles, but also blocked by steric hindrance binding of other kinesins, 
potentially KIF3A and KIF13A. Under this condition, MT1-MMP vesicles would be 
released from the microtubule, trapped in the cytosol and as a result the total cell 
surface level of the enzyme would be reduced. This hypothesis needs to be 
verified by flow cytometry.  
While this thesis was in preparation, it was reported that KIF5B and 
KIF3A/KIF3B drive cell surface delivery of MT1-MMP in primary human 
macrophages (Wiesner et al., 2010). Knockdown of KIF5B and KIF3A/KIF3B 
were shown to decrease cell surface levels of the enzyme, MT1-MMP-mediated 
shedding of CD44 and syndecan-1 as well as degradation of gelatin, fibronectin 
and type-I collagen films at podosomes (Wiesner et al., 2010). In agreement with 
this report, our data suggest a potential involvement of KIF3A in intracellular 
trafficking of MT1-MMP. However, knockdown of KIF3A in HT-1080 did not 
considerably affect the cell surface level of the enzyme. Furthermore, KIF3B and 
KIF5B were dispensable for MT1-MMP-mediated gelatin film degradation in HT-
1080 cells. It is plausible that the observed discrepancies reflect differences in 
cell type.   
KIF1C has been previously described to regulate maintenance of 
podosomes in primary human macrophages and its depletion resulted in 
podosomes deficiency. KIF1C was shown to accumulate at the plus ends of 
microtubules that contact podosomes, and bind to myosin II, coupling 
microtubules with the podosomes-connecting actin cables. It is not clear if KIF1C 
only tethers the microtubule plus ends to podosomes or if it also participates in 
vesicle trafficking to these structures (Kopp et al., 2006). Knockdown of KIF1C in 
primary human macrophages was shown to inhibit degradation of underlying 
gelatin, fibronectin and collagen at podosomes, which is likely to be, at least in 
part, a result of podosome downregulation (Wiesner et al., 2010). In contrast, we 
found that silencing of KIF1C in HT-1080 cells enhanced gelatin film degradation. 
As podosomes have similar function and molecular organisation to invadopodia, 
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it is tempting to speculate that KIF1C knockdown downregulated invadopodia in 
HT-1080 cells. If this is the case, than this result would support our previous 
finding showing that downregulation of invadopodia by cortactin knockdown 
enhances degradation of the underlying matrix (Section 4.2.3). However, further 
studies are needed to examine this hypothesis.  
 Taken together, data in this chapter suggest that vesicle trafficking of 
MT1-MMP can be regulated by multiple kinesin molecules (Figure 5.8). Here, we 
hypothesise that KIF3A and KIF13A may be involved in trafficking of MT1-MMP-
containing vesicles to substrate attachment sites, whereas KIF9 and KIF1C may 
be involved in trafficking to other areas of plasma membrane distinct from 
substrate attachment sites, e.g., lamellipodia. Interestingly, kinesin-mediated 
trafficking pathways of MT1-MMP seem to compete with each other and when 
one pathway is switch off, MT1-MMP vesicles may be recognised and trafficked 
by other kinesin pathways. 
 
 
 
 
Figure 5.8: Multiple KIFs regulate vesicle trafficking of MT1-MMP. Here, we 
speculate that KIF3A and KIF13A may be involved in trafficking of MT1-MMP-
containing vesicles to substrate attachment sites, whereas KIF9 and KIF1C may 
regulate trafficking to other area of the plasma membrane, potentially to 
lamellipodia.   
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In future experiments, it will be important to clone full-length constructs of 
KIF3A, KIF13A, KIF9 and KIF1C and investigate the effect of their 
overexpression on enzyme localisation to substrate attachment sites and 
lamellipodia. Colocalisation studies need be performed to investigate if these 
kinesins bind to MT1-MMP-containing vesicles. In addition to 2D culture, it will be 
interesting to analyse the effect of these KIFs on enzyme localisation to the 
leading edge in 3D. Finally, it will be important to examine the effect of KIF3A, 
KIF13A, KIF9 and KIF1C on cellular invasion using a transwell invasion assay 
and a microcarrier bead invasion assay.  
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6. GENERAL DISCUSSION AND FUTURE PROSPECTS 
Cell migration regulates fundamental physiological processes such as 
embryonic development, immune defense, angiogenesis and wound healing, and 
its misregulation results in severe pathological conditions such as cancer 
invasion and metastasis (Itoh, 2006; Itoh and Seiki, 2006; Nelson et al., 2000; 
Page-McCaw et al., 2007; Sato et al., 2005). MT1-MMP is a key regulator of cell 
migration and its elevated expression level in tumours is associated with cellular 
invasiveness and malignancy (Itoh, 2006; Li et al., 2008; Sato et al., 2005). 
Localisation of MT1-MMP at the cell surface is highly polarised and is considered 
to be an important regulatory mechanism for the enzyme (Artym et al., 2006; 
Bravo-Cordero et al., 2007; Clark and Weaver, 2008; Galvez et al., 2001; 
Marrero-Diaz et al., 2009; Mori et al., 2002; Sato et al., 1997). In this thesis, 
mechanisms regulating localisation of MT1-MMP to motility-associated 
structures, in particular to lamellipodia and substrate attachment sites, have been 
investigated. 
When cells are cultured on a 2D matrix, the area where cells contact the 
ECM is referred to as the substrate attachment site. The discovery that invasive 
tumor cells extend proteinases-containing membrane protrusions called 
invadopodia into the ECM (Chen et al., 1985) resulted in the widely accepted 
notion that the formation of invadopodia represents an early step in tumor cell 
invasion, intravasation and extravasation (Poincloux et al., 2009; Weaver, 2006; 
Yamaguchi et al., 2006). However, conclusive evidence supporting the role of 
invadopodia in tumor invasion has not yet been published. In contrast to previous 
reports, I found that cortactin, an essential component of invadopodia structures, 
was dispensable for localisation of MT1-MMP to substrate attachment sites in 
HT-1080, MDA-MB-231 and TR131 cells, and its knockdown in HT-1080 cells 
enhanced cell invasion in a transwell invasion assay. These results suggest that 
cortactin-mediated invadopodia structures are not required for localisation of 
MT1-MMP to substrate attachment sites and further suggest that invadopodia 
may not be the essential membrane structure enabling cancer cells to invade into 
the underlying matrix. The discrepancies between my results and previously 
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published reports may be explained by the different experimental conditions used 
and have been discussed in Section 4.3. In agreement with previous reports, my 
results indicate that tumor cells indeed form cortactin-mediated invadopodia prior 
to invasion and that MT1-MMP accumulates to these structures. My data, 
however, suggest that the ability of cancer cells to form invadopodia does not 
necessarily correspond with their invasive potential. 
The enhanced degradation of underlying gelatin and collagen induced by 
cortactin knockdown implies a potential role of cortactin in localisation of MT1-
MMP to areas of plasma membrane distinct from the substrate attachment sites. 
Interestingly, enhanced degradation of the underlying matrix was also observed 
upon CD44, KIF9 and KIF1C knockdown. As cortactin accumulated 
predominantly at lamellipodia of HT-1080 cells, it is tempting to speculate that 
cortactin may be involved in localisation of MT1-MMP to lamellipodia. A previous 
report indicated that MT1-MMP localisation to lamellipodia was mediated by 
CD44 (Mori et al., 2002). The common characteristic of CD44 and cortactin is 
that they both bind to F-actin and accumulate in lamellipodia (Bryce et al., 2005; 
Mori et al., 2002; van Rossum et al., 2006). Furthermore, cortactin has been 
shown to stabilise the Arp2/3-induced actin filament network in lamellipodia 
(Weaver et al., 2001) and to promote lamellipodia persistence (Bryce et al., 
2005). These findings suggest that an intact branched actin network may be 
required for localisation of MT1-MMP to lamellipodia, and that CD44 and 
cortactin may regulate the same pathway of MT1-MMP vesicle trafficking. Since 
silencing of the KIF9 and KIF1C genes showed a similar phenotype in the gelatin 
film degradation assay to CD44 and cortactin knockdown, all four molecules may 
be involved in the same pathway of MT1-MMP vesicle trafficking (Figure 6.1). In 
the future, it will be interesting to investigate the link between cortactin, CD44, 
KIF9 and KIF1C as this may provide a novel insight into the mechanism of MT1-
MMP lamellipodial localisation.  
Although the lamellipodium is the leading edge of cells migrating on a 2D 
substratum, it is substantially different from the leading edge of cells migrating 
through a 3D matrix. In contrast to the 3D leading edge, the lamellipodium does 
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not encounter the ECM barrier, therefore accumulation of proteolytic enzymes at 
this structure is not required to support cell movement. What is more, 3D matrix 
significantly influences the cell shape with cells adopting front-rear polarity (Petrie 
et al., 2009). In contrast, cell migrating on a 2D substratum are less polarised and 
form broad lamellipodia that extend in various directions. The described 
differences between the leading edge of cell migrating through 2D versus 3D 
matrix raise the possibility that the mechanism of MT1-MMP localization to the 
leading edge may be different depending on the dimensionality of the matrix. In 
fact, although CD44 has been reported to direct MT1-MMP localization to 
lamellipodia (Mori et al., 2002), a recent study has shown that in cells migrating 
through HA-containing 3D collagen-I matrices, MT1-MMP-CD44 interaction took 
place preferentially at the trailing edge (Marrero-Diaz et al., 2009). It is therefore 
important to evaluate the role of CD44 in MT1-MMP localization to the leading 
edge in a 3D matrix.  
As a potential mechanism of MT1-MMP localisation to substrate 
attachment sites, I report here the involvement of the MT-Loop region of the 
enzyme. Deletion of the MT-Loop markedly decreased degradation of an 
underlying gelatin matrix, but did not affect the overall cell surface level of the 
enzyme. Interestingly, similar phenotypes were observed upon silencing of the 
KIF3A and KIF13A genes. These data suggest that KIF3A, KIF13A and the MT-
Loop region may be involved in the trafficking of MT1-MMP vesicles to substrate 
attachment sites (Figure 6.1). It is therefore appealing to hypothesise that the 
MT-Loop region is an interface of enzyme interaction with an as yet unidentified 
protein, which may potentially be involved in sorting of MT1-MMP molecules to 
the vesicles targeted to substrate attachment sites. Therefore identification of 
proteins that can interact with the MT-Loop will be important for understanding 
this mechanism. This can be done by overexpression of MT1F and MT1F-∆Loop 
in COS-7 cells and subsequent immunoprecipitation of FLAG-tagged proteins 
using anti-FLAG-M2 conjugated beads. Molecules co-immunoprecipitated with 
MT1F-∆Loop will be compared and the proteins that bind to MT1F but not to 
MT1F-∆Loop will be identified by proteomics.   
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It was of interest to learn that deletion of the MT-Loop and silencing of the 
KIF3A or KIF13A genes, which decreased gelatin film degradation, did not 
reduce the cell surface level of the enzyme. Silencing of the KIF9, CD44 and 
cortactin genes enhanced the degradation of underlying matrix, but they did not 
affect the cell surface level of MT1-MMP. These results suggest that the 
trafficking pathway that regulates localisation of MT1-MMP to lamellipodia may 
compete with one that directs the enzyme to substrate attachment sites. When 
one pathway is switched off, the other pathway may take over. These findings 
may suggest that the same MT1-MMP-containing vesicles can potentially be 
recognised by both pathways. 
In future experiments, it will be important to define mechanisms of MT1-
MMP localisation to different areas of the plasma membrane of invading cells. To 
achieve this goal, further investigation of the regulatory mechanism of kinesin-
mediated transport of MT1-MMP-containing vesicles and identification of 
signaling pathways that induce enzyme localisation to invasive structures will be 
key. It will be also important to analyse the content of MT1-MMP-containing 
vesicles to identify partner proteins that may mediate sorting of MT1-MMP to 
certain vesicles or act together on the cell surface.  To analyze molecules co-
trafficked with MT1-MMP, MT1-MMP-containing vesicles will be isolated and 
molecules in the vesicles will be identified by proteomics. To release MT1-MMP-
vesicles from microtubules, cells can be transfected with specific motor-less 
kinesin mutants that cannot bind to microtubules. Alternatively vesicles can be 
released by de-polymerization of microtubules at low temperature. Cells can be 
then ruptured by French Press or dounce homogenizer and MT1-MMP-
containing vesicles can be isolated using either antibodies against kinesin 
mutants or antibodies directed against the cytoplasmic tail of MT1-MMP. In the 
latter case, cell surface biotinylation will be performed prior to cell rupture. The 
biotinylated molecules will be removed by streptavidin-conjugated beads. 
Unbound fraction will then be subjected to immunoprecipitation for MT1-MMP-
containing vesicles. By doing this, contamination of the vesicular fraction of MT1-
MMP by the cell surface enzyme will be eliminated.   
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Work described in this thesis contributes to an understanding of the spatial 
regulation of MT1-MMP during cell migration and invasion. We believe that 
vesicle trafficking of MT1-MMP to lamellipodia and substrate attachment sites 
regulates the pro-invasive properties of the enzyme. Therefore, further 
investigation of the mechanisms that regulate the fate of MT1-MMP-containing 
vesicles will not only deepen our understanding of cellular invasion in different 
pathophysiological events, but would also help to develop new strategies to 
inhibit uncontrolled cell migration in diseases such as arthritis and cancer. 
 
 
 
 
 
Figure: 6.1 Intracellular trafficking of MT1-MMP-containing vesicles 
regulates spatial localisation of the enzyme on the cell surface. We 
hypothesise that polarised localisation of MT1-MMP at the cell surface is 
regulated by kinesin-dependent trafficking of MT1-MMP-containing vesicles. A 
trafficking pathway that localises the enzyme to lamellipodia is potentially 
mediated by CD44, cortactin, KIF9 and KIF1C. The alternative pathway that 
localises the enzyme to substrate attachment sites is likely to involve KIF3A and 
KIF13A and depends on presence of the MT-Loop region of MT1-MMP.  
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